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SUMMARY 
This dissertation focuses on effects of human pharmaceuticals towards fish. Residues 
of pharmaceuticals are regularly found in surface waters in the range of ng/L to μg/L 
and consequently, aquatic organisms living at polluted sites are exposed during their 
whole life to a variety of micro-pollutants including pharmaceuticals, but the risk of such 
an exposure is largely unknown. Pharmaceuticals are designed to exhibit specific 
modes of action on target biomolecules in humans at often low concentrations and 
current data indicate that most of the targets are also present in lower vertebrates. 
Therefore, we hypothesized that in all vertebrates the modes of action of 
pharmaceuticals found in the environment are mediated by the interaction with defined 
targets like receptors, enzymes and transporters and so are the effects. This 
mechanism-based approach allows the investigation of potential chronic effects in 
aquatic organisms. 
 
The aim of this dissertation is to study and elucidate cellular mechanisms of 
pharmaceuticals in fish. First, the cytotoxicity of environmentally important 
pharmaceuticals in the two stable fish cell lines PLHC-1 (Poeciliopsis lucida 
hepatocellular carcinoma) and RTG-2 (rainbow trout gonadal) is assessed and 
correlated to their partition coefficient LogD as well as to existing data for Daphnia 
magna and fish. Further, a doxorubicin-resistant PLHC-1 subclone (PLHC-1/dox) is 
selected and found to be characterized by an overexpression of the transporter P-
glycoprotein (ABCB1). This transporter plays a crucial role in detoxification processes 
and its inhibition can essentially increase the intracellular concentration of compounds. 
The data demonstrate for the first time the presence of a classical multidrug resistance 
phenotype in a non-mammalian cell system. Subsequently, several pharmaceuticals – 
among them the statins atorvastatin, pravastatin and simvastatin as well as gemfibrozil, 
sildenafil and furosemide – are found to affect the multidrug resistance mechanism in 
both normal PLHC-1 cells and in PLHC-1/dox cells. Finally, the presence of the 
peroxisome proliferator-activated receptors (PPARα, PPARβ und PPARγ) and the 
retinoid X receptor is detected in PLHC-1 cells. Effects mediated by fibrates 
(bezafibrate, clofibric acid, fenofibrate, gemfibrozil) on the expression of these 
receptors as well as on the activity of a peroxisomal enzyme confirm its functionality.  
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In conclusion, this dissertation gives new insights on the interaction of pharmaceuticals 
in fish cell lines with different targets like ABC-transporters and PPARs. The PLHC-1 
cells were found to be a reliable in vitro model system for the investigation of 
biochemical and molecular-biological effect mechanisms in fish. Furthermore, 
cytotoxicity assays in fish cell lines can be a valuable tool in the risk assessment to 
estimate and rank the acute toxicities of compounds in order to minimize acute toxicity 
tests in vivo. 
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ZUSAMMENFASSUNG 
In dieser Doktorarbeit werden Effekte von Arzneistoffen, welche als Verunreinigungen 
in Gewässern auftreten, auf Wasserorganismen untersucht. In Oberflächengewässern 
werden regelmässig Medikamentenrückstände im Bereich von ng/L bis hin zu μg/L 
gefunden. Wasserorganismen, die an belasteten Stellen leben, werden oft während 
ihres ganzen Lebens an eine grosse Vielfalt verschiedener, umweltrelevanter 
Spurenstoffe ausgesetzt. Die damit verbundenen Risiken sind jedoch wenig bekannt. 
Arzneistoffe haben in der Regel spezifische Wirkungen auf bestimmte definierte 
Biomoleküle beim Menschen - und dies oft bereits bei tiefen Konzentrationen. Aktuelle 
Ergebnisse deuten darauf hin, dass die meisten der Zielmoleküle auch bei einfacheren 
Organismen vorhanden sind. Daraus stellten wir die Hypothese auf, dass die 
Wirkungsmechanismen bei allen Wirbeltieren durch spezifische Interaktionen von 
Umweltstoffen mit Zielmolekülen wie Rezeptoren, Enzymen und Transportern erfolgen. 
Damit sind auch die toxischen Wirkungen analog. Dieses auf Wirkungsmechanismen 
basierende Konzept sollte damit erlauben, chronische Wirkungen auch bei 
Wasserorganismen zu ermitteln. 
 
Diese Dissertation untersucht und beleuchtet zelluläre Mechanismen von Arzneistoffen 
in Fischen. Als erstes wurden zytotoxische Effekte von umweltrelevanten Arzneistoffen 
in der Fischzelllinie PLHC-1 (Poeciliopsis lucida Leberkrebszellen) und RTG-2 (Gona-
denzellen von Regenbogenforellen) bestimmt und diese mit vorhandenen akuten 
Toxizitätsdaten für Daphnia magna und Fischen korreliert. Weiter gelang es uns, einen 
Doxorubicin-resistenten PLHC-1-Klon (PLHC-1/dox) zu selektieren. Dieser zeichnet 
sich durch eine erhöhte Expression von P-glycoprotein (ABCB1-Transporter) aus. 
Dieser Transporter spielt eine wichtige Rolle im Fremdstoffmetabolismus 
(Ausscheidung aus der Zelle) und seine Hemmung kann die intrazelluläre 
Konzentration von Fremdstoffen entscheidend erhöhen. Diese Arbeit weist zum ersten 
Mal nach, dass ein klassischer Multidrugresistenz-Phänotyp auch bei Fischzellen 
auftritt. Weiterführende Untersuchungen zeigten, dass mehrere Arzneistoffe - darunter 
die Statine Atorvastatin, Pravastatin und Simvastatin sowie Gemfibrozil, Sildenafil und 
Furosemide - Effekte auf den Multidrugresistenz-Mechanismus in normalen PLHC-1- 
und PLHC-1/dox-Zellen ausüben. Schliesslich wurden auch erstmals drei 
Peroxisomenproliferations-aktivierende Rezeptoren (PPARα, PPARβ und PPARγ) in 
PLHC-1-Zellen identifiziert. In der Folge untersuchten wir Effekte von Fibraten auf die 
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Expression der drei Rezeptoren sowie auf die Aktivität eines peroxisomalen Enzyms, 
welche durch Fibrate (Bezafibrat, Clofibrinsäure, Fenofibrat und Gemfibrozil) initiiert 
wurden. Damit konnte gezeigt werden, dass das PPAR-System in der Zelllinie 
funktionell ist. 
 
Zusammengefasst gibt diese Doktorarbeit neue Erkenntnisse über Wechselwirkungen 
von Arzneistoffen mit verschiedenen Zielmolekülen wie ABC-Transportern und PPARs 
in Fischzelllinien. Die PLHC-1-Zellen erwiesen sich als zuverlässiges Modellsystem für 
die Untersuchung biochemischer und molekularbiologischer Mechanismen von Arz-
neimittelwirkungen auf Fische. Weiter könnten PLHC-1-Zellen damit als mögliche 
Alternativen zu in-vivo-Versuchen in der Risikobeurteilung akut toxischer Effekte von 
Substanzen Anwendung finden. 
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General introduction 
It was only in the 1970’s that it became aware that pharmaceuticals occur in the 
environment when clofibric acid was found in the range of 0.8-2 μg/L in treated 
wastewater in the U.S.A. (Garrison et al. 1976). However, only during the last decade 
the improvement of analytical methods, especially the ability to determine polar 
compounds at trace quantities, increased the knowledge about the environmental 
occurrence of pharmaceuticals. Analytical studies showed that complex mixtures of 
environmental pollutants (xenobiotics), among them pharmaceuticals occur in surface 
waters like rivers, lakes and the sea and, even more surprisingly, in groundwater and 
drinking water (Calamari et al. 2003; Kolpin et al. 2002; Wiegel et al. 2004).  
 
In contrast to analytical studies, only few studies have investigated biological effects of 
pharmaceuticals to aquatic organisms (Fent 2004; Lindqvist et al. 2005; Quintana et al. 
2005; Roberts and Thomas 2005; Stuer-Lauridsen et al. 2000; Tauxe-Wuersch et al. 
2005; Ternes 1998; Thomas and Foster 2004; Weigel et al. 2004). One of the reasons 
for the scarce knowledge is the more complex nature of the question. Ultimately, the 
key question is: 
• Do the concentrations of pharmaceuticals found in the environment pose a risk 
for aquatic organisms and do they cause adverse effects? 
 
However, this question is divided into several other questions that have to be answered 
first: 
• What are the most relevant pharmaceuticals found in the environment in terms 
of unexpected/adverse effects on aquatic organisms?  
• Which organism(s) and systems shall be chosen for the investigation?  
• Are acute toxic effects occurring?  
• How can chronic effects be measured and what are the relevant endpoints?  
• Are there differences between mechanisms and specificities in mammals and 
in aquatic organisms?  
• How do compound mixtures modulate effects?  
• How do environmental concentrations correlate with effect concentrations? 
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These questions guided this doctoral thesis and therefore, they will be addressed and 
discussed in respect towards a better understanding of the potential risk of 
pharmaceuticals to the aquatic environment.  
 
In the introduction a short overview of the current knowledge on the ecotoxicology of 
human pharmaceuticals is presented. Sources, pathways to the environment and the 
fate of pharmaceuticals are discussed followed by an overview on the concentrations in 
the environment. In the following the most relevant modes of action of pharmaceuticals 
in humans are reviewed and the occurrence of target biomolecules in aquatic 
organisms is described. Concluding the general introduction, known adverse effects of 
pharmaceuticals on non target-organisms are discussed. Our review ‘Ecotoxicology of 
Human Pharmaceuticals’ in the appendix gives more detailed information on that topic. 
Finally, the concept of this study is introduced and the following chapters are shortly 
summarized. 
 
Sources, pathways and fate of pharmaceuticals 
Pharmaceuticals are a class of chemical compounds produced to induce a beneficial 
effect usually on specific targets like receptors, enzymes and transporters in humans 
(human medicine), but also in animals (veterinary medicine). They are used to treat 
illnesses and diseases, but also to improve the lifestyle. About 3000 different 
Table 1 
Annual consumption of different classes of prescribed drugs for different countries. A top 15 sold-
list is shown for every country. 
References: 1) Khan, S. J. and Ongerth, J. E. (2004). Chemosphere 54(3): 355-67. 2) Jones, O. A., 
Voulvoulis, N., et al. (2002). Water Res 36(20): 5013-22. 3) Huschek, G., Hansen, P. D., et al. 
(2004). Environ Toxicol 19(3): 226-40. 4) ©IMS Health Incorporated or its affiliates. All rights 
reserved. MIDAS–02/03/05. 
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substances are used in the European Union (EU) such as analgesics and anti-
inflammatory drugs, lipid regulators, contraceptives, antibiotics, beta-blockers, 
neuroactives and many others. The consumption of pharmaceuticals is substantial 
(Tab. 1). In countries like Australia, England and Germany, the 15 most frequently sold 
drugs account for hundreds of tons per year (Calamari et al. 2003; Huschek et al. 2004; 
Jones et al. 2002; Khan and Ongerth 2004). The amounts consumed in Switzerland 
are smaller due to its smaller population; however, the annual consumption of 
paracetamol reaches still 95 t per year. The consumption of pharmaceuticals (Tab. 1) 
may be even higher as only figures about annual sales of mainly prescribed drugs sold 
in pharmacies and drugstores are known. Data on sales over-the-counter are not  
known, nor are internet sales that may be of significant amounts for some drugs like 
sildenafil (the active ingredient of Viagra). 
 
After consumption pharmaceuticals finally reach the environment (Fig. 1), either in their 
form by which they reach the targets within an organism to exhibit the expected effect 
or as metabolites. Therefore, pharmaceuticals are often excreted in their native form or 
as rather stable metabolites, but they may enter aquatic systems also after improper 
disposal (Fig. 1). Hospital wastewater, wastewater from manufacturers and landfill 
leachates may contain significant concentrations of pharmaceuticals (Holm et al. 1995; 
Metcalfe et al. 2003a; Metcalfe et al. 2003b). In addition, accidents in the chemicals 
industry may cause acute damage to ecosystems. Pharmaceuticals and their 
metabolites not readily degraded during the processing in sewage treatment plants 
(STP) are being discharged in treated effluents and finally resulting in the 
Figure 1 
Pathways of human pharmaceuticals to the environment. The main route is excretion from 
humans and via STP to the environment. However, direct disposal to STPs or to the 
environment are further alternatives. At all stations, biotransformations occur (see text). 
Human
Drug
Sewage Treatment Plant
Environment
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contamination of rivers, lakes, estuaries and rarely, the sea, groundwater and drinking 
water. Contamination of soil, runoff into surface water but also drainage may occur 
where sewage sludge is applied to agricultural fields. Pharmaceuticals used in 
veterinary medicines enter soil and aquatic systems via manure application to fields 
and subsequent runoff, but also directly via application in aquaculture (fish farming). 
 
The behaviour and fate of pharmaceuticals and their metabolites in the aquatic 
environment is not well known (Fent 2004; Gross et al. 2004; Khan and Ongerth 2004; 
Kümmerer 2004). Their low volatility indicates that the distribution in the environment 
occurs primarily through aqueous transport, but also via food chain dispersal. In the 
wastewater treatment, two elimination processes are generally important: adsorption to 
suspended solids (sewage sludge) and biodegradation. The physicochemical 
properties, especially the pKa, value are important factors for the fate and degradation 
of the compounds. In general, sorption of acidic pharmaceuticals to sludge is 
suggested to be not very important for their elimination from wastewater and surface 
water, as was demonstrated in several monitoring studies (Stackelberg et al. 2004; 
Ternes et al. 2004; Urase and Kikuta 2005). In contrast, basic pharmaceuticals and 
zwitterions can adsorb to sludge to a significant extent as shown for fluoroquinolone 
antibiotics (Golet et al. 2002).  
 
Biodegradation is suggested to be the most important elimination process in 
wastewater treatment as most pharmaceuticals occur in the dissolved phase. In 
general, biological decomposition of micro-pollutants including pharmaceuticals 
increases with increased hydraulic retention time and with age of the sludge in the 
activated sludge treatment. However, there are considerable differences in the 
efficiency of the biodegradation process found for different compounds. It should be 
noted that a bio(re)activation of compounds may also occur. Conjugates can be 
cleaved during sewage treatment resulting in the release of the active parent 
compound as shown for estradiol (Panter et al. 1999; Ternes et al. 1999) and the 
steroid hormone in the contraceptive pill, 17α-ethinylestradiol (D'Ascenzo et al. 2003).  
 
Elimination rates during the STP process are mainly studied by measuring the influent 
and effluent concentrations. As expected, they vary according to the construction and 
treatment technology, hydraulic retention time, season and performance of the STP. 
Temperature is an essential factor for good efficiencies of most STPs. Studies revealed 
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that elimination efficiencies of pharmaceuticals span a large range from 0-100% 
(Carballa et al. 2004; Stumpf et al. 1999; Ternes 1998). Very high total eliminations 
were found (90-100%) for propranolol, salicylic acid, ibuprofen, naproxen, ketoprofen 
and diclofenac (Metcalfe et al. 2003a; Ternes 1998; Thomas and Foster 2004). On the 
other hand, low removal rates (0-10%) were measured for the very hydrophilic X-ray 
contrast media (diatrizoate, iopamidol, iopromide, iomeprol), the anticancer drug 
tamoxifen (Roberts and Thomas 2005; Ternes and Hirsch 2000) and carbamazepine. 
The latter is hardly biodegradable independently from hydraulic retention times 
(Metcalfe et al. 2003a; Metcalfe et al. 2003b; Roberts and Thomas 2005; Tauxe-
Wuersch et al. 2005).  
 
Biodegradation still occurs in surface waters, but abiotic transformations are probably 
more important. Photolysis plays the most important role in the removal of diclofenac in 
surface water (Buser et al. 1998) and laboratory experiments indicate that photolysis 
may also be an important removal process for other pharmaceuticals like 
sulfamethoxazole, ofloxacin and propranolol (Andreozzi et al. 2003). In contrary, 
hydrolysis is generally negligible for environmentally relevant pharmaceuticals. 
 
 
Environmental concentrations of pharmaceuticals 
Despite biotic and abiotic transformations residues of pharmaceuticals and their 
metabolites occur in the environment (Daughton and Ternes 1999; Fent 2004; Halling-
Sorensen et al. 1998; Heberer 2002; Kümmerer 2001, 2004). About 100 different 
pharmaceuticals from many classes of drugs (lipid regulators, anti-inflammatory, beta-
blockers, sympathomimetics, antiepileptics, etc.) and some of their metabolites have 
been reported in many countries in treated sewage, rivers and creeks, seawater, 
groundwater and even in drinking water. An extended monitoring study in the U.S.A. 
detected in some sites as many as 38 out of 95 studied micro-pollutants, among them 
steroids, insect repellent, caffeine, antibiotics and some pharmaceuticals (Kolpin et al. 
2002). In the river Po and river Lambro (Italy), atenolol, bezafibrate, furosemide, and 
antibiotics were found at all sampling sites (Calamari et al. 2003). Similarly, the 
presence of many pharmaceuticals (diclofenac, ibuprofen, carbamazepine, lipid 
regulators) was shown in the river Elbe (Germany) (Wiegel et al. 2004). A monitoring 
study upstream and downstream of selected towns in Iowa (U.S.A.) detected 
prescription drugs only frequently during low-flow conditions (Kolpin et al. 2004).  
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Environmental concentrations of pharmaceuticals occur in the low ng/L (detection limit) 
to μg/L range. Some data from analytical studies are compiled in figure 2 representing 
maximal, median and mean concentrations in treated sewage (a) and in surface waters 
(b). Surface water concentrations are often measured at locations near STPs. 
Generally, the effluents bear an about 10-fold higher concentration than surface 
waters. Caffeine, due to its world-wide consumption and high persistence in the 
environment proposed as anthropogenic marker, has been found in concentrations up 
to 100 μg/L in treated sewage (Weigel et al. 2004). Besides its use in beverages it is 
also part of different combinations of medicines due to its analeptic characteristics. The 
rather persistent clofibric acid, a metabolite of the lipid lowering agents clofibrate, 
etofibrate and etofyllin clofibrate, and the antiepileptic carbamazepine have been 
detected regularly in STP effluents, rivers and lakes and even in seawater (Buser et al. 
1998; Weigel et al. 2004). In surface water, maximal concentrations of 1.2 μg/L 
carbamazepine and 0.55 μg/L clofibric acid were measured. 
 
Figure 2 
Concentrations of pharmaceuticals in treated wastewater (a) and surface water (b). References: 
(Andreozzi et al. 2003; Calamari et al. 2003; Gross et al. 2004; Halling-Sorensen et al. 1998; 
Jones et al. 2002; Khan and Ongerth 2004; Kolpin et al. 2002; Kümmerer 2004; Lindqvist et al. 
2005; Metcalfe et al. 2003a; Metcalfe et al. 2003b; Quintana et al. 2005; Roberts and Thomas 
2005; Stackelberg et al. 2004; Stuer-Lauridsen et al. 2000; Tauxe-Wuersch et al. 2005; Ternes 
1998; Thomas and Foster 2004; Weigel et al. 2004). According to Fent et al. (2006). 
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Modes of action of pharmaceuticals in humans and occurrence of target 
biomolecules in aquatic organisms 
According to their therapeutic use, pharmaceuticals are divided into different classes as 
non-steroidal anti-inflammatory drugs (NSAIDs), lipid lowering agents, beta-blocker, 
neuroactive compounds (antiepileptics, antidepressants), cytostatics and cancer 
therapeutics and various others. Here, only the ecotoxicologically most relevant drugs 
and those included in this dissertation are regarded. 
 
Due to their broad range of applications, NSAIDs like acetyl salicylic acid, diclofenac, 
ibuprofen, mefenamic acid and naproxen belong to the most often used 
pharmaceuticals and in many countries, they are available over-the-counter. NSAIDs 
exhibit analgesic, antipyretic and anti inflammatory effects. Also paracetamol is often 
mentioned within the NSAIDs. It has only negligible anti-inflammatory activities and 
therefore, strictly speaking, does not belong to NSAIDs. 
 
NSAIDs act by inhibiting either reversibly or irreversibly one or both of the two isoforms 
of the cyclooxygenase enzymes (COX-1 and COX-2), which catalyze the synthesis of 
different prostaglandins from arachidonic acid (Vane and Botting 1998). Earlier NSAIDs 
inhibited both COX-1 and COX-2 at different degrees, whereas new products are 
designed to act more selectively on COX-2, the inducible form responsible for the 
inflammatory reactions (Kurumbail et al. 1997). Recently, a third cyclooxygenase-1 
variant, COX-3, has been found and characterized towards its interaction with 
paracetamol (Chandrasekharan et al. 2002). The authors argue that inhibition of COX-
3 could represent a primary central mechanism by which drugs like paracetamol 
decrease pain and possibly fever. 
 
In fish, several COX homologues have been found. An inducible COX-2 has been 
shown to be expressed in macrophages of Onchorhynchus mykiss and in goldfish 
(Carassius auratus) (Zou et al. 1999). COX-1 and COX-2 homologues were cloned 
from brook trout (Salvelinus fontinalis) ovary and a shark COX was found in Squalus 
acanthias (Roberts et al. 2000; Yang et al. 2002).  
 
Fibrates as well as statins belong to the class of lipid lowering drugs. They are used for 
the treatment of hypercholesterolemia and decrease the concentration of cholesterol - 
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and fibrates also of triglycerides - in the blood plasma. Whereas the statins inhibit the 
3-hydoxymethylglutaril coenzyme A reductase (HMG-CoA) (Endo 1992), the fibrates 
exhibit their effects through alterations in the transcription of genes encoding for 
proteins controlling the lipoprotein metabolism. The target of fibrates was found to be 
the peroxisome proliferator-activated receptors (PPAR), mainly the PPARα isoform 
(Staels et al. 1998). 
 
PPARs belong to the steroid/thyroid/retinoid receptor superfamily of ligand-activated 
nuclear transcription factors. Upon activation, they form a heterodimer with the retinoid 
X receptor (RxR) and bind to specific regions – the peroxisome proliferator response 
elements (PPRE) - of target genes. To date, three subtypes of PPAR have been 
described, namely PPARα, PPARβ (or PPARδ) and PPARγ. They play a key role in the 
lipid metabolism and the lipids homeostasis (Escher and Wahli 2000). In addition, all 
PPAR isoformes can participate in the regulation of inflammatory responses (Moraes et 
al. 2006). A simplified scheme of the PPAR pathway is presented in figure 3. 
 
Figure 3 
Simplified scheme of the PPAR-pathway. Fatty acids regulate PPARα and weakly PPARβ 
activity. Prostaglandins and leukotrienes regulate PPARγ and weakly PPARβ activity. Upon 
activation PPARs form a heterodimer with RxR and bind to PPREs of target genes.  
(Taken from: ©www.sigma-aldrich.com) 
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PPARα regulates the expression of various genes implicated in the lipid oxidation, 
mainly in liver and oxidative muscles, such as the heart, and is therefore involved in 
peroxisome proliferation (Escher and Wahli 2000; Schoonjans et al. 1996). Many 
enzymes involved in the peroxisomal β-oxidation pathway are regulated by PPARα like 
fatty acyl-CoA oxidase (Dreyer et al. 1992; Tugwood et al. 1992), enoyl CoA 
hydratase/3-OH-acyl-CoA dehydrogenase or bifunctional enzyme (Zhang et al. 1992) 
and thiolase (Lee et al. 1995). PPARα has also been reported to be involved in 
hepatocarcinogeneses in mice and rats but not in humans (Cattley et al. 1998). 
 
PPARγ is a key transcription factor involved in the differentiation of adipose tissue 
(Rosen et al. 1999) and it is the molecular target for thiazolidinedione (TZD) anti-
diabetic agents, which improve insulin sensitivity, glucose tolerance, and lipid 
homeostasis in vivo (Lehmann et al. 1995). 
 
The least well studied isoform in terms of its biological functions and endogenous 
ligands is PPARβ/δ. However, it plays an important role in differentiation of epithelial 
tissues, fatty acid catabolism in skeletal muscle, improvement of insulin sensitivity, 
attenuated weight gain, and elevated HDL levels (Burdick et al. 2006). 
 
Several studies have investigated PPARs in aquatic organisms. Full PPAR coding 
sequences have been described in fish such as plaice Pleuronctes platessa and 
gilthead sea bream Sparus aurata (Leaver et al. 1998), sea bass Dicentrarchus labrax 
(Boukouvala et al. 2004), zebrafish Danio rerio (Robinson-Rechavi et al. 2001), 
thicklipp grey mullet Chelon labrosus (Raingeard et al. 2006), and torafugu pufferfish 
Takifugu rubripes (Kondo et al. 2007). In addition, partial nucleotide sequences have 
been published for atlantic salmon Salmo salar (Ruyter et al. 1997), rainbow trout 
Onchorhyncus mykiss (Liu et al. 2005), brown trout Salmo trutta (Batista-Pinto et al. 
2005), and goldfish Carassius auratus (Mimeault et al. 2006). Fish PPARs display an 
amino acid sequence identity of 46-73% to the human amphibian PPARs (Kondo et al. 
2007).  
 
Cytostatic compounds and cancer therapeutics are rarely found in the environment; 
however, they exhibit specific interactions on the cell proliferation and are already 
cytotoxic at low concentrations. There are different modes of actions of the different 
compounds. For example methotrexate acts as a potent inhibitor of the folate 
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dehydroreductase enzyme, which is responsible for the purine and pyrimidine 
synthesis (Rang et al. 2003). The anthracycline doxorubicin intercalates in the DNA 
and RNA thereby interrupts the DNA and RNA synthesis. Furthermore the inhibition of 
topoisomerase II and the formation of radicals leads to DNA strand breaks (Forth et al. 
2001), and hence inhibition of cell proliferation.  
 
Besides its cytotoxic effect, doxorubicin has been found to induce ABC-transporters 
especially ABCB1 (P-glycoprotein). As doxorubicin is a substrate itself of this ATP-
driven transporter, cells acquire a resistance mechanisms towards this and various 
others structurally related substances. This phenomenon was first observed during 
cancer treatment and is referred to as multidrug resistance (MDR) (Juliano and Ling 
1976). In aquatic toxicology, multidrug resistance came into focus when populations of 
aquatic organisms were observed that could survive in highly polluted environments. 
This phenomenon was soon termed the MultiXenobiotic Resistance mechanism (MXR) 
in contrast to the MDR in humans (Kurelec 1992). Presently, ABCB and ABCC 
transporters have been found in aquatic organisms such as clam, crab, mussel, oyster 
shrimp, snail, sponge, toad, worm and several fish species (Bard 2000). An analysis of 
the zebrafish genome revealed that over 77% of all human ABC transporters have a 
homologue in zebrafish (Annilo et al. 2006). 
 
 
Ecotoxicological effects of pharmaceuticals 
The best documented ecotoxicological effect represents the decline of three spieces of 
vultures (Gyps bengalensis, Gyps indicus and Gyps tenuirostris) in India and Pakistan 
caused by diclofenac (Oaks et al. 2004). High adult and subadult mortality resulting in 
population loss are associated with renal failure and visceral gout, the accumulation of 
uric acid throughout the body cavity following kidney malfunction. A direct correlation 
between residues of diclofenac and renal failure was reported both by experimental 
oral exposure and through feeding diclofenac treated livestock to vultures. Diclofenac 
has recently got into widespread use in these countries as a veterinary medicine to 
treat all kind of hoofed livestock. Furthermore, livestock that die of disease or injury are 
typically left for scavengers such as vultures to remove. Apart from this severe case, 
potential ecotoxicological effects of drug residues in the environment on wildlife are 
largely unknown. 
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Pharmaceuticals are designed to target specific metabolic and molecular pathways in 
humans and animals, but they often have important side effects as well. When 
introduced into the environment they may affect the same pathways in animals having 
identical or similar target organs, tissues, cells or biomolecules. For many of them 
homologue forms have been found in lower animals, however, there might also be 
differences in the specificities of targets, effects and species. For many 
pharmaceuticals specific modes of actions are unknown and often different modes of 
action may occur for a single substance. This is one reason for the difficult analysis of 
specific toxicities in lower animals. Despite this, toxicity experiments should be targeted 
and designed for specific targets of the pharmaceutical, based on the assumption of 
similarity of modes of actions. However, current toxicity testing is not designed in this 
way, as rather general and established test systems and traditional organisms 
according to guidelines are being used and traditional end points such as mortality are 
assessed. 
 
Acute toxicity tests are regularly performed according to established guidelines (e.g. 
OECD, U.S. EPA, ISO) using established laboratory organisms such as algae, 
zooplankton and other invertebrates and fish. These data are ultimately used for 
ecological risk assessments. Due to animal welfare and screening purposes, in vitro 
analyses are becoming more important and they may be an alternative for the first 
screening and assessment of acute toxicity (see chapter 2).  
 
For the assessment of chronic effects of pharmaceuticals to aquatic species, it is 
important to investigate key targets as well as different organisms. More specific 
investigations including analysis of possible targets of the pharmaceutical or over 
different life stages are lacking or have only rarely been performed. Only for the 
synthetic steroid ethinylestradiol (EE2) contained in the contraceptive pills life-cycle 
analysis have been performed. Estrogenic effects were found at concentrations as low 
as 1 ng/L (Brian et al. 2005; Länge et al. 2001; Parrott and Blunt 2005). 
 
 
Objectives 
The aim of this dissertation was the investigation and assessment of effects of human 
pharmaceuticals in an in vitro model system for fish, the stable cell line PLHC-1 
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(Poeciliopsis lucida hepatocellular carcinoma). Environmentally important 
pharmaceuticals as well as pharmaceuticals exhibiting specific modes of action and 
representing different therapeutic classes were chosen. Only little is known about 
effects of human pharmaceuticals to the aquatic environment. Therefore, established 
endpoints as well as new, mechanism-based endpoints were investigated. Further, the 
reliability and limitations of the used in vitro systems were critically evaluated and 
correlated to available in vivo data.  
 
The areas of research included the assessment of cytotoxicity as established endpoint, 
investigations on the interactions of pharmaceuticals with ABC-transporters, which are 
involved in the efflux of xenobiotics as final step in the detoxification process, and the 
cloning and functional characterisation of PPARs in PLHC-1 cells.  
 
Cytotoxicity as established endpoint 
Acute toxicity tests with fish are used in the environmental risk assessment for general 
rankings of substances. These in vivo studies provide only limited information as the 
relevance of the findings is not related to the chronic exposure situation in the 
environment. The acute effect concentrations are generally a factor of 1x106 higher 
than environmental concentrations. We hypothesize that fish cell lines can partly 
replace in vivo acute tests at least for screening purposes as most substances act by 
an unspecific mode of toxic action and therefore, cytotoxicity in fish cell lines should 
correlate with acute toxicity in vivo. Further, unspecific cytotoxicity has been found to 
correlate with the physicochemical property of the compounds such as the partition 
coefficient LogD; a deviation from this correlation can indicate specific cytotoxicity. We 
tested 34 pharmaceuticals from different classes of modes of action in two fish cell 
lines (PLHC-1 and RTG-2) and with two different cytotoxicity assays. We correlated the 
effect concentrations between the cell lines as well as between the cytotoxicity assays 
to first assess the reliability of fish cell lines and cytotoxicity assays. Subsequently, the 
partition coefficient LogD of the pharmaceuticals as well as data from in vivo Daphnia 
and fish tests was correlated to the effect concentrations of the cell lines. 
 
Effects of pharmaceuticals on ABC-transporters 
ABC-transporters are involved in the detoxification process by excreting a broad range 
of xenobiotics and their metabolites from the cell. The development of a resistance 
towards substances like cytostatics is called MultiDrug Resistance (MDR) mechanism 
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and is well documented in mammals; in aquatic organisms, MDR came into focus when 
populations of aquatic organisms were observed that were able to survive in highly 
polluted environments. This phenomenon was soon termed MultiXenobiotic Resistance 
mechanism (MXR). In order to test whether a classical MDR mechanism also exists in 
fish cells, we tried to select a doxorubicin-resistant PLHC-1 subclone by exposure of 
normal PLHC-1 cells to doxorubicin. The resulting PLHC-1 cells (PLHC-1/dox) showed 
the expected characteristics like overexpression of P-gp1 and resistance towards 
several cytostatics, and thus, represent a model system for the investigation of P-gp1 
driven mechanisms. 
 
The tested cytostatics used in the study on MDR mechanisms in the PLHC-1 cells 
revealed similar specificities as the one described in human cells. We concluded that 
other pharmaceuticals might also have similar effects in PLHC-1 cells like in human 
systems. We screened 33 pharmaceuticals for inhibitory effects in the wild type PLHC-
1 cells as well as in the PLHC-1/dox cells. Substances that inhibit the efflux transport 
change also the bioavailability of substrates, thus leading to more sensitive effects e.g. 
modulation of cytotoxicity. We investigated such effects in co-exposure studies if 
inhibitors can change cytotoxicity of P-gp1 substrates in PLHC-1/dox cells. 
 
Cloning and functional characterisation of PPARs 
We proposed that pharmaceuticals act also in aquatic organisms on specific targets 
like enzymes, transporters and receptors. In humans, the target of fibrates like 
bezafibrate, clofibric acid (a metabolite of several fibrates), fenofibrate and gemfibrozil 
is PPARα. We proposed that all receptors belonging to the PPAR-system (PPARα, 
PPARβ, PPARγ and RxR) are expressed and functional in the PLHC-1 cells. 
Therefore, we tried to clone the receptors and investigated effects of fibrates on the 
expression of PPARs as well as on the activity of the peroxisomal enzyme fatty acyl 
CoA oxidase. 
 
To prove the correlation of in vitro assays in PLHC-1 cells with findings in vivo we 
designed 14-21 days exposure experiments with fathead minnows using bezafibrate 
and clofibric acid as test substances. In addition to common endpoints like mortality, 
length, weight and numbers of eggs layed by adult fish, the expression of PPARα and 
the FAO-activity was measured. 
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The thesis is presented in 7 chapters, examining and assessing effects of 
pharmaceuticals in aquatic organisms: 
 
Chapter 1: Here a general introduction to the topic and the thesis is given. 
 
Chapter 2: Based on the fact that only little is known on effects of human 
pharmaceuticals in fish we assess the cytotoxicity as established endpoint in the two 
fish cell lines PLHC-1 and RTG-2 (rainbow trout gonadal) and correlate the data with 
physicochemical properties of the pharmaceuticals as well as with acute toxicity data 
for Daphnia magna and fish from the literature. 
 
Chapter 3: This chapter describes the selection of a doxorubicin-resistant PLHC-1 
subclone (PLHC-1/dox) characterized in an about 40-fold overexpression of P-
glycoprotein (ABCB1). Further, the functional activity found in PLHC-1/dox is compared 
to wild type cells PLHC-1/wt using different cytostatics as substrates and different 
model inhibitors. The subclone PLHC-1/dox represents a valuable model for the 
investigation of transport mechanisms mediated by the P-glycoprotein. 
 
Chapter 4: Effects of pharmaceuticals on ABC-transporters are investigated in PLHC-
1/wt and PLHC-1/dox cells. In efflux assays and by fluorescent microscopy, the 
inhibitory potential of pharmaceuticals is assessed in both subclones using two 
different fluorescent model substrates. Further, the potential of pharmaceuticals to 
modulate cytotoxicity in PLHC-1/dox cells is assessed in co-exposure experiments. 
 
Chapter 5: Fibrates are designed to target peroxisome proliferator-activated receptor 
alpha (PPARα) in humans. Here we describe the expression of all three PPAR 
subtypes (PPARα, PPARβ, PPARγ) and of the retinoid X receptor (RxR) that is 
required for a functional response by the PPAR pathway. In addition, after exposure of 
fibrates to PLHC-1 cells, an induction of the expression of PPARα and PPARγ is found 
as well as an increased activity of the peroxisomal enzyme fatty acyl oxidase that is 
regulated by PPARα and that is involved in the β-oxidation pathway of fatty acids. 
 
Chapter 6: This chapter focuses on effects of the lipid lowering agents bezafibrate and 
clofibric acid mainly on liver enzymes in fish (fathead minnows) after 14 and 21 days of 
exposure. We focused particularly on peroxisome proliferator-activated receptors and 
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related enzymes. In addition, we monitored reproductive parameters such as egg 
production and vitellogenin induction to investigate the hypothesis, whether potential 
adverse effects of these human pharmaceuticals may be also linked to reproductive 
toxicity. We investigated whether both the expression of PPARα and the fatty-acyl 
oxidase (FAO) activity were affected in liver of fathead minnows and compared the 
effects to those found in PLHC-1 cells.  
 
Chapter 7: Here, a general conclusion and outlook is given. 
 
This thesis reveals new grounds and insights towards a mechanism-based approach in 
the evaluation of ecotoxicological effects of pharmaceuticals in aquatic organisms. For 
the first time the expression of PPARs was demonstrated in conjunction with its 
functionality in an in vitro system for fish, thus allowing further investigations of their 
mechanism, function and regulation. In vivo exposure assays in fathead minnow with 
two fibrates showed that these substances can have slight effects on the activity of 
peroxisomal enzymes after exposure for 14-21 days. Efflux transporters from the ABC-
family play an important role in the elimination of compounds from cells. A doxorubicin-
resistant PLHC-1 subclone characterized by an overexpression of P-gp1 (ABCB1) was 
selected. Effects of pharmaceuticals on efflux transporters, especially P-gp1, are 
described. The modulation of these transporters changes the intracellular concentration 
of a compound, thus leading to effects at lower concentrations. Finally, we showed that 
the cytotoxicity of pharmaceuticals in two in vitro model systems correlates well with 
their physicochemical properties and with in vivo data. Thus, in vitro cytotoxicity assays 
in fish cell lines can be a valuable tool in the risk assessment to estimate and rank the 
acute toxicity of compounds in order to minimize acute toxicity tests in vivo. 
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Abstract 
There is need for a better understanding of the ecotoxicity of pharmaceuticals present 
in aquatic systems as only little is known about their potential acute and chronic toxicity 
to aquatic organisms. In our work we evaluated the in vitro cytotoxicity of 34 common 
pharmaceuticals from different classes and with different modes of action using the 
mitochondrial thiazolyl blue tetrazolium bromide (MTT) reduction and neutral red (NR) 
uptake assays in the two fish cell lines, PLHC-1 and RTG-2. Cytotoxicity was found for 
21 pharmaceuticals with EC50-values ranging from 2.1 µM (1.14 mg/L) (doxorubicin) to 
8.66 mM (1200 mg/L) (salicylic acid). There was no significant difference between the 
MTT and NR assays except for an increase in absorption observed with four 
pharmaceuticals at low concentrations in the MTT assay with PLHC-1 cells indicating a 
hormesis effect. The comparison of the cell lines revealed that the PLHC-1 cell line was 
slightly more sensitive than the RTG-2 cell line, showing cytotoxicity at smaller 
concentrations. The cytotoxicity of pharmaceuticals showed a correlation with their 
LogD values at physiological conditions (pH 7.0). A correlation between the in vitro 
data and in vivo data was found for Daphnia magna, but not for fish due to insufficient 
and heterogeneous data. Our work provides an indication that in vitro cytotoxicity 
assays with fish cell lines could be suited for the first screening of the acute in vivo 
toxicity of pharmaceuticals, thereby contributing to the reduction of in vivo experiments. 
Further investigations with a larger set of pharmaceuticals are needed to strengthen 
the reliability of the assays and to validate the correlation with in vivo data. 
 
 
Key words: Pharmaceuticals, cytotoxicity, fish cell lines, comparison in vitro-in vivo, 
aquatic environment, REACH 
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Introduction 
Pharmaceuticals have frequently been detected in their parent form or as metabolites 
in effluents of sewage treatment plants, surface waters, ground waters and even in the 
sea (for reviews (Daughton and Ternes 1999; Fent et al. 2006; Halling-Sorensen et al. 
1998)). Several  monitoring studies have shown that many pharmaceuticals from 
different therapeutic classes are present in surface waters with median concentrations 
in the range of ng/L up to μg/L (Calamari et al. 2003; Kolpin et al. 2002; Wiegel et al. 
2004). At present, little is known about their potential adverse effects on aquatic 
organisms and ecosystems, despite their ubiquitous occurrence and high biological 
activity (Fent et al. 2006). 
 
Acute toxicity tests with algae, Daphnia and fish are widely used for assessing the 
potential impact of pharmaceuticals on the environment, but there is a lack of 
appropriate chronic toxicity experiments that focus on potential long-term effects of 
pharmaceuticals. Moreover, toxicity tests are generally not designed for the specific 
modes of actions, and known side-effects in humans are not considered (Fent et al. 
2006). However, chronic toxicity studies with diclofenac have shown that this 
compound induces effects on the kidneys of fish at environmentally relevant 
concentrations (Schwaiger et al. 2004) that resemble those in humans and in vultures 
on the Indian subcontinent (Oaks et al. 2004). Recently, the potential impact of 
pharmaceutical mixtures on aquatic life was shown in a study, where a complex 
mixture of 13 therapeutic drugs in the range of environmental concentrations caused a 
decrease in cell proliferation on human embryonic cells (Pomati et al. 2006). 
 
For assessing the acute toxicity of pharmaceuticals to aquatic organisms, in vitro 
systems are rarely considered (Laville et al. 2004). This also holds true for chronic 
toxicity parameters that may be important for long-term effects. In the case of 
estrogenic pharmaceuticals, the recombinant yeast estrogen receptor assay (YES) has 
been demonstrated among other systems to be very important in the screening of pure 
compounds (Routledge and Sumpter 1996) and environmental samples (Desbrow et 
al. 1998). Using this assay, some widely used pharmaceuticals were identified as 
having estrogenic activity (Fent et al. in press).  This in vitro assay has been 
demonstrated to be related to in vivo effects in fish (Kunz et al. 2006), and therefore in 
vitro systems may be indicative for effects in vivo.  Furthermore, for animal welfare and 
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due to economic implications it is important to consider in vitro assays or other 
procedures to reduce the number of acute fish tests for assessing the ecotoxicity of 
chemicals. Recently, a strategy has been proposed to reduce fish numbers in acute 
toxicity tests of pharmaceuticals (Hutchinson et al. 2003).  
 
The environmental safety assessment of pharmaceutical ingredients may require acute 
ecotoxicity data as a base set for new drugs (FDA-CDER 1998). The European 
Medicines Evaluation Agency (EMEA) proposed a draft guideline on the environmental 
risk assessment of medicinal products for human use (EMEA 2005).  Depending on the 
predicted environmental concentration (PEC), the ecotoxicological assessment may 
consist of a base set of algal growth inhibition test, Daphnia reproduction test, and fish 
early life stage test, when the initial PEC is > 0.01 μg/L.  In these guidelines, no in vitro 
assays are considered. However, with the White Paper on the strategy for a future 
chemicals policy in the European Union (EUROPEAN UNION 2001) emphasis is 
placed on the reduction of animal tests and on the development and application of non-
animal in vitro testing. 
 
A critical step towards the use of in vitro assays as models for in vivo animal 
experiments is the correlation between in vitro and in vivo activities. Several fish cell 
lines from different species and different organs have been used for cytotoxicity assays 
(Fent 2001; Segner 1998) and they have been shown to estimate the basal toxicity 
equally as well as mammalian cells when correlating the EC50 values (Castano and 
Gomez-Lechon 2005). In several cell lines and different fish species, good correlations 
between cytotoxicity in vitro and lethality in vivo have been reported (Brüschweiler et al. 
1995; Castano et al. 1996; Fent 2001; Saito et al. 1991; Segner and Lenz 1993). This 
has been demonstrated for different compounds including phenols, toluenes, 
pesticides, metals, antimicrobials, organotins, some pharmaceuticals and others 
(Babich and Borenfreund 1987; Babin and Tarazona 2005; Brüschweiler et al. 1995; 
Castano and Gomez-Lechon 2005; Ni Shuilleabhain et al. 2004; Saito et al. 1991). 
Furthermore, the cytotoxicity has been assessed in mixtures of compounds and 
environmental samples (Babin et al. 2001; Castano et al. 1994; Hollert et al. 2000). 
High reproducibility, fast and economic use of fish cell cytotoxicity assays and potential 
correlation with in vivo acute toxicity are promising properties associated with these in 
vitro assays.  
 
 Chapter 2 
 
 33
The aim of this work was to investigate the cytotoxicity of a series of 34 
pharmaceuticals from different therapeutic classes and modes of action by applying the 
thiazolyl blue tetrazolium bromide ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide; MTT) (Mosmann 1983) and the neutral red (NR) assay (Borenfreund and 
Puerner 1985). Both assays are widely used for investigations of cytotoxicity in many 
different cell lines and proven for their accurate cytotoxicity assessment (Brüschweiler 
et al. 1995). Moreover, we compared both the sensitivity of the two assays and the cell 
lines PLHC-1 and RTG-2, and evaluated whether the cytotoxicity of a given compound 
was correlated with its LogD value at physiological conditions (pH 7.0) and with the 
acute toxicities in vivo of fish and Daphnia. Our study gives in vitro toxicity data on a 
series of important pharmaceuticals that may serve for toxicity identification and initial 
environmental assessment. 
 
 
Materials and Methods 
Chemicals 
Calcium chloride, fetal bovine serum (FBS), glycine, HEPES, neutral red, 
paraformaldehyde, and thiazolyl blue tetrazolium bromide (MTT) were purchased from 
Sigma-Aldrich (Switzerland). Dulbeccos minimum essential medium with F-12 nutrient 
mixture (DMEM/F12) with and without phenol red, trypsin/ethylenediamine tetraacetic 
acid (EDTA), L-glutamine and penicillin G/streptomycin were obtained from LuBio 
Science GmbH (Switzerland). 
 
Acebutolol hydrochloride (>99%), caffeine (≥ 98.5%), cimetidine (≥ 98%), clofibric acid 
(97%), fenofibrate (≥ 99%), furosemide (≥ 98%), gemfibrozil (≥ 99%), 
hydrochlorothiazide (≥ 99%), hydroxytamoxifen (≥ 98%), ibuprofen (≥ 98%), mefenamic 
acid (> 99%), metformin hydrochloride (≥ 98%), methotrexate hydrate (> 98%), 
naproxen (98%), phenazone (≥ 98%), paracetamol (≥ 99%), (±)-propranolol 
hydrochloride (≥ 99%), (S)-(−)-propranolol hydrochloride (≥ 99%), ranitidine 
hydrochloride (> 99%), salicylic acid (≥ 99%), and tamoxifen (≥ 99%) were purchased 
from Sigma-Aldrich (Switzerland), doxorubicin hydrochloride (≥ 99%), rofecoxib 
(98.7%), and sildenafil base (≥ 99%) from Sequoia Research Products Ltd. (United 
Kingdom), and pravastatin (98.7%) from ChemPacific Corporation (USA). Bezafibrate 
(≥ 99.3%), and diazepam (≥ 99%) were kindly supplied by F. Hoffmann-La Roche Ltd 
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(Switzerland), atenolol (≥ 99%), atorvastatin calcium (≥ 99%), carbamazepine (≥ 99%), 
diclofenac sodium salt (≥ 99%), fluoxetine (≥ 99%), (±)-metoprolol tartrate (≥ 99%), and 
simvastatin (98.7%) by Novartis International AG (Switzerland).  
Stock solutions of all pharmaceuticals where soluble were prepared in DMSO at a 
concentration of 500 mM, otherwise substances were diluted corresponding to their 
solubility. For the cytotoxicity assays, stock solutions were diluted at least 50-times in 
the buffered cell culture medium (20 mM HEPES/pH 7.2) resulting in a maximal DMSO 
concentration of 2%, which has been shown not to be cytotoxic (data not shown). 
Further concentrations were prepared by serial dilution at a ratio of 1:1. All 
concentrations are nominal concentrations. 
 
Cell culture 
PLHC-1. The fish hepatoma cells PLHC-1 (Poeciliopsis lucida hepatoma cell) kindly 
supplied by L.E. Hightower (Ryan and Hightower 1994) were grown in DMEM/F12 
supplemented with 5% FBS, 20 mM HEPES/pH 7.2  and 50 U ml−1 of penicillin 
G/50 μg ml−1 streptomycin in a humidified incubator with 5% CO2 at 30°C. Cells were 
usually split every 4 days by dissociating with 0.05% (w/v) trypsin and 0.5 mM EDTA 
and subcultured at split ratios of about 1:6. 
 
RTG-2. The rainbow trout gonadal cell line (RTG-2) was grown in DMEM/F12 
supplemented with 5% FBS, 20 mM HEPES/pH 7.2 and 50 U ml−1 penicillin 
G/50 μg ml−1 streptomycin at room temperature (21±2°C). Cells were usually split every 
7 days by dissociating with 0.05% (w/v) trypsin and 0.5 mM EDTA and subcultured at 
split ratios of about 1:3. 
 
Cytotoxicity assays 
For the cytotoxicity assays, cells were split and plated at densities of 
6.0 x 105 cells ml−1 (PLHC-1) and 3.5 x 105 cells ml−1 (RTG-2) in 96-well tissue-culture 
microtiter plates (Huber & Co., Switzerland). Before exposure to pharmaceuticals, the 
sealed microtiter plates with cells were incubated for 24 h. Then, serial dilutions of 
pharmaceuticals prepared as described above were added in quadruplicates and the 
cells were incubated for another 24 h.  
Wells without cells, cells with cell culture medium alone, cells with 2% DMSO (negative 
controls) and cells with a cytotoxic concentration of 5 mM naproxen or 0.16 mM 
fluoxetine (positive controls) were used as controls on each microtiter plate. The 
 Chapter 2 
 
 35
cytotoxicity was determined in at least three independent experiments in 
quadruplicates for all pharmaceuticals. 
 
 
MTT Assay. The MTT assay is based on the uptake of thiazolyl blue tetrazolium 
bromide (MTT) and its following reduction in the mitochondria of living cells to MTT 
formazan while dead cells are almost completely negative in this cleavage activity 
(Mosmann 1983). After 24 h of exposure to individual pharmaceuticals, 20 μl MTT 
solution (5 mg MTT ml−1 PBS) were added to each well. The microtiter plates were 
incubated for 4 h before cell culture medium with pharmaceuticals and MTT solution 
was removed and 200 μl DMSO were added to each well. After shaking for 10 min at 
450 rpm, 25 μl Sorensen’s Glycine buffer (50 mM glycine, 50 mM sodium 
chloride/NaOH pH 10.5) was added to each well. Absorption was measured 
spectrophotometrically at 540 nm on a microplate reader (GENios, Tecan, 
Switzerland). Cell viability was expressed as fraction of negative control (cells with 
medium only). 
 
NR Assay. The NR assay is based on the uptake and accumulation of NR in the 
lysosomes of living cells. Damaged cells have altered uptake rates and dead cells are 
not able to retain the dye (Krone et al. 2005; Ryan and Hightower 1994). The NR assay 
was performed as described before (Brüschweiler et al. 1995; Ryan and Hightower 
1994). After 24 h of exposure to individual pharmaceuticals, the medium was removed, 
the cells were washed with PBS, 200 μl NR solution (50 μg/ml medium) was added to 
each well and incubated for another 3 h. Afterwards, the NR solution was removed. NR 
taken up by cells was extracted from the cells and solubilised with isopropanol. Plates 
were read spectrophotometrically at 540 nm on a microplate reader (GENios, Tecan, 
Switzerland). Cell viability was expressed as fraction of negative control (cells with 
medium only).  
 
Data analysis 
Data were graphically and statistically evaluated with GraphPad Prism 4 (GraphPad 
Software, Inc. San Diego, CA). The raw data were logarithmically transformed. For 
comparison of the data evaluated in independent assays, the data were normalized to 
a cytotoxic concentration of naproxen or fluoxetine (positive controls) and to cells 
grown in medium only (negative control). Wherever applicable, the data were fitted with 
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the four-parameter logistic equation (Hill equation), a nonlinear regression model. In 
those cases where the data could not be fitted to assign an EC50-value but where 
cytotoxicity was evident, the EC50-value was deduced from the normalized data. 
 
 
Results 
The pharmaceuticals included in this study were chosen on the basis of their 
occurrence in the environment and their ecotoxicological potential. Thus, compounds 
most commonly found in the aquatic environment (Fent et al. 2006) and compounds 
exhibiting specific modes of action were selected. A series of 34 pharmaceuticals (Tab. 
1) were chosen from different therapeutic classes including analgesics and anti-
inflammatory drugs, blood lipid lowering drugs (fibrates, statins), β-blockers, 
neuroactive compounds (antiepileptic, selective serotonin reuptake inhibitor) and 
various others (cytostatic drugs, anti-acidic, diuretics). This broad spectrum of drugs 
with different characteristics allowed a comprehensive cytotoxicity assessment, and 
both a comparison between different cytotoxicity assays and the different fish cell lines 
PLHC-1 and RTG-2. 
 
Cytotoxicity was determined for 21 pharmaceuticals using the MTT assay in PLHC-1 
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Figure 1. Ranges of cytotoxicity of doxorubicin (EC50 = 2.60 μM; 1.41 mg/L), fluoxetine (EC50 = 
20.5 μM; 6.34 mg/L), diazepam (EC50 = 0.36 mM; 103.4 mg/L), and furosemide (EC50 = 3.4 mM; 
1130 mg/L) observed in the MTT assay with PLHC-1 cells. Standard error of means are indicated. 
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cells. Acebutolol, carbamazepine, fenofibrate, and ranitidine exhibited only low 
cytotoxicity, i.e. the percentage of dead cells was > 50% at the highest concentration 
measured, and nine compounds (atenolol, caffeine, cimetidine, metformin, metoprolol, 
methotrexate, paracetamol, phenazone, sildenafil) showed no measurable cytotoxicity 
(Table 1).  Figure 1 illustrates the whole range of concentrations, where complete 
cytotoxicity was found, as exemplified by the four pharmaceuticals doxorubicin, 
fluoxetine, diazepam and furosemide. Doxorubicin was the most toxic compound 
(EC50-value 2.1 μM ≈ 1.14 mg/L), and the diuretic furosemide with a 1,000-fold higher 
EC50-value (3.4 mM ≈ 1130 mg/L) was one of the least toxic compounds exhibiting a 
full dose response curve. The EC50-values of all compounds are given in Table 1. 
 
Figure 2 shows the concentration-dependent cytotoxicity of pharmaceuticals of different 
therapeutic classes. Within each class, cytotoxicity of the various compounds varied 
over a considerable range. Within the class of analgesics and anti-inflammatory drugs 
(Fig. 2A) the EC50-values ranged from 0.24 mM (≈ 77.3 mg/L) for diclofenac to 
7.24 mM (≈ 1.0 mg/L) for salicylic acid in the MTT assay. Paracetamol and phenazone 
did not induce cytotoxicity. The highest tested concentration for most pharmaceuticals 
was 10 mM (≥ 1500 mg/L), at which the DMSO concentration did not exceed 2%. 
Figure 2. Cytotoxicity of different pharmaceutical classes in the MTT assay with PLHC-1 cells. 
A, nonsteroidal-antiinflammatory drugs: diclofenac, ibuprofen, mefenamic acid, paracetamol, 
rofecoxib. B, fibrates and statins: bezafibrate, clofibric acid, gemfibrozil, atorvastatin, pravastatin, 
simvastatin. C, β-blockers: acebutolol atenolol, metoprolol, propranolol. D, compounds with 
different therapeutical use: furosemide, hydrochlorothiazide, metformin, tamoxifen. Standard 
error of means are indicated. 
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Among the class of lipid lowering drugs, statins showed higher cytotoxicity than fibrates 
(Fig. 2B). However, pravastatin exhibited only slight cytotoxicity in the highest 
concentrations (estimated EC50-value of 5.5 mM ≈ 2330 mg/L). In contrast, only low 
cytotoxicity was observed with bezafibrate, fenofibrate, gemfibrozil and the metabolite 
clofibric acid (Table 1). The cytotoxicity of β-blockers (Fig. 2C) was not pronounced 
with the exception of propranolol (EC50-value 0.16 mM ≈ 46.7 mg/L). Acebutolol, 
atenolol and metoprolol showed slight cytotoxicity in the highest concentrations, but an 
EC50-value could not be assessed. The cytotoxicity of neuroactive compounds and 
various other pharmaceuticals is depicted in Figures 1 and 2D. Tamoxifen and its 
metabolite hydroxy-tamoxifen exhibited high cytotoxicity with an EC50-value of 20 μM 
(≈ 7.4 mg/L) and 14 μM (≈ 5.4 mg/L), respectively. For carbamazepine, caffeine, 
cimetidine, metformin, methotrexate, ranitidine, and sildenafil, no EC50-value could be 
established.  
 
In order to compare the applicability and accuracy of different cytotoxicity assays, the 
34 pharmaceuticals were evaluated in the NR assay. The cytotoxicities in both assays 
were very similar. The EC50-values were within a factor less than two (Tab. 1). 
However, the COX II-inhibitor rofecoxib showed cytotoxicity in the MTT, but not in the 
NR assay. The largest difference between the assays was found with hydroxy-
tamoxifen (EC50-value of 13.8 μM and 46.4 μM in the MTT and NR assay, 
respectively). Figure 3A illustrates typical concentration dependent cytotoxicity curves 
for diclofenac and clofibric acid from both assays and Table 1 demonstrates that the 
EC50-values for these and other compounds are very similar. Figure 3B depicts the 
logarithmic EC50-values of both assays that were plotted and fitted with linear 
Figure 3. Comparison of MTT and NR assay. A, Cytotoxicity of diclofenac and clofibric acid. B, 
Linear regression of the Log EC50-values in the MTT and the NR assay. Dotted line shows a 
1:1 correlation where Log EC50 (MTT) = Log EC50 (NR). Standard error of means are 
indicated. 
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regression (Fig. 6A). The MTT and NR assays yielded a significant correlation 
(R = 0.9809; P < 0.0001) and a regression equation (y = 1.0378x – 0.009; R2 = 0.9686) 
that was close to the ideal case of y = x (y corresponds to log EC50 (MTT assay), x 
corresponds to log EC50 (NR assay)).  
 
In a second series of experiments, pharmaceuticals were evaluated in rainbow trout 
RTG-2 cells using the MTT assay. This allowed a comparison of cell lines of different 
origin and cultivation conditions. Figure 4A illustrates representative cytotoxicity curves 
of a few compounds. There was a significant difference in the cytotoxicities of 
pharmaceuticals between the cell lines. Most of the EC50-values in the RTG-2 cells 
were slightly higher than in PLHC-1 cells which indicates a higher sensitivity of PLHC-1 
cells. Exceptions were bezafibrate, propranolol, hydrochlorothiazide, and tamoxifen 
showing smaller values with RTG-2 cells up to a factor of two (Tab. 1). Salicylic acid 
was the only pharmaceutical where an EC50-value (7.24 mM) could be determined in 
the PLHC-1, but not the RTG-2 cell line. However, non-cytotoxic pharmaceuticals in 
PLHC-1 cells were also not cytotoxic in RTG-2 cells so a significant correlation was 
Figure 4. Comparison of cytotoxicity between PLHC-1 and RTG-2 cells. A, Cytotoxicity of 
clofibric acid, atorvastatin and diazepam. B, Linear regression of the Log EC50-values from 
PLHC-1 and RTG-2 cells in the MTT assay. Dotted line shows a 1:1 correlation where Log EC50 
(PLHC-1) = Log EC50 (RTG-2). Standard error of means are indicated.
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Figure 5. Hormesis effect in the 
MTT assay in PLHC-1 cells with 
gemfibrozil, ibuprofen, tamoxifen 
and OH-tamoxifen. Standard error 
of means are indicated. 
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found (R = 0.9317; P < 0.0001). The higher sensitivity of PLHC-1 compared to RTG-2 
cells is shown in Figure 4B. The intercepts of the linear regression and the model case 
(x = y; x corresponds to log EC50 (PLHC-1), y corresponds to log EC50 (RTG-2)) 
showed a statistically significant difference (P < 0.02). The equation of the linear 
regression was y = 1.0717x + 0.2614 (R2 = 0.868). 
 
Gemfibrozil, hydroxy-tamoxifen, tamoxifen, ibuprofen, and mefenamic acid exhibited a 
higher absorption (increased formation of formazan in mitochondria) at non-cytotoxic 
concentrations (Fig. 5). Whereas the increase was only slight for ibuprofen and 
mefenamic acid gemfibrozil, tamoxifen and hydroxy-tamoxifen exhibited a more 
pronounced effect with an increase of almost 150% compared to controls. This effect 
was only observed in the MTT assay in the PLHC-1 cells and is considered an 
indication of a hormesis effect (i.e. enhanced metabolic activity like uptake of 
compounds at sub-toxic levels). 
 
Figure 6 shows the correlation of the cytotoxicities of pharmaceuticals with their 
octanol-water partition coefficient LogD at physiological pH 7.0. The LogD coefficients 
were obtained from the SciFinder® Scholar (American Chemical Society) database. In 
the correlation analysis, the cytostatic drug doxorubicin and fluoxetine diverged 
apparently but also atorvastatin, propranolol and diclofenac deviated from the other 
compounds. The data without doxorubicin and fluoxetine showed a statistically 
Figure 6. Correlation between Log D and –Log EC50 in PLHC-1 cells (MTT assay). Doxorubicin 
and fluoxetine were not included in the analysis. Log D values were obtained from the databank 
SciFinder. 
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significant correlation (R = 0.9050; P < 0.0001) between the LogD and cytotoxicity. The 
linear regression (y = 0.3472x - 0.2832; R2 = 0.8116) of the data is shown in Figure 6. 
 
In order to evaluate whether in vitro cytotoxicity may be indicative for acute toxicity in 
vivo, the in vitro cytotoxicity in fish cell lines was compared to in vivo data derived from 
reported acute toxicity data in Daphnia and fish. For some pharmaceuticals, several 
48 h Daphnia data were found in the literature (clofibric acid, diazepam, diclofenac, 
ibuprofen, naproxen, and propranolol) so the geometric mean was taken for the 
correlation analysis. For caffeine, carbamazepine, cimetidine, metoprolol, paracetamol, 
and ranitidine the highest concentration showing cytotoxicity in vitro above the EC50 
was taken. The Daphnia EC50-values were about a factor of five lower than the in vitro 
data suggesting that the fish cell lines are more sensitive. The in vitro cytotoxicity 
(negative logarithmic EC50-values) and the acute Daphnia toxicity (negative 
logarithmic EC50-values) show a significant correlation (R = 0.9530; P < 0.0001). The 
linear regression equation was y = 0.8159x - 0.5268  (R2 = 0.9077) (Fig.  7A), but this is 
not the case with the acute toxicity data from fish where no significant correlation is 
found (R = 0.4852; P = 0.1552) (Fig. 7B). 
Figure 7. Comparison of in vitro fish cell cytotoxicity with in vivo data. A, correlation of 
cytotoxicity (-Log EC50) in PLHC-1 (MTT assay) and acute toxicity in Daphnia (-Log EC50) 
(data from: (Calleja et al., 1994; Lilius et al., 1994; Halling-Sorensen et al., 1998; Brooks et al., 
2003; Cleuvers, 2003; Cleuvers, 2004; Ferrari et al., 2004; Hernando et al., 2004; Kümmerer, 
2004)) B, correlation of cytotoxicity (-Log EC50) in PLHC-1 cells (MTT assay) and acute toxicity 
in fish (-Log LC50). In vivo fish data refer to different exposure times (24 h, 48 h, 96 h) and 
different fish species (data from (Knie et al., 1983; Halling-Sorensen et al., 1998; Ferrari et al., 
2004; Kümmerer, 2004; Straub, personal communication), Novartis MSDS for diclofenac (2005) 
and metoprolol (2004), and Roche (2002): MSDS for Valium (Diazepam), F. Hoffmann La Roche 
AG, Basel ). Numbers refer to the following pharmaceuticals; 1, bezafibrate; 2, caffeine; 3, 
carbamazepine; 4, cimetidine; 5, clofibric acid; 6, diazepam; 7, diclofenac; 8, fluoxetine; 9, 
gemfibrozil; 10, ibuprofen; 11, metoprolol; 12, naproxen; 13, paracetamol; 14, propranolol; 15, 
ranitidine; 16, salicylic acid. 
(A) (B)
 Chapter 2 
 
 43
Discussion 
In this study, the in vitro cytotoxicity of 34 pharmaceuticals and their metabolites have 
been assessed in the two fish cell lines, PLHC-1 and RTG-2, applying the MTT and NR 
assay. Half-maximal cytotoxicity (EC50-value) could be determined for 21 compounds, 
the remaining compounds showed no or only slight cytotoxicity even at the highest 
concentrations. The most toxic compound found in this study was the cytostatic drug 
doxorubicin exhibiting an EC50-value of 21 μM (≈ 1.14 mg/L) determined with the MTT 
assay in PLHC-1 cells. Compared to environmental concentrations, which are in the 
range of ng/L to μg/L, cytotoxicity occured at concentrations of about a factor 1’000’000 
higher. 
 
Despite the slightly different cytotoxic endpoints of the two cytotoxicity assays, the 
effects measured in the MTT as well as in the NR assay indicate a damage of the cell 
membranes. The uptake and retention of MTT and NR to the mitochondria and 
lysosomes, respectively, are prevented. So the result was expected that both 
cytotoxicity assays yielded nearly the same results with a high correlation (R = 0.98). 
Moreover, the cytotoxicity in both cell lines PLHC-1 and RTG-2 was very similar 
(R = 0.93), although PLHC-1 cells were slightly more sensitive than the RTG-2 cells 
(Fig. 4B). The reasons behind these slight differences may be related to the higher 
growth temperature and the faster proliferation (Clemedson et al. 1998a; Clemedson et 
al. 1998b) of the PLHC-1 cells (30°C) compared with the RTG-2 cells (21°C) or to a 
more pronounced metabolism of PLHC-1 cells. 
 
Our results demonstrate that the cytotoxicities of pharmaceuticals in both the NR and 
MTT assay are basically the same, and therefore, both cytotoxicity assays gave equal 
results. This is consistent with previous studies, where the EC50-values in the MTT 
and NR assay were in the same order of magnitude for a series of organotin 
compounds (Borenfreund et al. 1988; Brüschweiler et al. 1995), phenols (Fent and 
Hunn 1996), and an organophosphorus insecticide (Li and Zhang 2002). 
 
The cytotoxicity of some pharmaceuticals has previously been assessed in different 
cell lines. A comparison of cytotoxicities of chemicals including four pharmaceuticals 
showed similar sensitivities of mammalian and fish cell lines (Castano et al. (2005)). 
Our data with caffeine, diazepam, paracetamol and propranolol were also almost 
identical to the reported data. Laville et al. (2004) determined the cytotoxicity of 
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fenofibrate, fluoxetine, propranolol, diclofenac, and carbamazepine in PLHC-1 cells and 
primary cultures of rainbow trout hepatocytes. PLHC-1 cells seemed to be more 
sensitive than the primary cells. Our data correspond well with these data in case of 
fluoxetine, propranolol and diclofenac, with the exception of fenofibrate and 
carbamazepine, where we did not observe cytotoxicity. 
 
Five pharmaceuticals were found to lead to an increase in absorbance at low and non-
cytotoxic concentrations in the MTT assay in the PLHC-1 cells. This is interpreted as a 
hormesis effect, which has already been observed for example after exposure of 
PLHC-1 cells to cadmium (Ryan and Hightower 1994), and of RTG-2 cells to zinc salts 
(Ni Shuilleabhain et al. 2004). Often, hormesis is associated with an increase in cell 
proliferation compared to controls (Ni Shuilleabhain et al. 2004), but this could not 
explain why this effect is found in our study with the MTT assay and PLHC-1 cells only. 
Possibly the uptake of MTT is increased or the dehydrogenase enzyme responsible for 
the cleavage of the MTT in the mitochondria is increasingly being produced in PLHC-1 
cells. The lack of this effect in RTG-2 cells may be related to a lower metabolic activity. 
 
The cytotoxicity of the pharmaceuticals has been found to be related to their LogD-
value (Fig. 6). Baseline toxicity is believed to be a result of non-specific disturbance of 
membrane integrity and functioning as a result of the partitioning of chemical 
compounds into biological membranes (van Wezel and Opperhuizen 1995). The LogD-
value predicts the situation in the cytotoxicity assays more accurate than the KOW-value 
as it considers the partition of a compound at a specific pH, in our case at physiological 
conditions with pH 7.0. The EC50-values of the pharmaceuticals showing a correlation 
with their LogD indicates that the cytotoxic effect is probably due to non-specific toxicity 
or narcosis. The cytostatic drug doxorubicin and the neuroactive compound fluoxetine 
exhibited a clearly lower EC50-value than expected from their LogD-value. Also 
atorvastatin, propranolol and diclofenac deviated from the other compounds. 
Fluoxetine, propranolol and diclofenac are known to exhibit rather thigh acute and/or 
chronic toxicity on aquatic organisms (Fent et al. 2006). About the statin atorvastatin 
and the cytostatic doxorubicin only few is known. The high cytotoxic effect of 
doxorubicin is due to its intercalation in the DNA and RNA thereby interrupting the DNA 
and RNA synthesis. Furthermore the inhibition of topoisomerase II and the formation of 
radicals leads to DNA strand breaks (Forth et al. 2001), and hence inhibition of cell 
proliferation. Therefore a specific mode of toxic action probably occurs for five 
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pharmaceuticals out of 34 assessed in this study. All other substances show a clear 
correlation with their LogD value indicating cytotoxicity due to non-specific action or 
narcosis (R = 0.9805; P < 0.0001).  
 
Our in vitro data in fish cell lines were found to correlate to in vivo data in Daphnia 
(Fig.7A). In the correlation, pharmaceuticals acting in a non-specific way as well as in a 
specific way were represented. This suggests that the mechanism of toxicity in vitro 
and in vivo is the same. Acute toxicity data from Daphnia mainly determined at an 
exposure time of 48 h were less heterogeneous than data from fish, for which only a 
sparse set of acute in vivo data was found in the literature (Fent et al. 2006). 
Furthermore, the fish data themselves are heterogeneous, showing high variability with 
species of fish, times of exposure and experimental conditions. Therefore, no 
correlation can be found between our in vitro data in fish cell lines and acute in vivo 
data in fish (Fig. 7B). The fact that a correlation exists with a more homogenous set of 
data in Daphnia suggests that in vitro cytotoxicity data may also be correlated with 
more homogeneous in vivo data from fish (if based on similar species and exposure 
time).  
 
Conclusion 
Our results show that fish cell lines are an excellent tool for cytotoxicity assessment of 
pharmaceuticals. Both the MTT and NR assay are equally well suited for the 
cytotoxicity assessment. The different cell lines showed cytotoxicity in a similar range, 
although PLHC-1 cells were slightly more sensitive than the RTG-2 cells. The EC50-
values of the compounds were correlated to the partition coefficient LogD of 
pharmaceuticals indicating that cytotoxicity was prevailing due to unspecific toxicity or 
narcosis. However, some pharmaceuticals known to exhibit higher toxicities on aquatic 
organisms deviated from the dataset indicating a specific mode of toxic action. 
 
A correlation is found with acute toxicity data from Daphnia, indicating that in vivo 
toxicity may be estimated from in vitro experiments in fish cells. The advantages of in 
vitro assays are their simple handling, high reproducibility, and the possibility to screen 
a large number of compounds in a short period of time. The MTT and NR assays used 
in this work are well established cytotoxicity assays that have already widely been 
applied to a broad set of different compounds (Babich and Borenfreund 1987; Babin 
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and Tarazona 2005; Brüschweiler et al. 1995; Castano and Gomez-Lechon 2005; Ni 
Shuilleabhain et al. 2004; Saito et al. 1991) and environmental samples (Babin et al. 
2001; Castano et al. 1994; Hollert et al. 2000). In the future, cytotoxicity assays in fish 
cell lines can be a valuable tool in the risk assessment to estimate and rank the acute 
toxicity of compounds in order to minimize acute toxicity tests in vivo. They may be 
included in a tiered approach to assess the ecotoxicity of pharmaceuticals, but may 
also gain importance in the toxicity assessment of chemicals in the future strategy of 
the European Union within the REACH concept. Further investigations are needed with 
a broader set of compounds and the correlation with in vivo data has to be further 
validated.  
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Abstract 
The development of the multidrug resistance (MDR) phenotype in mammals is often 
mediated by the overexpression of the P-glycoprotein1 (Pgp, ABCB1) or multidrug 
resistance associated protein (MRP)-like ABC transport proteins. A similar 
phenomenon has also been observed and considered as an important part of the 
multixenobiotic resistance (MXR) defence system in aquatic organisms. We have 
recently demonstrated the presence of ABC transporters in the widely used in vitro fish 
model, the PLHC-1 hepatoma cell line. In the present study we were able to select a 
highly resistant PLHC-1 sub-clone (PLHC-1/dox) by culturing the wild type cells in the 
presence of 1 µM doxorubicin. Using quantitative PCR a 42-fold higher expression of 
ABCB1 gene was determined in the PLHC-1/dox cells compared to non-selected wild 
type cells (PLHC-1/wt). The efflux rates of model fluorescent Pgp1 substrates 
rhodamine 123 and calcein-AM were 3- to 4-fold higher in the PLHC-1/dox in 
comparison to the PLHC-1/wt cells. PLHC-1/dox were 45-fold more resistant to 
doxorubicin cytotoxicity than PLHC-1/wt. Similarly to mammalian cell lines, typical 
cross-resistance to cytotoxicity of other chemotherapeutics such as daunorubicin, 
vincristine, vinblastine, etoposide and colchicine, occurred. Furthermore, cyclosporine 
A, verapamil and PSC833, specific inhibitors of Pgp1 transport activity, completely 
reversed resistance of PLHC-1/dox cells to all tested drugs, resulting in EC50 values 
similar to the EC50 values found for PLHC-1/wt. In contrast, MK571, a specific inhibitor 
of MRP type of efflux transporters, sensitized PLHC-1/dox cells, neither to doxorubicin, 
nor to any other of the chemotherapeutics used in the study. These data demonstrate 
for the first time that a specific, Pgp1 mediated doxorubicin resistance mechanism is 
present in the PLHC-1 fish hepatoma cell line. In addition, the fact that low micromolar 
concentrations of specific inhibitors may completely reverse a highly expressed 
doxorubicin resistance points to the fragility of Pgp1 mediated MXR defence 
mechanism in fish. 
 
Key words: Pgp1, fish cells, MXR, MDR, induction 
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Introduction 
The major obstacle to successful cancer treatment is tumour resistance to a wide 
spectrum of chemotherapeutics. The development of multidrug resistance (MDR) 
phenotype is characterized by the marked increase in tumour resistance to structurally 
different antineoplastic drugs (Ricardo, 2006). The MDR phenotype can arise as a 
result of different molecular mechanisms, like differential expression of topoisomerase 
IIα, subcellular redistribution of drug into lysosomes, induction of detoxifying enzymes 
or alterations of the genes and proteins involved in the control of apoptosis (Ades et al., 
2006; Gong et al., 2003; Townsend and Tew1, 2003; Kaufmann and Vaux, 2003). 
However, one of the major and most studied MDR mechanisms is the enhanced ability 
of tumour cells to actively efflux drugs, leading to lower concentrations inside the cells 
and lower toxic potential of chemotherapeutics (Bates, 2003). MDR associated with 
increased efflux of drugs is a result of overexpression of several members of the ATP-
binding cassette (ABC) family of membrane transport proteins. Through binding and 
hydrolyzation of ATP, ABC proteins obtain the energy necessary for active transport of 
their substrates across cell membranes. In mammals, the ABC superfamily of proteins 
is subdivided into seven families designated A through G 
(http://nutrigene.4t.com/humanabc.htm). Different mammalian models indicate that 
members from the ABCB1 (MDR, P-glycoprotein), ABCC (multidrug resistance 
associated proteins, MRPs) and ABCG2 (breast cancer resistance protein, BCRP) 
family are directly involved in the efflux of xenobiotics and/or their metabolites, 
representing the toxicologically most relevant ABC transport proteins (Leslie et al., 
2005). 
 
Because of its overexpression in various tumour tissues and cell lines the P-
glycoprotein 1 (Pgp1) became the first and best characterised ABC transporter. The 
Pgp1, product of the ABCB1 (MDR1) gene, is a 170 kD glycoprotein organised in two 
transmembrane domains (TMDs) and two nucleotide binding domains (NBDs). Each of 
the TMD consists of six alpha-helices which together form two substrate binding sites. 
The binding of a substrate results in the activation of one ATP-binding domain which 
hydrolyses ATP. This enables the conformational changes and leads to the extrusion of 
the substrate out of the cell (Callaghan et al., 2006). Through the described mechanism 
Pgp1 transports a wide range of structurally diverse xenobiotics, which have common 
properties such as moderate hydrophobicity, amphiphilicity, neutral or positive charge, 
a basic nitrogen atom and a high molecular weight (Litman et al., 2001). A vast number 
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of Pgp1 substrates are important anti-cancer agents, like anthracyclines (doxorubicin, 
daunorubicin, epirubicin), vinca alkaloids (vinblastine, vincristine), taxanes (paclitaxel, 
docetaxel), epipodophyllotoxins (etoposide, teniposide), topotecan, actinomycines 
(actinomycin D), alkylating agents (mytomycin C), peptide antibiotics (valinomycin, 
gramicidin) and antigout agents (colchicin) (Chan et al., 2004). 
 
The initial observation that many populations of aquatic organisms can survive in a 
highly polluted environment triggered the first identification of the Pgp-like efflux activity 
in aquatic organisms (Kurelec and Pivčević, 1989). The related phenomenon was soon 
termed the MultiXenobiotic Resistance mechanism (MXR; Kurelec, 1992) and the 
presence and function of Pgp1 (ABCB1) has been identified in almost 40 aquatic 
organisms investigated so far (Bard, 2000). Similarly to MDR in mammals, Pgp1 
catalyzes the efflux of many structurally different xenobiotics out of the cell, reducing 
their cytotoxicity (Britvić and Kurelec, 1999). The induction of Pgp-like proteins, as 
important feature of MXR, has been shown at protein and functional levels in different 
tissues of fish and mussels (Minier et al, 1993; Tutundjian et al., 2002; Smital et al., 
2003; Williams et al., 2003). However, it has been demonstrated that specific class of 
environmental compounds of both, natural or anthropogenic origin, can lead to potent 
inhibition of Pgp-like proteins (Smital et al, 2004). Through competitive or non-
competitive blockage of Pgp1 mediated efflux, those MXR inhibitors or 
chemosensitizers can cause the increased concentration of toxic compounds inside 
cells (Smital and Kurelec, 1998).  
 
Besides Pgp1, other proteins from the ABC family, especially MRPs (ABCC) and 
BCRP (ABCG2), have recently been detected in aquatic organisms (Cai et al., 2003; 
Sauerborn et al, 2004). Although members of the MRP family predominantly mediate 
efflux of xenobiotics or their conjugated metabolites (glutathiones, glucoronides or 
sulphate esters), some of them also transport physiological substrates such as 
hormones and bile salts (Deeley et al., 2006). Similarly, apart from transporting 
different xenobiotics (mitoxantrone, etoposide), BCRP (ABCG2) is also implicated in 
the transport of important physiological molecules like cholesterol, and most recently, 
its role in the metabolism of hem has been identified (Doyle et al., 2003; Latunde-Dada 
et al., 2006). Consequently, chemicals that can interact with either Pgp1 or the other 
efflux transporters like MRPs and BCRP, may not only directly modulate the toxic 
potential of different xenobiotics, but may also interfere with important physiological 
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processes. Due to that fact it is important to identify and characterize ABC proteins 
involved in the overall MXR phenomenon in aquatic organisms, as well as to develop 
relevant models that could be used in the detection and characterization of MXR 
inhibitors among conventional and emerging environmental pollutants. 
 
The PLHC-1 hepatoma cell line derived from topminnow (Poeciliopsis lucida) is 
frequently used in aquatic ecotoxicology (Fent, 2001). This cell line is well 
characterized to the presence of phase I (i.e. CYP1A), and to lesser extent phase II 
enzymes (GSTs, UGTs) and has been widely used for identification and evaluation of 
overall toxicity, CYP1A induction and genotoxic potential of individual compounds and 
complex environmental samples (Hahn et al., 1996; Fent and Bätscher, 2000). Other 
toxic responses like lipid peroxidation and induction of metallothioneins and heat-shock 
proteins were also successfully determined using PLHC-1 cells (Rau et al., 2004; 
Schlenk and Rice, 1998; Babich et al., 2001, Caminada et al., 2006). Most recently, our 
group described the expression of two (eco)toxicologically relevant ABC transporters, 
Pgp1 (ABCB1) and MRP3 (ABCC3) in PLHC-1 cells (Žaja et al., 2006). The initial 
characterization of these two proteins using model fluorescent substrates and model 
inhibitors revealed similar substrate/inhibitor profiles as those found for mammalian 
transporters. 
 
In order to better understand the MXR mechanism in fish the aim of the present study 
was the selection and characterization of highly doxorubicin-resistant fish PLHC-1 
cells. Similarly to mammalian multidrug resistance, the obtained resistance cells 
(PLHC-1/dox), selected by culturing wild cells in high doxorubicin concentrations, 
exhibited pronounced Pgp1 (ABCB1) expression, resulting in decreased basal 
accumulation of model fluorescent substrates and cross-resistance to a wide range of 
chemotherapeutics. 
 
 
Material and methods 
Chemicals 
Cyclosporin A (CYC), rhodamine 123 (Rh123), monochlorbimane (MCB), verapamil 
(VER), vincristine sulfate (VCR), vinblastine sulfate salt (VBL), colchicine (COL), 
diammineplatinum (II) dichloride (CIS), daunorubicin hydrochloride (DNR), etoposide 
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(ETO), methotrexate (MET), 1-chloro-2,4-dinitrobenezene (CDNB), buthionine 
sulfoximine (BSO), N-Acetyl-L-cysteine (NAC), 5,5'dithio-bis-2-nitrobenzoic acid 
(DNTB), thiazolyl blue tetrazolium bromide (MTT), Triton X-100, dimethyl sulphoxide 
(DMSO), phosphate buffered saline without Ca2+ and Mg2+ (PBS), pyruvat and HEPES 
were purchased from Sigma, St. Louis, MO, USA. Doxorubicin hydrochloride (DOX) 
was obtained from Pharmacia & Upjohn S.p.A. (Milan, Italy). Glutathione was 
purchased from BDH (Poole, England). Minimum Essential Medium (MEM) and fetal 
bovine serum (FBS) were obtained from Gibco (Karlsruhe, Germany). MK571 was 
obtained from Cayman Chemicals Co. (Michigan, OR, USA). Calcein-AM (Ca-AM) was 
purchased from Molecular Probes (Eugene, OR, USA). DC Protein assay kit was 
obtained from BioRad. Bovine serum albumine (BSA) was obtained from Roth 
(Karlsruhe, Germany). PSC833 (SDZ 215-833) was kindly provided by Novartis 
Pharma AG (Basel, Switzerland). Ethanol, isopropanol and all other chemicals used 
were of the highest analytical grade available and purchased from the Kemika, Zagreb, 
Croatia. 
 
Growth and selection of PLHC-1 cells 
PLHC-1 (Poeciliopsis lucida hepatocellular carcinoma) cells were obtained from the 
American Type Culture Collection (ATCC; LGC Promochem, Teddington, UK). The 
cells were grown at 30°C in MEM containing Earle's salts, nonessential amino acids, L-
glutamine and 5% FBS as previously described (Hahn et al., 1996). Doxorubicin 
resistant cells were selected by exposure of wild type PLHC-1 cells (PLHC-1/wt) to 1 
μM doxorubicin in 75 cm2 flask (Nunc, Roskilde, Denmark) at 90% cell confluency. 
After three days of exposure a small number of survived cells were cultured in 
doxorubicin-free medium and grown up to 70-90% confluence (approximately one 
month period). The medium was renewed every 72 h. An additional selection was done 
by repeated exposure of cells to 1 μM doxorubicin for three days. Survived cells were 
again cultured for seven days to 90% confluence in doxorubicin free medium. Using 
this procedure, PLHC-1 cells highly resistant to doxorubicin (PLHC-1/dox cells) were 
selected. From that point the selected cell line was continually cultivated under 
selection pressure of 0.5 μM doxorubicin. In these conditions PLHC/dox cells exhibited 
growth rate similar to normal PLHC-1 cells. A part of the PLHC-1/dox cells that were 
transferred to and cultured in flasks containing doxorubicin-free medium did not show 
any sign of sensitization during one month period, suggesting that PLHC-1/dox develop 
a stable resistance phenotype. 
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Depending on the experimental protocol two days prior to transport activity experiments 
the cells were seeded in 6-, 48- or 96-wells plates (Tchno Plastic products AG, 
Trasadingen, Switzerland) in 5, 0.4 and 0.2 mL of doxorubicin free medium per well, 
resulting in seeding density of 3.5 x 105, 3.0 x 105 and 1.5 x 105 cells per cm2, 
respectively. 
 
Real-Time PCR measurements of ABCB1 and ABCC3 gene expression levels 
PLHC-1/wt and PLHC-1/dox cells were seeded on a 10 cm2 cell culture dish and grown 
to 80-90% confluency in medium with and without 0.5 μM doxorubicin, respectively. 
The cells were lysed directly in the cell culture dish and homogenized using 
QIAshredder Kit (Qiagen, Basel, Switzerland). RNA extraction was performed using 
RNeasy Mini Kit (Qiagen, Basel, Switzerland). The concentration of the RNA was 
spectrophotometrically measured at 260 nm and the quality was verified on a RNA 
6000 Nano LabChip Kit (Agilent Technologies, Basel, Switzerland). 
 
For ABCB1 and ABCC3, the following primers were designed for real time analysis: For 
ABCB1 Fw 5’-GGAGAAAGCTGGAAAGATCG-3’, Rv 5’-
AAGGAGAAGGTGAAGCCGTA-3’ and for ABCC3 Fw 5’-
CAGGAGACAGAGCCAGAAGA-3’, Rv 5’-AAGCAAATGATCACCGACAG-3’. β-actin 
was used as housekeeping gene for normalization. One µg of the total RNA template 
was reverse transcribed using poly-dT-primer and Transcriptor Reverse Transcriptase 
(Roche Diagnostics, Basel, Switzerland). Real time PCR amplification was performed 
on a RotorGeneTM 6000 (Corbett Life Sciences, Brisbane, Australia) using the 
FastStart SYBR Green System (Roche Diagnostics, Switzerland). The amplification 
conditions consisted of initial denaturation at 95°C for 10 min, followed by 50 cycles of 
denaturation at 95°C for 30 sec, annealing at 58°C for 45 sec, and elongation at 72°C 
for 45 sec. A melting curve analysis was performed after the run. 
 
The data were analysed using the two standard curve method (Rotor-gene 6000 series 
software, Corbett Life Science, Australia). 
 
Membrane vesicles preparation and Western blot analysis 
The plasma membrane vesicles were prepared from 2 x 108 PLHC-1/wt or PLHC-1/dox 
cells according to the method described by Cornwell et al. (1986). The cells were 
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scraped, washed once in PBS, resuspended, frozen, thawed, and finally sonicated in 1 
ml of vesicle buffer (10 mM Tris, 250 mM sucrose, 0.2 mM CaCl2, 1 mM EDTA, 10 μM 
PMSF, pH 7.5). The cell lysate was centrifuged (1,000 x g, 10 min) and layered on 35% 
sucrose. After centrifugation at 16,000 x g for 30 min in swinging rotor, the layer formed 
at the top of 35% sucrose was collected, diluted in sample buffer (10 mM Tris, 250 mM 
sucrose, pH 7.5) and centrifuged at 100,000 x g for 1 h. The pellet containing the 
plasma membrane vesicles was resuspended in 0.5 ml of sample buffer. Total proteins 
concentration in membrane vesicle fractions was determined according to Lowry et al. 
(1951). Thirty micrograms of protein per lane were separated by electrophoresis in 
7.5% sodium dodecyl sulphate polyacrilamide gel (Laemmli, 1970). The proteins were 
then transferred to polyvinylidene difluoride membrane by semidry blotting. After 
blocking and washing steps the membranes were incubated overnight at 4°C with anti-
Pgp MAb C-219 (Signet, Dedham, MA, USA). Goat anti-mouse IgG-HRP was used as 
secondary antibody (Bio-Rad Laboratories, Hercules, CA, USA). The proteins were 
visualized using Opti-4CN Substrate Kit (Bio-Rad). 
 
Light and fluorescent microscopy 
For the purpose of light and fluorescent microscopy experiments, cells were seeded in 
24-well microplates at seeding density of 2 x 105 cells/cm2. After 24h, untreated cells 
were washed in PBS and 0.5 ml PBS was added to each well. Cells were immediately 
used for light microscopy. For fluorescent microscopy cells were exposed to Ca-AM 
(0.5 μM) or Rh123 (1 μM) in the presence or absence of CYC (10 μM). After 30 
minutes accumulation period cells were washed four times in PBS and finally 0.5 ml 
PBS was added to each well. To prevent the efflux of fluorescent dyes the plates were 
kept on ice until microscopic evaluations were performed. Cells were visualised with an 
inverted fluorescence microscope (Axiovert 40, Zeiss) and CCD camera (Zeiss) using 
0.6 second exposure time and same filter set (excitation 450-490, beam spliter 510, 
emission 515) in the case of both fluorescent dyes. All images were taken with 200x 
magnification. 
 
Measurements of Pgp1- and MRP-like transport activities 
Measurements of Pgp1- and MRP-like mediated transport activities in PLHC-1/wt and 
PLHC-1/dox cells were performed as previously described, with slight modifications 
(Žaja et al, 2006). When Rh123 or Ca-AM was used as model substrate the cells were 
seeded in 48-well culture plates. The cells were washed in PBS, and fresh medium 
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containing variable concentrations of CYC (dissolved in 96% EtOH), VER (dissolved in 
96% EtOH), MK571 (dissolved in DMSO), or PSC833 (dissolved in 96% EtOH) was 
added to each well. After a short (3-5 min) pre-incubation period with inhibitors Ca-AM 
or Rh123 (all dissolved in DMSO) were added at desired concentrations in a final 
volume of 400 μL/well. The final concentrations of the solvents never exceeded 0.1%. 
The cells were then incubated for 60 min at 30ºC. At the end of incubation period, the 
cells were washed two times in PBS and finally lysed in 0.1% Triton-X100/PBS (400 
μL/well). The fluorescence was measured using microplate reader (Fluorolite 1000, 
Dynatech, Chantilly, VA, USA) at 485 nm excitation and 530 nm emission wavelengths. 
The results were expressed as fluorescence units (FU) per 7x105 cells.  
 
When MCB was used as fluorescent substrate, the cells were seeded in 6-well plates 
24 h prior to experiments and the retention version of assay was used to measure the 
MRP-like activity. The cells were washed in PBS and then loaded with 25 μM MCB for 
20 minutes at 30ºC. After two washing steps, the inhibitors were added at desired 
concentrations in 2.5 mL of fresh medium. At the end of the 20 min efflux period, the 
cells were washed twice in PBS, and finally lysed in 0.1% Triton-X100/PBS (2.5 
mL/well). The fluorescence of bimane-GS retained in cells was measured in 96-well 
plates at 390 nm and 480 nm excitation and emission wavelengths, respectively (Cary 
Eclipse Microplate reader, Varian Inc., Palo Alto, CA, USA). 
 
Measurements of total glutathione (GSH) levels and glutathione-S-transferase 
(GST) activity 
Cells from one fully confluent 75 cm2 flask were scraped, centrifuged and finally 
disrupted by two freezing/thawing cycles in 10 mM Tris-HCl buffer containing 1 mM 
EDTA (pH=7.4). The obtained homogenates were centrifuged at 10 000 x g at +4°C for 
10 minutes and the supernatant was used for subsequent measurements. GST activity 
was determined spectrophotometrically (340 nm) according to Habig et al. (1974). The 
reaction mixture was composed of 200 µl of assay buffer (100 mM sodium phosphate 
buffer (pH 6.5), 1 mM GSH and 1 mM CDNB) and 20 µl of sample. The increase in 
absorbance was monitored during 3 min at 15 sec intervals and specific enzyme 
activity was calculated and expressed in μmol/min/mg protein. 
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Total glutathione was measured spectrophotometrically (405 nm) as described by 
Schlenk and Rice (1998) using DTNB (0.09 mg/ml) as thiol specific reagent. The 
obtained values were normalised to total proteins and expressed as nmol/mg protein. 
Protein concentration in all samples was measured according to the Lowry method 
(1951) using the BioRad Protein Assay Kit and BSA as standard. 
 
Cytotoxicity assay 
Cytotoxicity was determined by the MTT reduction assay adapted according to the 
Mosmann’s procedure (Mosmann, 1983). The cells were seeded in 96-well plates and 
exposed to a range of concentrations of tested chemicals for 72 h. Subsequently, the 
medium was removed and the cells were incubated for 3 h with 0.5 mg/ml MTT (50 
µl/well) dissolved in MEM. The formazan salts were dissolved in isopropanol and the 
plates were read on a microplate reader Anthos HT-III (Asys Hitech GmbH, Eugendorf, 
Austria) at 570 nm using 750 nm as a reference wavelength. Cytotoxicity was 
expressed as the percentage of product amount formed by mitochondrial activity with 
respect to the corresponding control (untreated cells) level. 
 
Data analysis 
With the exception of gene expression levels in real time PCR experiments (where 
standard error of means are given), all experimental data are given as mean ± 
standard deviation and analyzed by t-test and one-way ANOVA (p-value < 0.05). For 
the purpose of EC50 values calculation the data were normalised and fitted to classical 
sigmoidal four parameters dose-response model: 
 
    y = b + (a - b) / (1 + 10 ((LogEC50-x)*h))) 
 
where y is the response, b represents the minimum of response, a represents the 
maximum of response, h is the shape parameter, and x is the logarithm of inhibitor 
concentration. The EC50-value is the concentration of inhibitor that corresponds to 
50% of maximal effect. The parameter a was constrained to 100 and rest of the 
parameters were fitted. 
 
The resistance factor (RF) was defined as the ratio of EC50 values obtained with 
PLHC-1/wt and PLHC-1/dox cells: 
    RF = EC50PLHC-1/dox / EC50PLHC-1/wt 
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The potency of inhibitors to reverse the MXR phenotype developed in PLHC-1/dox 
cells was expressed as the modulation factor (MF) and calculated according to the 
equation: 
 
 MF(%) = (EC50PLHC-1/dox  - EC50-INPLHC-1/dox) / (EC50PLHC-1/dox – EC50PLHC-1/wt) ● 
100 
 
where EC50PLHC-1/dox and EC50PLHC-1/wt are EC50-values of specific drug obtained for 
PLHC-1/dox and PLHC-1/wt cells, respectively. EC50-INPLHC-1/dox is the EC50 of drug 
obtained with PLHC-1/dox cells in the presence of specific transport inhibitor 
(cytotoxicity modulator). 
 
All experiments were independently repeated 3-5 times and the results of typical 
experiments are shown. All calculations were preformed using GraphPad Prism 4 for 
Windows and Microsoft Excel. 
 
 
Results 
Morphology of PLHC-1/wt and PLHC-1/dox cells 
Both PLHC-1 sub-lines were equally well attached to the surface of cell culture dish 
and there were no other differences that may be related to different physiology and/or 
metabolism: growth rate (doubling time) was similar in both sub-lines; nonspecific 
esterase activities did not reveal any major difference; the total GSH levels were 
similar; and the activities of crucial phase I (CAP1A as evaluated by the EROD method, 
data not shown) and phase II (GST) detoxification enzymes were not significantly 
different. However, marked difference in predominant cell types could be observed 
between PLHC-1/dox and PLHC-1/wt cells (Fig. 1). PLHC-1/dox sub-line was 
homogenous consisting predominantly of smaller and round shaped cells. In contrast, 
PLHC-1/wt sub-line was more heterogeneous consisting mostly of large cells with 
irregular shape.  
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Expression of ABCB1 and ABCC3 in PLHC-1/wt and PLHC-1/dox cells 
The expression levels of ABCB1 and ABCC3 were assessed using quantitative RT-
PCR (Fig. 2A). The amounts of mRNA for targeted genes were normalized to the 
mRNA levels of β-actin gene.  Relative concentrations of ABCB1 and ABCC3 were 
similar in PLHC-1/wt cells (0.97 and 1.08, respectively). However, PLHC-1 cells 
adapted to doxorubicin showed a marked up-regulation of the Pgp1 (ABCB1) gene 
expression. The relative concentration of ABCB1 in PLHC-1/dox cells was 40.8, which 
indicates a marked, 42-fold induction when compared to PLHC-1/wt cells. In contrast, 
the selection of cells with doxorubicin resulted in slight down regulation of ABCC3 gene 
Figure 1. Cell morphology of two PLHC-1 sub-lines. Images of PLHC-1/wt (A) and PLHC-1/dox 
cells (B) were taken with differential interference contrast (PlasDic, 200 x magnification). 
Figure 2. Expression of Pgp1 (ABCB1) and MRP3 (ABCC3). (A) Real-Time PCR analysis of 
gene expression levels. Relative gene expression of Pgp1 (ABCB1) and MRP3 (ABCC3) in 
PLHC-1/wt and PLHC-1/dox cells were measured and normalized to the gene expression level 
of β-actin. The values represent means ± standard deviations (n=3). (B) Western blot analysis 
of Pgp1 (ABCB1) expression in PLHC-1/dox (lane 1) and PLHC-1/wt (lane 2) sub-lines. MAb C-
219 was used as the primary antibody. The same amount of total proteins (40 μg/lane) was 
loaded on gel in case of both, PLHC-1/dox and PLHC-1/wt cells. 
0
5
10
15
20
25
30
35
40
45
β-actin P-gp (Abcb1) MRP3 (Abcc3)
N
or
m
al
is
ed
 c
on
ce
nt
ra
tio
n
PLHC-1/wt
PLHC-1/dox
B A 
 Chapter 3 
 63
– the relative concentration of ABCC3 transcript in PLHC-1/dox cell was 0.64, 
indicating a 1.7-fold down-regulation in comparison to PLHC-1/wt cells. 
 
Western blot using the MAb C-219 revealed a single band corresponding to a protein of 
~165 kDa in membrane fractions of PLHC-1/wt as well as PLHC-1/dox cells (Fig. 2B). 
However, intensity of this band was markedly stronger in doxorubicin than in wild type 
PLHC-1 cells, suggesting that over-expression of ABCB1 mRNA is followed by over-
expression of Pgp in PLHC-1/dox cells. 
 
Functional characterization of Pgp1- and MRP-like transport activities 
Pgp1- and MRP-like transport activities in PLHC-1/wt and PLHC-1/dox cells were 
measured using three different model fluorescent substrates. Ca-AM and Rh123 are 
substrates for both Pgp1 and MRP-like transporters (Holló et al., 1996; Daoud et al., 
2000). The third substrate used in this study was MCB, a non-fluorescent compound 
readily taken up by the cells through simple diffusion. Inside the cells it becomes a 
substrate for glutathione-S-transferases which catalyze its conjugation with glutathione 
(GSH). The resulting bimane-GS conjugate is a highly fluorescent substrate of the 
MRP subfamily, more specifically of MRP1-4 (Bai et al, 2004; Lou et al., 2003). 
 
Different accumulation rates of CaAM and Rh123 were first demonstrated with 
fluorescent microscopy. Marked increase in accumulation rates of both dyes were 
observed in the presence of 10 μM CYC in comparison to wild type cells (Fig. 3). There 
was also difference in basal accumulations of fluorescent dyes in the two PLHC-1 sub-
lines, but the observed discrepancy was more prominent when Rh123 was used as a 
model substrate (Fig. 3A-B and Fig. 3E-F).  
 
Although the fluorescent microscopy clearly revealed that PLHC-1/wt and PLHC-1/dox 
cells are different with respect to their transporter activities, in order to obtain more 
quantitative results and define dose-response relations for other specific Pgp-1 and 
MRPs inhibitors, accumulation rates of fluorescent substrates were further evaluated 
using a microplate reader. The basal accumulation of both Ca-AM and Rh123 was 
approximately three times lower in the PLHC-1/dox cells in comparison to the PLHC-
1/wt cells, reflecting higher efflux rates of these fluorescent substrates. In contrast, the 
retention of MCB-GSH conjugate was higher in the PLHC-1/dox cells (Fig. 4). 
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Figure 3. Fluorescent microscopy of PLHC-1/wt and PLHC-1/dox cells. Images were taken after 
30 min accumulation period in either 0.5 μM calcein-AM (A-D) or rhodamine 123 (E-F), in the 
absence and presence of 10 μM cyclosporine A. Exposure time was 0.6 s in  the case of both 
fluorescent substrates. 
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The specificity of efflux mechanism was verified using prototypic inhibitors of Pgp1 and 
MRP-like transporters. The summary of these functional experiments is given in Table 
1. In PLHC-1/dox cells all the inhibitors used lead to marked increase in the 
accumulation of Ca-AM in a dose-response manner. CYC (10 µM) and PSC833 (10 
μM) resulted in more than 7-fold increase in Ca-AM accumulation over basal level. 
Verapamil was less potent and resulted in a 3-fold increase at 20 µM concentration.  
 
The effects of the same inhibitors on Ca-AM accumulation in PLHC-1/wt cells were 
significantly lower. Although potencies of CYC and PSC833 expressed in EC50 values 
were similar, the maximal increase in Ca-AM accumulation was only two fold. Similarly, 
Figure 4. Basal accumulation rates of model fluorescent substrates. The accumulation levels of 
calcein-AM (0.25 μM), rhodamine 123 (2.5 μM) and retention of monochlorbimane (25 μM) 
were measured in the absence of model inhibitors as described in the Materials and Methods 
section. Data represents means ± standard deviations (n=4) of fluorescent units (FU) 
determined per 7x105 cells. 
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Table 1. EC50 (μM) values and maximal accumulations (fold increase, in parentheses) of 
fluorescent substrates with model inhibitors used. 
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no or weak effect on Ca-AM accumulation in PLHC-1/wt cells was observed when VER 
was used as inhibitor. The opposite effect was observed with MK571, a specific 
inhibitor of MRP-like proteins. The maximal accumulation of Ca-AM was similar in both 
cell lines (~2-fold) but a better defined dose-response curve and lower EC50 value was 
obtained in the PLHC-1/wt cells.  
 
The same pattern of potencies and maximal accumulation was observed with Rh123 
as substrate but overall effects were lower than with Ca-AM and well defined dose-
response relationships could not be obtained. Again, MK571 exhibited a significantly 
higher potency in the wild type than in doxorubicin-selected cells. The dose-response 
curve was well defined yielding an EC50 value of 4.1 μM and a maximal level of Rh123 
accumulation of 3.6-fold over the basal level. In PLHC-1/dox, MK571 resulted in low 
accumulation even at high concentration (80 μM). When MCB was used as substrate, 
both CYC and MK571 resulted in similar dose-response curves. Estimated EC50 
values and maximal accumulations were similar as with PLHC-1/wt cells. Similar 
results were obtained with PLHC-1/dox cells but lower maximal accumulations were 
observed for both inhibitors. 
 
Modulation of cytotoxicity 
Our Real-Time PCR results and functional experiments clearly indicated that Pgp1 is 
highly up-regulated in PLHC-1/dox cells. In order to evaluate whether this 
overexpression would result in a classical MDR phenotype similar to those found in 
mammalian cells, we determined the cytotoxicity of several commonly used 
Table 2. EC50 (μM) values and confidence intervals for tested chemotherapeutics in PLHC-
1/wt and PLHC-1/dox cells. The resistance factors (RF) were calculated as simple ratio of EC50 
values obtained in the two cell lines. 
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chemotherapeutics. Obtained EC50 values after 72 h exposure to the tested drugs in 
both PLHC-1/wt and PLHC-1/dox and the corresponding resistance factors (RF) are 
summarized in Table 2. The most cytotoxic to PLHC-1/wt cells was MET with EC50 
value of 2.4 nM. Two vinca alkaloids, VCR and VBL, exhibited similar toxicity as MET 
(EC50 values of ~4 nM). Approximately 100-times lower potencies were determined for 
anthracyclines, DOX and DNR, with respective EC50 values of 144 and 340 nM. The 
EC50 value obtained for colchicine (130 nM) was in the same range as for the 
anthracyclines. Etoposide showed approximately ten times lower cytotoxicity, with 
EC50 value of 4.3 µM. The least potent compound was cisplatin with an EC50 of 19.1 
μM.  
 
As can be observed in Fig 5A-F and Table 2, a significant shift in cytotoxicity curves 
and EC50 values occurred in the PLHC-1/dox cells, demonstrating that PLHC-1/dox 
cells developed, in addition to doxorubicin, resistance to cytotoxic effects of a range of 
other compounds, with the exception of cisplatin and methotrexate. The resistance 
factor (RF) ranged from 7.6, observed for ETO, to more than 550 for VCR (Table 2.). 
 
In order to further characterize the underlying mechanism of MDR phenotype observed 
in PLHC-1/dox cells, the cytotoxicity was measured in the presence of model Pgp1 and 
MRPs inhibitors. All tested Pgp1 inhibitors lead to almost complete reversion of the 
MDR phenotype in PLHC-1/dox cells, resulting in EC50 values similar to those 
determined in wild type cells (Table 3). Low concentrations of CYC (1 µM) and PSC833  
(1 µM) resulted in an almost complete (90-100%) reversion of the MDR phenotype 
against the tested chemotherapeutics. VER was significantly less potent; a 
Table 3. Modulator factors (MF) calculated for model inhibitors and cytotoxic drugs tested in 
two PLHC-1 sub-lines. Data are expressed as percentages 
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Figure 5. Cytotoxicity of chemotherapeutics to PLHC-1/wt and PLHC-1/dox cells. Cells were 
exposed to a wide concentration range of drugs for 72 h and their cytotoxicity was evaluated 
using the MTT assay as described in the Materials and Methods section. Data represents 
means ± standard deviations (n=3). 
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concentration of 7.5 μM did not result in a complete reversion of MDR for all 
compounds. In the case of VBL, VER resulted in less than 70% of maximal reversion. 
None of the Pgp1 inhibitors used modulated the cytotoxicity of cisplatin and 
methotrexate. When MK571 was used as a specific MRP inhibitor a weak cytotoxicity 
modulation was observed only for colchicine. 
 
Glutathione-S-transferase (GST) activity and total GSH levels  
No significant difference was observed between PLHC-1/wt and PLHC-1/dox cells in 
the levels of total GSH (Fig. 6A). As expected, BSO lead to depletion of GSH level in 
both cell lines, but PLHC-1/wt cells were more sensitive to BSO exposure. The GST 
activity was significantly higher in PLHC-1/dox (15%), although the observed increase 
was probably of no physiological relevance (Fig. 6B). In both cell lines, exposure to 
BSO resulted in more than two fold induction of GST activity. 
 
 
Discussion 
MXR is a multifactorial resistance mechanism present in aquatic organisms and 
mediated predominantly by the activity of ABC efflux transporters. In its nature, this 
mechanism is similar to well characterized MDR of mammalian cells. The major 
property of mammalian ABC transporters involved in MDR is their high inducibility. 
During the last two decades several mammalian cancer cell lines isolated through 
Figure 6. Total GSH level and activity of GST. Total levels of GSH (A) and GST activity (B) 
measured in the absence and presence of BSO for 72 h. Data represents means ± standard 
deviations (n=4). Asterisks denote statistical significance set at p<0.1 (*), p<0.01 (**) and 
p<0.001 (***), respectively. 
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selection with different drugs such as doxorubicin, mitoxantrone, etoposide or 
daunorubicin, exhibited high resistance to a wide range of chemotherapeutics primarily 
due to the overexpression of Pgp1 (ABCB1), MRP1/2 (ABCC1/2) or BCRP (ABCG2). 
 
In our previous study we demonstrated that fish hepatoma PLHC-1 cells express two 
ABC efflux transporters possibly implicated in MXR – the Pgp1 (ABCB1) and MRP3 
(ABCC3) (Žaja et al., 2006). In the present study we used doxorubicin to select and 
isolate a PLHC-1 sub-line (PLHC-1/dox) that exhibits a high resistance to structurally 
different drugs. In order to elucidate the mechanism of resistance found in PLHC-1/dox 
cells, we measured the gene expression levels of ABCB1 and ABCC3. A pronounced 
overexpression (> 42-fold) of ABCB1 in PLHC-1/dox in comparison to normal cell line 
(PLHC-1/wt) was observed (Fig. 1). At the same time, the selection with doxorubicin 
resulted in slight down-regulation of ABCC3 expression. Although the phenomenon of 
Pgp1 (ABCB1) overexpression is detected in numerous mammalian cell lines 
(Bohacova, et al., 2006; Arora et al., 2004), this is the first study proving that a similar 
mechanism of induction and selection by doxorubicin is present in fish cell lines.  
 
Functional experiments using model fluorescent Pgp1 and MRP substrates confirmed 
the results of gene expression measurements. PLHC-1/dox cells exhibited 3- to 4-fold 
lower Ca-AM and Rh123 accumulation rates (Fig. 4). However, in the case of specific 
MRP1-4 substrate, bimane-GSH conjugate, the retention was slightly higher in PLHC-
1/dox cells. Together with gene expression data, functional experiments clearly 
demonstrated differential regulation of ABCB1 and ABCC3 genes. Doxorubicin acts as 
a specific and selective pressure leading to selection of PLHC-1 with high and stable 
overexpression of Pgp1 (ABCB1), while expression of MRP3 (ABCC3) was reduced. 
Using vesicles obtained from Sf9 cells or cell lines transfected with human MRP3 
(ABCC3) several studies showed that doxorubicin is not a substrate of human MRP3 
(Zelcer et al., 2001). Consequently, MRP3 could not provide resistance to doxorubicin 
and no selection of cells expressing high MRP3 levels could be expected. In 
accordance with these observations, we did not detect higher expression of MRP3 
(ABCC3) gene expression in PLHC-1/dox cells. 
 
Almost all of the model Pgp1 and MRPs inhibitors used in this study lead to significant 
increase in accumulation of prototypic fluorescent substrates in both cell lines. These 
results are in accordance with our recent study which demonstrates the presence of 
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Pgp1 and MRP3 in PLHC-1 cells. The PLHC-1/dox cells respond to the model 
inhibitors in the same way as PLHC-1/wt cells and the maximal accumulation of 
substrates, in terms of absolute fluorescence per cell achieved in the presence of 
inhibitor, was approximately the same. The magnitude of inhibitors effect was 2- to 3-
fold higher in the PLHC-1/dox cells due to their lower basal accumulation rate. Only the 
effect of the MRP inhibitor MK571 was approximately the same in PLHC-1/dox as in 
PLHC-1/wt cells. These data prove the specificity of Pgp1 mediated mechanism 
underlying the lower basal accumulation of fluorescent substrates in PLHC-1/dox 
compared to PLHC-1/wt cells. 
 
In mammalian cells, the overexpression of Pgp1 is clearly related to the development 
of MDR phenotype resulting in high resistance to different chemotherapeutics. In order 
to evaluate whether the measured overexpression of Pgp1 in fish cells would result in a 
similar pattern of cross-resistance to a wide spectrum of chemotherapeutics, we 
performed the cytotoxicity experiments. Among the tested drugs the antifolate 
methotrexate and two vinca alkaloids, vincristine and vinblastine, were the most 
cytotoxic to PLHC-1/wt. Approximately hundred times less potent were the antracycline 
drugs (doxorubicin and daunorubicin). The cytotoxicity of colchicine was in the same 
range as antracyclines, and the least potent compounds were etoposide and cisplatin. 
A similar order of cytotoxicity is observed in numerous mammalian cell lines, such as 
HL60, HepG2, K-562 or MCF-7 (Materna et al., 2005) and in fish cell lines (Caminada 
et al. 2006). PLHC-1/dox cells exhibited marked resistance to all tested drugs except 
cisplatin and methotrexate. This indicates that Pgp1 in PLHC-1 fish hepatoma cells 
posses broad substrate specificity similar to that reported for mammalian cells and 
tissues. Although the cells were selected with doxorubicin, the highest shift in 
cytotoxicity was observed for two vinca alkaloids. Relatively high resistance to a 
structurally unrelated but known substrate of mammalian Pgp1, the antigout agent 
colchicine, was observed. 
 
Although studies on mammalian cell lines often found high correlation between the 
increase in expression of efflux transporters (Pgp1 and MRP1/2) and resistance to 
cisplatin (Nakatani et al., 2005), no resistance of PLHC-1/dox cells towards this 
compound was measured. However, it is known that resistance to cisplatin is 
multifactorial and often specific depending on the cell type. Our finding that cisplatin is 
not a substrate for fish Pgp1 is in accordance with the recent study of Ikuta et al. 
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(2005), who found that expressions of Pgp1 and Mrp1 are not related to intracellular 
accumulation of cisplatin, and consequently, that these proteins do not represent a 
major mechanisms of cisplatin resistance. 
 
Cellular uptake of methotrexate occurs by carrier-mediated transport via reduced folat 
carrier (RCF1) (Dixon et al., 1994). Once inside cells methotrexate undergoes 
extensive polygultamylation through activity of folylpolyglutamylate synthetase (FPGS) 
resulting in highly toxic polyglutamylated metabolites (Moran, 1999). High toxicity of 
methotrexate indicated that basic components identified in mammalian cells, like RCF1 
and FGPS, may also be present in fish cells. It is known that non-polyglutamylated 
methorexate is substrate of mammalian MRP1-3 (Zeng et al., 2001) and the fact that 
we did not observe any difference in toxicity between PLHC-1/wt and PLHC-1/dox cells 
is in accordance with our real-time and functional experiments which showed relatively 
low expression of MRPs in both PLHC-1 sub-lines. 
 
Further proof of specific Pgp1 mediated resistance of PLHC-1/dox cells towards tested 
drugs was obtained using specific inhibitors of Pgp1 and MRP-related transport 
activities. All inhibitors of Pgp1 transport almost completely reversed the resistance of 
PLHC-1/dox cells to all drugs to which resistance was developed. CYC and PSC833 
were the most potent compounds, while a 7.5-times higher concentration of VER was 
necessary to achieve a similar level of reversal. This order of potencies confirms the 
findings of functional experiments using fluorescent substrates. 
 
Some of the chemotherapeutics tested in this study are also transported by the 
members of the MRP family of efflux transporters, but also through activity of BCRP 
(ABCG2). The only MRP found in PLHC-1 cells is MRP3 (ABCC3) and up to now we 
were not able to detect gene expression of MRP1 (ABCC1) or MRP2 (ABCC2) in these 
cells. Our finding that MK571, a potent inhibitor of MRP1-3 did not modulate 
cytotoxicity of these drugs further demonstrates that MRPs are probably expressed at 
very low levels in PLHC-1 cells. Furthermore, although etoposide and polyglutamylated 
forms of methotrexate are also BCRP substrates, novobiocin, a specific inhibitor of 
BCRP mediated transport, did not result in increased toxicity of these drugs in PLHC-
1/dox cells (data not shown). Etoposide is also a known substrate of mammalian Pgp1 
and cyclosporine A completely reversed the resistance of PLHC-1/dox cells toward this 
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compound. These results further suggest that resistance mechanism developed in 
PLHC-1/dox is highly Pgp1 specific. 
 
The amplification of ABCB1 chromosomal region has been reported as major 
underlying mechanism of MDR in mammalian drug-resistant cell lines from various 
cancer types, including breast (Turton et al., 2001), liver (Pang et al., 2005) and ovary 
(Takano et al., 2001). In addition, selection of cells after point mutation induced by 
selecting agents, or a combination of point mutation and gene amplification, as 
proposed by Chen et. al. (1994), may be another possible explanation. Nevertheless, 
the selection mechanism responsible for doxorubicin resistance in PLHC-1 cells is still 
not clear. The pictures obtained by light microscopy suggest that PLHC-1/wt cells are a 
mixture of two cell types. The wild type cells are obviously dominant under normal 
culture conditions. Yet, under doxorubicin selection pressure a small fraction of cells 
was able to quickly adapt to doxorubicin, most likely by over-expressing Pgp1. These 
cells express different morphology and are the predominant type of cells in PLHC-
1/dox sub-line. Furthermore, they were able to maintain resistant phenotype even for 
long period after doxorubicin withdrawal. Recent evidence indicate that small 
population of tumor cells (~1%) are cells with 'stem like cell' characteristics, and 
besides high capacity for self-renewal these cells also express high levels of ABC 
transporters (Lou and Dean, 2007). Consequently, it is possible that exposure to 
doxorubicin lead to selection of 'stem like cells' with high capacity to quickly over-
express Pgp1 and adapt to doxorubicin selection pressure.  
 
Besides, selection with cytotoxic concentrations of MRPs or BCRP substrates in the 
presence of a specific Pgp1 inhibitor could potentially lead to a development of 
resistance phenotype mediated through the activity of these transporters. Such 
experiments, as well as experiments aimed at selection of fish cell lines with other 
specific types of resistance mechanisms, can further contribute to the knowledge of 
resistance mechanisms developed in aquatic species. 
 
In conclusion, our study demonstrate that fish PLHC-1/dox cells highly express Pgp1 
(ABCB1) mediated multidrug resistance, exhibiting similar cross-resistance pattern to 
structurally different compounds as the one described in mammalian cells. This finding 
affirms the PLHC-1 cell line as important model for studying the development of basic 
resistance mechanisms to different chemicals in aquatic organisms. Furthermore, apart 
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from being a promising tool for basic and applied research, these data demonstrate 
relevance of PLHC-1 cells for rapid initial ecotoxicity screening and environmental risk 
evaluation of drugs. As current techniques rely mainly on in vivo systems, the proposed 
in vitro model may help to reduce animal testing in product registration and safety.  
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Abstract 
The ubiquitous presence of pharmaceuticals in aquatic systems is a challenging 
problem as their potential effects on aquatic organisms remain largely unknown. The 
ABC transport proteins contributing to the multidrug/multixenobiotic resistance 
(MDR/MXR) phenomenon seem to have an important role in the elimination of 
xenobiotics in aquatic organisms. Modulation of their efflux activities by contaminants 
may lead to substantial increase in intracellular accumulation and toxic effects of other 
xenobiotics.  
 
The aim of our work was to analyse a series of pharmaceuticals for their potential to 
modulate the activity of xenobiotic efflux transporters from the ABCB and ABCC sub-
family in the PLHC-1 fish cell line (PLHC-1/wt) and a doxorubicin-resistant PLHC-1 
subclone (PLHC-1/dox) characterised by an elevated expression of related ABC 
transporters. Cellular accumulation of the model fluorescent ABC substrates calcein-
AM and rhodamine123 were used to determine an inhibitory effect on efflux 
transporters. A number of pharmaceuticals had an inhibitory activity with IC50 values 
occurring in the lower micromolar to millimolar range. Further, cytotoxic effects of 
pharmaceuticals were analysed in PLHC-1/dox cells. Co-exposure of resistant cells to 
pharmaceuticals found to have an inhibitory effect and to different pharmaceuticals 
acting as substrates of ABCB1, resulted in up to five times increased cytotoxicity in 
comparison to cells exposed without inhibitor.  
 
Our work revealed significant inhibitory effects of environmentally relevant 
pharmaceuticals on ABC transporters, demonstrating that this class of compounds 
interacts with the MDR/MXR mechanism in fish. Our findings correspond well with data 
from mammalian systems indicating that the specificity and roles of the efflux 
transporters are similarly in both systems. Furthermore, the PLHC-1 cells turned out to 
be a useful system for the investigation of MDR/MXR mechanisms in fish due to the 
presence of active and inducible MDR (ABCB) and MRP (ABCC) proteins in this in vitro 
system. 
 
Key words: Multidrug/multixenobiotic resistance (MDR/MXR), pharmaceuticals in the 
environment, fish cell lines, in vitro 
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Introduction 
The ubiquitous presence of pharmaceuticals in aquatic systems has become well 
documented during the past years (for reviews (Daughton and Ternes 1999; Fent et al. 
2006; Halling-Sorensen et al. 1998)). Various monitoring studies have demonstrated 
pharmaceuticals and their metabolites from different therapeutic classes in surface 
waters with median concentrations in the range of ng/L up to μg/L (Calamari et al. 
2003; Kolpin et al. 2002; Wiegel et al. 2004). However, only little is known about effects 
of pharmaceuticals on aquatic organisms and ecosystems, despite their ubiquitous 
occurrence and high biological activity (Fent et al. 2006). 
 
The excretion of xenobiotics through export pumps is often the final step in 
detoxification processes. In addition, these transporters have been proposed as a first-
line defence in aquatic organisms (Epel 1998). In toxicological terms the most 
important transporters are the P-glycoprotein1 (P-gp1, MDR1, ABCB1), the multidrug-
resistance associated proteins MRP1 (ABCC1), MRP2 (ABCC2) and MRP3 (ABCC3), 
as well as the breast cancer resistance protein BCRP (ABCG2) (Leslie et al. 2005). 
They belong to the ATP-binding cassette (ABC) transporter superfamily and transport a 
wide range of xenobiotics and metabolites through the cell membrane by hydrolysis of 
ATP. The consequence is a lower intracellular concentration of xenobiotics and lower 
toxic potential.  
 
This phenomenon was first observed during cancer treatment and is referred to 
multidrug resistance (MDR). P-gp1 was found to be the main cause for a resistance 
towards cytostatic drugs observed during chemotherapy (Juliano and Ling 1976). This 
170-kDa membrane protein transports moderately hydrophobic, amphipathic, neutral or 
positively charged planar organic molecules of low molecular weight with a basic 
nitrogen atom (Leslie et al. 2005). Many anti-cancer agents have been identified as P-
gp1 substrates like anthracyclines, vinca alkaloids, taxanes, epipodophyllotoxins, 
topotecan, actinomycines, alkylating agents, peptide antibiotics and antigout agents 
(Chan et al. 2004). Unmodified xenobiotics are mostly transported by P-gp whereas 
substrates of MRP are direct products of phases I and II metabolism, i.e. they are 
predominantly present in the form of glutathione, glucuronate or sulphate water-soluble 
conjugates. Besides xenobiotics, some MRP also transport physiological substrates 
such as hormones and bile salts (Deeley et al. 2006). Many compounds, called 
chemosensitizers, have been identified that show an inhibitory effect on efflux 
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transporters and they may have the potential to reverse multidrug resistance (Litman et 
al. 2001; Smital and Kurelec 1998).  
 
In aquatic toxicology, multidrug resistance came into focus when populations of aquatic 
organisms were observed that were able to survive in highly polluted environments. 
This phenomenon was soon termed MultiXenobiotic Resistance (MXR) mechanism in 
contrast to MDR in humans (Kurelec 1992). Indeed, ABCB and ABCC transporters 
have been found in aquatic organisms such as clams, crabs, mussels, oyster shrimps, 
snails, sponges, toads, worms and several fish species (Bard 2000). Moreover, an 
analysis of the zebrafish genome revealed that over 77% of all human ABC 
transporters have an ortholog in zebrafish (Annilo et al. 2006).  
 
The permanent fish cell line PLHC-1 (Poeciliopsis lucida hepatoma cell) is regularly 
used in ecotoxicology as an in vitro model system to study detoxification mechanisms 
(phase I and phase II enzymes) (Fent 2001). The induction of the phase I enzyme 
CYP1A1 has widely been used for the assessment of the toxic potential of polycyclic 
aromatic hydrocarbons (PAHs), both as single compounds and as complex 
environmental mixtures (Fent and Batscher 2000). Furthermore, PLHC-1 cells have 
been used for the study of heat shock proteins, metallothionein induction and 
cytotoxicity (Babich and Borenfreund 1991; Caminada et al. 2006; Rau et al. 2004; 
Schlenk and Rice 1998). Recently, sequences of the two transporters P-gp1 (ABCB1) 
and MRP3 (ABCC3) have been detected in the PLHC-1 cell line and the functional 
characterization of the efflux activity using model fluorescent substrates and model 
inhibitors revealed similar substrate/inhibitor profiles to those found for mammalian 
transporters (Zaja et al. 2007). In a subsequent work, we succeeded in selecting a 
doxorubicin-resistant PLHC-1 subclone (PLHC-1/dox) characterized by an about 40-
fold overexpression of P-gp1 compared to wild type cells (PLHC-1/wt) (Zaja et al. in 
press). Similarly to mammalian cells, the PLHC-1/dox cells show cross-resistance to 
cytotoxicity of other chemotherapeutics such as daunorubicin, vincristine, vinblastine, 
etoposide and colchicine. However, specific inhibitors of P-gp were able to completely 
reverse the resistance. In contrast to PLHC-1/wt cells, the PLHC-1/dox cells represent 
a more accurate model system for the specific investigation of effects on P-gp1 and 
those mediated by P-gp1. Due to the presence of all three critical phases of the 
detoxification system the PLHC-1 cells (phase I, phase II and efflux transporters) they 
may serve as a reliable in vitro model in aquatic toxicology. 
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The aim of our present study was to investigate effects of pharmaceuticals found to be 
present in the aquatic environment on efflux transporters involved in the MDR/MXR 
mechanism of PLHC-1/wt and PLHC-1/dox cells. Some pharmaceuticals are known to 
be substrates or inhibitors of mammalian ABCB and ABCC transporters such as statins 
(atorvastatin, simvastatin), propranolol, tamoxifen and fluoxetine (Peer et al. 2004; 
Ramu et al. 1984; Wang et al. 2001; Zamora et al. 1988), however, data from aquatic 
organisms for these classes of pharmaceuticals are completely missing. In efflux 
assays and by fluorescent microscopy, the inhibitory potential of pharmaceuticals was 
assessed in both subclones using two different fluorescent model substrates. Further, 
the potential of pharmaceuticals to modulate cytotoxicity in PLHC-1/dox cells was 
assessed in co-exposure experiments. These studies are important for the 
interpretation of effects of mixtures of chemicals usually present in the environment, as 
they may interact by interfering with detoxification systems, thus leading to higher 
toxicity. 
 
 
Material and Methods 
Chemicals 
Dulbecco’s minimum essential medium with F-12 nutrient mixture (DMEM/F12) with 
phenol red, trypsin/ethylenediamine tetraacetic acid (EDTA), and L-glutamine were 
obtained from LuBio Science GmbH (Switzerland). Fetal bovine serum (FBS) was 
purchased from Sigma-Aldrich (Switzerland). 
 
Acebutolol hydrochloride (purity >99%), cimetidine (≥ 98%), ciprofloxacin (98%), 
clofibric acid (97%), cyclosporin A (≥ 98.5%), erythromycin (≥ 95%), fenofibrate 
(≥ 99%), furosemide (≥ 98%), gemfibrozil (≥ 99%), ibuprofen (≥ 98%), 2,3:4,6,-di-O-
isopropylidene-2-keto-gulonic acid monohydrate (≥ 98%), mefenamic acid (> 99%), 
methotrexate hydrate (> 98%), nonylphenol (techn., 85% of p-isomers), norfloxacin 
(≥ 98%), octylphenol (95%), paracetamol (≥ 99%), (±)-propranolol hydrochloride 
(≥ 99%), ranitidine hydrochloride (> 99%), rhodamine 123 (≥ 90%), sulfadiazine (99%), 
sulfamethoxazole (≥ 98%), tamoxifen (≥ 99%), and trimethoprim (98.5%) were 
purchased from Sigma-Aldrich (Switzerland), calcein-AM from LuBio Sciences GmbH 
(Switzerland), doxorubicin hydrochloride (≥ 99%), rofecoxib (98.7%), and sildenafil 
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base (≥ 99%) from Sequoia Research Products Ltd. (United Kingdom), azithromycin 
(techn.) from Pliva (Croatia), pravastatin (98.7%) from ChemPacific Corporation (USA), 
and MK571 from ALEXIS Corporation (Switzerland). Bezafibrate (≥ 99.3%) was kindly 
supplied by F. Hoffmann-La Roche Ltd (Switzerland), and atorvastatin calcium (≥ 99%), 
diclofenac sodium salt (≥ 99%), fluoxetine (≥ 99%), (±)-metoprolol tartrate (≥ 99%), and 
simvastatin (98.7%) by Novartis International AG (Switzerland). 
 
Stock solutions of all pharmaceuticals were prepared in DMSO at a concentration 
corresponding to their solubility. For the different assays, stock solutions were diluted in 
the cell culture medium resulting in a maximal DMSO concentration not exceeding 2%. 
Further concentrations were prepared by serial dilution.  
 
Cell culture 
The fish hepatoma cells PLHC-1 (Poeciliopsis lucida hepatoma cell) kindly supplied by 
L.E. Hightower (Ryan and Hightower 1994) were grown in DMEM/F12 supplemented 
with 5% FBS in a humidified incubator with 5% CO2 at 30°C. Cells were regularly split 
every 4 days by dissociating with 0.05% (w/v) trypsin and 0.5 mM EDTA and 
subcultured at split ratios of about 1:6. Wild type and a doxorubicin-resistant subclone 
of PLHC-1 cells called PLHC-1/wt and PLHC-1/dox, respectively, were used for this 
study. PLHC-1/dox cells were selected as described before (Zaja et al. in press) and 
are characterized by an increased expression of P-gp1 (ABCB1). As a consequence, 
they show an elevated resistance to doxorubicin. For the different assays, cells were 
seeded on 96-well (Huber & Co, Switzerland) or 24-well (Grogg Chemie, Switzerland) 
tissue culture microtiter plates (MTP).  
 
Measurements of P-gp1 and MRP-like transport activities 
Measurements of P-gp1- and MRP-like mediated transport activities in PLHC-1/wt and 
PLHC-1/dox cells were performed with the model substrates Rhodamine123 (Rho123) 
or calcein-AM (Ca-AM). 200 μl 80 x 104 cells mL−1 were seeded in each well of a 96-
well tissue culture MTP the day before the assay. For the assay, cells were washed in 
PBS, and 100 μl fresh medium containing variable concentrations of test compounds or 
model inhibitors were added to each well. After a short pre-incubation period (5 min) 
with inhibitors, 100 μl model substrate was added (assay concentration for Ca-AM was 
0.25 μM, for Rho123 2.5 μM). The final concentrations of the DMSO solvent never 
exceeded 2%. The cells were then incubated for 60 min at 30ºC. At the end of the 
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incubation period, cells were washed twice in PBS and finally lysed in 150 μl 
0.1% Triton-X100/PBS. The fluorescence was measured using a microplate reader 
(SynergeneTM 2, BioTek, USA) at 485 nm excitation and 530 nm emission 
wavelengths. The results are expressed as normalized fluorescent intensity (FI). 
 
Microscopy 
For the purpose of fluorescent microscopy experiments, 500 μl of cell suspension was 
seeded in each well of a 24-well MTP at a seeding density of 80 x 104 cells/mL. After 
24 h, cells were exposed to 0.25 μM Ca-AM or 2.5 μM Rho123 in the presence or 
absence of 10 μM cyclosporin A or pharmaceuticals. After 30 minutes accumulation 
period, cells were washed four times in ice-cold PBS and finally 0.5 ml ice-cold PBS 
was added to each well. To prevent the efflux of fluorescent dyes the plates were kept 
on ice until microscopic evaluations were performed. Cells were visualised with an 
inverted fluorescence microscope (Axiovert 40, Zeiss, Switzerland) and CCD camera 
(Zeiss, Switzerland) using 300 ms and 500 ms exposure time for Ca-AM and Rho123, 
respectively, and the same filter set (excitation 450–490 nm, beam spliter 510, 
emission 515 nm) in the case of both fluorescent dyes. All images were taken with 200-
fold magnification. 
 
Cytotoxicity assay 
For the cytotoxicity-modulation assays, cells were split and 200 μl cell suspension per 
well were plated at densities of 20 x 104 cells mL−1 in 96-well tissue-culture MTP (Huber 
& Co., Switzerland). After a preincubation of 24 h, PLHC-1/wt and PLHC-1/dox cells 
were exposed to inhibitors together with substrates of P-gp. Serial dilutions of 
pharmaceuticals were used as substrates combined with 0.5 μM model inhibitor 
cyclosporin A, or pharmaceuticals were used as inhibitors along with a serial dilution of 
the model substrate doxorubicin. The exposed cells were incubated for 72 h. 
Unexposed cells, cells exposed to the inhibitor and cells exposed to the substrate were 
used as controls. 
 
MTT Assay. The MTT assay is based on the uptake of methyl thiazolyl blue 
tetrazolium bromide (MTT) and its following reduction in mitochondria of living cells to 
MTT formazan, while dead cells are almost completely negative in this cleavage 
activity (Mosmann 1983). The assay was performed as described previously 
(Caminada et al. 2006). Shortly, cells were washed after 72 h of exposure as described 
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above with PBS and 220 μl fresh medium was added to each well containing 20 μl 
MTT solution (5 mg MTT ml−1 PBS). The MTPs were incubated for another 4 h before 
the cell culture medium containing the MTT solution was removed and 200 μl DMSO 
were added to each well. After shaking for 10 min at 450 rpm, 25 μl Sorensen’s Glycine 
buffer (50 mM glycine, 50 mM sodium chloride/NaOH pH 10.5) was added to each well. 
Absorption was measured spectrophotometrically at 540 nm on a microplate reader 
(SynergeneTM 2, BioTek, USA). Cell viability was expressed as fraction of negative 
controls (cells with medium only). 
 
Data analysis 
The experiments were performed in three independent experiments in triplicates or 
quadruplicates and the results of typical experiments are shown. Data were graphically 
and statistically evaluated with GraphPad Prism 4 (GraphPad Software, Inc., San 
Diego, CA). The raw data were logarithmically transformed.  
 
For the evaluation of the cytotoxicity assays, the data were normalized to a cytotoxic 
concentration of doxorubicin (positive controls) and to cells grown in medium only 
(negative control). Wherever applicable, the data were fitted with the four-parameter 
logistic equation (Hill equation), a nonlinear regression model.  
 
 
Results 
The tested pharmaceuticals were chosen due to their occurrence in the environment 
and their known potential to interact with human efflux transporters. They act by 
different modes of action and hence belong to different therapeutic classes including 
analgesics and anti-inflammatory drugs, blood lipid lowering drugs (fibrates, statins), β-
blockers, cytostatic drugs, neuroactive compounds (antiepileptic, selective serotonin 
reuptake inhibitor), antibiotics and various others (anti-acidic, diuretics). 
 
Intracellular accumulation of model substrates in PLHC-1/wt and PLHC-1/dox 
upon exposition to pharmaceuticals 
The potential of pharmaceuticals to inhibit transport activities of efflux transporters was 
assessed in PLHC-1/wt and PLHC-1/dox cells. Rho123 and Ca-AM were used as 
fluorescent model substrates. Both have been found to be substrates for P-gp1 and 
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Table 1: Effects of pharmaceuticals on intracellular accumulation of rho123 and Ca-AM in 
PLHC-1/wt and PLHC-1/dox cells. Indicated is the x-fold increase in fluorescence of model 
substrates after 60 min exposition to pharmaceuticals compared to control cells. cMax 
correlates to the concentration where the highest accumulation has been found. A half-
maximal inhibition concentration (IC50) could only be calculated when a full does-response 
curve was available. 
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MRP-like transporters (Daoud et al. 2000; Hollo et al. 1996). Effects were found for 18 
out of 33 substances evaluated. The antibiotics (ciprofloxacin, erythromycin, 2,3:4,6,-di-
O-isopropylidene-2-ketogulonic acid, nonylphenol, norfloxacin, octylphenol, 
sulfadiazine, sulfamethoxazole, trimethoprim, azithromycin) as well as cimetidine, 
methotrexate, metoprolol, paracetamol and fluoxetine did not show any effect neither in 
the PLHC-1/wt nor in the PLHC-1/dox cells. Seven pharmaceuticals (atorvastatin, 
furosemide, gemfibrozil, sildenafil, and simvastatin) and the two model inhibitors 
cyclosporin A (CyA) and MK571 showed an increased intracellular accumulation of 
both model substrates and in both subclones. In general, the difference in 
accumulation was more pronounced with Ca-AM used as model substrate than with 
Rho123. Furthermore, the PLHC-1/dox cells exhibited a more pronounced efflux 
activity due to the higher expression of P-gp. This is apparent in a lower basal 
accumulation of model substrates (Zaja et al. in press). Thus the measured inhibition of 
efflux of model substrates was more pronounced in the PLHC-1/dox cells. All results 
are summarized in Table 1. 
 
Figure 1: Comparison of intracellular accumulation of the model substrates Ca-AM (A and B) 
and Rho123 (C and D) in PLHC-1/wt (A and C) and PLHC-1/dox (B and D) after exposure to 
CyA (?), MK571 (?), atorvastatin (?), simvastatin (?), and pravastatin (?).Indicated are 
means and standard error of means (n=3). The data were normalized to the basal 
accumulation of model substrates. 
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Atorvastatin was the most potent inhibitory pharmaceutical at a concentration of 
160 μM. It led to a 5.2-fold and 12.9-fold increase in accumulation of Ca-AM in PLHC-
1/wt and PLHC-1/dox cells, respectively. When Rho123 was used as a model 
substrate, the increase was about 2-fold (Fig. 1 and Tab. 1). These findings are in the 
same range as the effects found for the model inhibitor CyA. However, atorvastatin was 
12-fold less potent as CyA (IC50 with Ca-AM: 24.05 μM for atorvastatin and 2.00 μM 
for CyA). The further analysed statins simvastatin and pravastatin, yielded an increase 
in accumulation of up to 5-fold. For pravastatin, no effects were found when Rho123 
was used as model substrate, however. 
 
Among the other pharmaceuticals furosemide, gemfibrozil, propranolol, and sildenafil 
lead to a more than twofold increase of accumulation (Fig. 2). All the other substances 
had only a slight effect on the efflux activity of the model substrates. 
 
Microscopy 
Increased accumulation rates of fluorescent substrates were also observed by 
fluorescence microscopy when atorvastatin, CyA, furosemide, gemfibrozil, sildenafil, 
and pravastatin were exposed to PLHC-1/wt or PLHC-1/dox together with the model 
substrate Rho123 or Ca-AM. These pharmaceuticals lead to a similar accumulation of 
the fluorescent substrates Ca-AM and Rho123 to the one observed with the model 
inhibitor CyA. Control cells exposed only to substrate showed clearly lower 
fluorescence (Fig. 3). There were only slight differences between PLHC-1/wt and 
PLHC-1/dox cells when Ca-AM was used as a substrate. Exposure to 20 μM 
atorvastatin led to a higher accumulation of substrate in PLHC-1/dox than in PLHC-1/wt 
Figure 2: Intracellular accumulation of calcein-AM (A) and rhodamine 123 (B) in PLHC-1/wt 
(full symbols) and PLHC-1/dox (open symbols). ?/? furosemide; ?/? gemfibrozil; ?/? 
sildenafil. Indicated are means and standard error of means (n=3). The data were normalized 
to the basal accumulation of model substrates.  
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cells, which is in agreement with the findings in the fluorospectrophotometric inhibition 
assays. When Rho123 was used as substrate, a higher efflux activity was observed 
with controls and 1200 μM gemfibrozil in the PLHC-1/dox cells indicating that 
gemfibrozil does not inhibit P-gp like transport mechanisms. 
 
Cytotoxicity 
The modulation of efflux activity may lead to higher concentrations of compounds 
within the cells and therefore to more sensitive responses of the cells. PLHC-1/dox 
cells export doxorubicin efficiently. Consequently, the EC50 value for cytotoxicity was 
Figure 3: Accumulation of model substrates calcein-AM (two columns on the left side) and 
rhodamine 123 (two columns on the right side) observed by fluorescent microscopy. Co-
exposure of PLHC-1/wt or PLHC-1/dox cells with model substrate and inhibitor led to 
increased intracellular accumulation. As inhibitor were used 10 μM CyA, 20 μM atorvastatin, 
30 μM sildenafil, 1200 μM gemfibrozil. 
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about 5.3 times higher (0.74 μM) than in PLHC-1/wt (0.14 μM) (Tab. 3). Doxorubicin 
was exposed to PLHC-1/dox and PLHC-1/wt cells together with pharmaceuticals 
assumed to have an inhibitory effect on P-gp. 8 μM tamoxifen, 30 μM fenofibrate, and 
30 μM sildenafil could reverse partly the resistance of the cells towards doxorubicin 
(Fig. 4). However, atorvastatin, simvastatin and gemfibrozil did not modulate the 
resistance. This difference was not found in PLHC-1/wt cells (Tab. 2). 
 
Currently, a system sensitive enough to measure ATP hydrolysis is missing for aquatic 
organisms. This would allow a direct correlation to the transport activity of ABC-
Figure 4: Co-exposure experiments performed in PLHC-1/dox cells with doxorubicin as 
substrate and different inhibitors: A) 0.6 μM CyA, B) 30 μM sildenafil (Sd), C) 8 μM tamoxifen 
(Ta), D) 30 μM fenofibrate (Ff). The inhibitors modulated the efflux of doxorubicin, which 
resulted in decreased cytotoxicity compared to cells exposed without inhibitors. The MTT-
assay was performed to measure cytotoxicity. Indicated are means, standard error of means 
and the 95% confidence interval (n=3). 
Table 2: EC50 values for doxorubicin found in PLHC-1/dox cells after exposure for 72 h with 
and without inhibitors. MF: modulation factor (EC50 w/o inhibitor / EC50 with inhibitor). 
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transporters. However, a shift found in cytotoxicity upon the exposition in PLHC-1/dox 
cells to an assumed substrate together with an inhibitor gives indirect evidence whether 
a compound is a substrate of P-gp. Acebutolol, atorvastatin, furosemide, propranolol, 
and ranitidine pharmaceuticals known to be substrates for human ABCB1 transporters 
were exposed to PLHC-1/dox and PLHC-1/wt cells together with the model inhibitor 
CyA. Cytotoxic effects for acebutolol, atorvastatin as well as doxorubicin were found at 
lower concentrations compared to cells exposed without 0.5 μM CyA (Fig. 5). This was 
not observed with propranolol and furosemide. 
 
 
Discussion 
In this study we assessed effects of pharmaceuticals from different classes and modes 
of action in PLHC-1 cells, an in vitro model system for fish. PLHC-1 cells were shown 
to posses MDR activities and the two toxicologically relevant transporters P-gp1 and 
MRP3 have been cloned (Zaja et al. 2007). Furthermore, a P-gp1 overexpressing 
subclone was selected and characterized towards its functional activity and resistance 
to various cytostatic drugs. Low concentrations of a specific inhibitor completely 
Figure 5: Co-exposure experiments performed in PLHC-1/dox cells with 0.5 μM CyA as 
inhibitor and different pharmaceuticals: A) acebutolol (Ace), B) propranolol (Pro), C) 
atorvastatin (Av), D) furosemide (Fur). CyA could modulate the cytotoxicity of Ace, Av and 
slightly Pro indicating that these substances are transported by P-gp. The MTT-assay was 
performed to measure cytotoxicity. Indicated are means, standard error of means and the 95% 
confidence interval (n=3).  
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reversed the resistance and revealed the fragility of the P-gp1-mediated MXR defence 
mechanism in fish (Zaja et al. in press). 
 
We screened 33 pharmaceuticals for inhibitory effects on the transport activity using 
the two model fluorescent substrates Ca-AM and Rho123 both in the PLHC-1/wt and 
PLHC-1/dox cells. 18 of the 33 tested compounds showed at least in one subclone an 
increased intracellular accumulation of the model substrates, which demonstrates their 
inhibitory effects on efflux transporters.  
 
The lipid-lowering agent atorvastatin was the most potent inhibitor and showed a 
similar inhibitory potency as the model inhibitor CyA on the efflux of both Ca-AM and 
Rho123. In the cytotoxicity assays, a 2.7-fold shift of the EC50 value to higher toxicity 
was found in PLHC-1/dox cells when atorvastatin and CyA were co-exposed as 
compared to solely exposure to atorvastatin. In contrast, atorvastatin could not 
modulate the cytotoxicity of doxorubicin. These findings indicate that atorvastatin was 
transported by P-gp and its inhibitory effects were due to competitive inhibition. 
Simvastatin led to an accumulation of model substrates of up to 5-fold, whereas 
pravastatin revealed only weaker inhibitory effects and only with Ca-AM as substrate. 
 
In human medicine, statins are used to decrease intracellular cholesterol biosynthesis 
by reversibly inhibiting the microsomal enzyme hydroxymethylglutaryl coenzyme A 
(HMG-CoA) reductase (Schachter 2005). However, they have also been found to 
exhibit effects on MDR transporters. Intracellular accumulation studies with different 
model substrates and ATP hydrolysis assays were performed to study the 
characteristics of statins in systems expressing human ABC-transporters. Atorvastatin, 
simvastatin as well as lovastatin were effective inhibitors of P-gp with IC50 values of 
307 μM, 46 μM and 67 μM, respectively (Wang et al. 2001). The results of ATP 
hydrolysis assays in the same study revealed lovastatin and simvastatin as rapid 
substrates (Km ~20 μM and ~18 μM for lovastatin and simvastatin, respectively) for P-
gp whereas atorvastatin seemed to be a slower substrate (Km ~84 μM). In contrast, 
pravastatin did not have any effect on the efflux of Rho123 and an inconclusive effect 
on ATP hydrolysis. Our studies with fish cells confirm these findings as did other 
studies on human P-gp (Chen et al. 2005; Sakaeda et al. 2002). 
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Sildenafil, the active ingredient of Viagra®, exhibited a 2.1- to 4.5-fold increased 
intracellular accumulation of model inhibitors and also modulated the cytotoxicity of 
doxorubicin. In humans, sildenafil was shown to inhibit MRP5 (ABCC5) (Reid et al. 
2003), an inhibition of P-gp-like transporters has not been reported so far. As the two 
model substrates Ca-AM and Rho123 are known to be transported by both P-gp and 
MRP-like transporters we propose that the effect found is at least partly due to the 
inhibition of a so far not described ABCC transporter in PLHC-1 cells, possibly MRP5. 
Furthermore, doxorubicin induced not only the expression of P-gp but also of MRP5 in 
human lung cancer cells (Yoshida et al. 2001). The authors proposed that this co-
overexpression may contribute to the doxorubicin-resistance found in cancer cells. 
These findings can explain why sildenafil could modulate the cytotoxicity of 
doxorubicin. Further studies are necessary in PLHC-1 cells to prove this conclusion. 
 
Weak effects on the transport activity of model substrates were also found for the 
fibrates gemfibrozil, fenofibrate, bezafibrate and the active metabolite of several 
fibrates, clofibric acid. 1500 μM bezafibrate and 3300 μM clofibric acid exhibited 
maximal inhibitory effects of 1.7-fold and 1.4-fold, respectively. The high concentrations 
and small effects found for bezafibrate and clofibric acid may be explained as 
unspecific inhibitions of the transporters. In contrast, gemfibrozil showed up to 3.5-fold 
inhibitory effects with PLHC-1/wt and PLHC-1/dox cells as well as with both model 
substrates. Fenofibrate inhibited the transport activity of Ca-AM in PLHC-1/dox only 
slightly but it modulated the cytotoxicity of doxorubicin.  
 
Fenofibrate was found to inhibit moderately human P-gp, whereas gemfibrozil, 
bezafibrate and clofibric acid did not exhibit any effect on P-gp (Yamazaki et al. 2005). 
However, gemfibrozil showed inhibition on human organic anion transporting-
polypeptide 1B1 (OATP2) (Yamazaki et al. 2005). Our findings suggest that the effect 
found for gemfibrozil is not due to an effect on P-gp as the dose-response curve was 
well defined in PLHC-1/wt but not in PLHC-1/dox cells. Rather, gemfibrozil may interact 
with other transporters expressed in PLHC-1 cells. 
 
Tamoxifen is used in the treatment against breast carcinoma. It exhibits its 
antiestrogenic properties due to its ability to compete with estrogen for its binding sites 
in target tissues (Furr and Jordan 1984). Different studies have demonstrated an 
inhibitory effect of tamoxifen on human P-gp in vitro as well as in vivo (Bekaii-Saab et 
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al. 2004; Frank et al. 2001; Keen et al. 1994; Saeki et al. 2005). Our study verified that 
tamoxifen modulates the cytotoxicity of doxorubicin also in fish cells. In intracellular 
accumulation assays a 1.4-fold maximal inhibition of tamoxifen occurred at 3.8 μM 
which is consistent with published IC50 values in the range of 1–30 μM.  
 
The two β-blockers acebutolol and proranolol were analysed in this study as they were 
reported to be substrates of human P-gp (Kawazu et al. 2006; Yang et al. 2000). In 
PLHC-1/dox cells, propranolol led to a 2.61-fold accumulation of Ca-AM, but acebutolol 
showed only a slight effect. When they were co-exposed with CyA, a shift in cytotoxicity 
was observed for acebutolol. For propranolol, there was only a small, but not significant 
modulation. These findings indicate that both β-blockers are moderate substrates of P-
gp, however, the sensitivity is not high enough to draw firm conclusion. 
 
In conclusion, our results confirm that the two subclones PLHC-1/wt and PLHC-1/dox 
are reliable tools for assessing inhibitory effects of human pharmaceuticals to fish ABC-
transporters. Cytotoxicity assays showed that inhibitors of multidrug resistance 
transporters like P-gp can exhibit indirect effects in cells. Furthermore, the modulation 
of cytotoxicity of pharmaceuticals such as atorvastatin and acebutolol indicate that 
these substances are transported by P-gp. The findings correlate well with effects 
found in human systems confirming that the transporters involved in MXR in fish play a 
similar role as in mammals. For further characterisation of MXR mechanisms in fish it is 
necessary to clone, transfect and express transporters like P-gp1 and MRP3 in 
appropriate model systems. However, the PLHC-1 cells are a reliable system for the 
screening and assessment of single compounds and likely also of environmental 
samples regarding their effects on MXR in aquatic organisms. Our study also 
demonstrates that human pharmaceuticals present in aquatic systems interact with 
efflux transporters, although at much higher concentrations than found in the 
environment. The interaction leads to inhibition of efflux activity and therefore mixtures 
of such compounds may increase the toxicity to environmental pollutants. 
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Abstract 
Lipid-lowering agents such as bezafibrate, fenofibrate, gemfibrozil and the metabolite 
clofibric acid belong to those pharmaceuticals most often found in aquatic systems, 
with concentrations as high as several micrograms per litre. However, only sparse data 
are available on potential adverse effects in aquatic organisms. The peroxisome 
proliferator-activated receptor α (PPARα) is the specific targets of fibrates in humans 
and there is evidence that the latter also interact with these receptors in fish. Upon 
activation PPARs form a heterodimer with the retinoid X receptor (RxR) and bind to 
specific regulatory regions in target genes. 
 
The aim of our work was the detection and characterisation of the three receptors 
PPARα, PPARβ and PPARγ in the fish cell line PLHC-1. By using degenerated primers 
designed for conserved regions of the different receptors, we found all PPARs as well 
as RxR present in the cells. The gene sequences showed high similarities to other 
known sequences in fish, especially with Dicentrarchus labrax and Sparus aurata. In 
expression analysis, the highest expression level was found for PPARα followed by 
PPARγ and PPARβ. Upon exposition to different fibrates for 6 h, the expression level of 
PPARα and PPARγ was induced up to tenfold. Further, we measured an increased 
activity of the peroxisomal enzyme fatty acyl coenzyme A oxidase (FAO) after 
exposure of PLHC-1 cells to fibrates. All fibrates investigated showed effects on FAO, 
and gemfibrozil showed the highest increase (30%) in FAO activity over control level. 
These results demonstrate for the first time the presence and function of PPARs in the 
fish cell line PLHC-1. 
 
 
Key Words: Fibrates, peroxisome proliferator-activated receptors, peroxisome 
proliferation, PLHC-1, fish cell line, in vitro 
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Introduction 
Pharmaceuticals have frequently been detected in their parent form or as metabolites 
in effluents of sewage treatment plants, surface waters, ground waters and even in the 
sea (for reviews (Daughton and Ternes 1999; Fent et al. 2006; Halling-Sorensen et al. 
1998)). Several monitoring studies have shown that many pharmaceuticals from 
different therapeutic classes are present in surface waters with median concentrations 
in the range of ng/L up to μg/L (Fent et al. 2006). At present, little is known about their 
potential adverse effects on aquatic organisms and ecosystems, despite their 
ubiquitous occurrence and high biological activity (Fent et al. 2006). 
 
Fibrates and their metabolites belong to pharmaceuticals regularly found in aquatic 
systems with concentrations as high as several micrograms per litre (Fent et al. 2006). 
Clofibric acid, the persistent and active metabolite of clofibrate, etofyllin clofibrate and 
etofibrate, belongs to the most frequently detected pharmaceuticals in monitoring 
studies. It has been found in numerous wastewaters, surface waters, in seawater 
(Weigel et al. 2002) and even in concentrations up to 4 μg/L in the groundwater and in 
the drinking water (0.07-0.27 μg/L) (Heberer 2002). Bezafibrate, fenofibrate and 
gemfibrozil have been detected in sewage water and surface water with concentrations 
up to 4.6 μg/L and 3.1 μg/L, respectively.  
 
Fibrates as another group of pharmaceuticals, the statins, are lipid-lowering drugs. 
They are used for the treatment of hypercholesterolemia and decrease the 
concentration of cholesterol – and fibrates also of triglycerides – in the blood plasma. 
Whereas the statins inhibit the 3-hydoxymethylglutaril coenzyme A reductase (HMG-
CoA) (Endo 1992), the fibrates exhibit their effects through alterations in the 
transcription of genes encoding for proteins controlling the lipoprotein metabolism. The 
target of fibrates was found to be the peroxisome proliferator-activated receptors 
(PPAR), manly the PPARα isoform (Staels et al. 1998). 
 
PPARs belong to the steroid/thyroid/retinoid receptor superfamily of ligand-activated 
nuclear transcription factors. Upon activation, they form a heterodimer with the retinoid 
X receptor (RxR) and bind to specific regions – the peroxisome proliferator response 
elements (PPRE) – of target genes. To date, three subtypes of PPAR have been 
described, called PPARα, PPARβ (or PPARδ) and PPARγ. They play a key role in the 
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lipid metabolism and the lipid homeostasis (Desvergne et al. 2006; Escher and Wahli 
2000). In addition, all PPAR isoformes can participate in the regulation of inflammatory 
responses (Escher and Wahli 2000). 
 
Several studies have investigated PPARs in aquatic organisms. Full PPAR coding 
sequences have been described in fish such as plaice Pleuronctes platessa and 
gilthead sea bream Sparus aurata (Leaver et al. 1998), seabass Dicentrarchus labrax 
(Boukouvala et al. 2004), zebrafish Danio rerio (Robinson-Rechavi et al. 2001), 
thicklipped grey mullet Chelon labrosus (Raingeard et al. 2006), and torafugu pufferfish 
Takifugu rubripes (Kondo et al. 2007). In addition, partial nucleotide sequences have 
been published for atlantic salmon Salmo salar (Ruyter et al. 1997), rainbow trout 
Oncorhynchus mykiss (Liu et al. 2005), brown trout Salmo trutta (Batista-Pinto et al. 
2005), and goldfish Carassius auratus (Mimeault et al. 2006). Fish PPARs display an 
amino acid sequence identity of 46–73% to the human and amphibian PPARs (Kondo 
et al. 2007).  
 
Like in humans PPARα was mainly expressed in hepatocyte and tissues that 
catabolize high amounts of fatty acids (Ibabe et al. 2002). Furthermore, PPARγ was 
shown to be induced in response to clofibrate and bezafibrate in salmon hepatocytes 
(Ruyter et al. 1997), although their PPARγ seem to be less responsive than PPARγ of 
rodents (Andersen et al. 2000). All three PPAR receptors were found to be already 
expressed in the larval stage, with a similar tissue distribution pattern to that found in 
adult zebrafish  (Ibabe et al. 2005a). Activators of PPARα include a variety of 
endogenously present fatty acids, leukotrienes, hydroxyeicosatetraenoic acids and 
drugs, such as fibrates (Cajaraville et al. 2003). PPARβ activators include fatty acids, 
prostaglandin A2 and prostacyclin. PPARγ is the most selective receptor and 
prostaglandin J2 has been described to be a specific ligand (Ibabe et al. 2005b). In 
isolated zebrafish hepatocytes, mRNA of both PPARα and PPARγ was induced by 
clofibrate at 0.5–2 mM, although to a low extent (Ibabe et al. 2005b). The physiological 
and toxicological roles of PPARs have yet to be investigated, but there is evidence that 
there may be differences to other vertebrates. Kondo et al. (2007) found that activators 
of mammalian PPARβ and PPARγ failed to have an effect on these receptors in 
Takifugu rubripes. These finding indicate that the PPARs of T. rupripes require either 
undefined ligands or that the molecular mechanisms involved in their activation are 
different from those of other vertebrates. 
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The PLHC-1 cell line (Poeciliopsis lucida hepatoma cell) has widely been used in 
aquatic ecotoxicology as an in vitro model system (Fent 2001). The presence of phase 
I enzymes, especially CYP1A1, and to a lesser extent phase II enzymes (GSTs, UGTs) 
has been reported. Recently, the expression of two toxicologically relevant ABC 
transporters, Pgp1 (ABCB1) and MRP3 (ABCC3) has been described (Zaja et al. 
2007). Furthermore this cell line has been widely used for the identification and 
evaluation of cytotoxicity, CYP1A induction, genotoxic potential of individual 
compounds and complex environmental samples, toxic responses like lipid 
peroxidation, induction of metallothioneins and heatshock proteins (Caminada et al. 
2006; Fent and Batscher 2000; Rau et al. 2004; Schlenk and Rice 1998). 
 
The aim of our study was the detection and primary characterisation of the three 
receptors PPARα, PPARβ and PPARγ in the fish hepatoma cell line PLHC-1. The 
receptor sequences found revealed high similarities to other known fish PPARs. In 
addition, the retinoid X receptor (RxR) was detected, a necessary preliminary for a 
functional activation by the PPARs. Further, the induction of the receptors was 
investigated after exposure to fibrates as well as the activity of the fatty acyl-CoA 
oxidase (FAO) to prove the functionality of the PPAR activation and to assess effects of 
ecotoxicologically relevant fibrates in the PLHC-1 cell line following a mechanism-
based approach to assess ecotoxicity of environmental pharmaceuticals. 
 
 
Materials and Methods 
Chemicals 
Dulbeccos minimum essential medium with F-12 nutrient mixture (DMEM/F12) with 
phenol red, trypsin/ethylenediamine tetraacetic acid (EDTA), and L-glutamine were 
obtained from LuBio Science GmbH (Switzerland). Fetal bovine serum (FBS) was 
purchased from Sigma-Aldrich (Switzerland). Dimethyl sulfoxide (DMSO), di-chloro-di-
hydro-fluorescamine, aminotriazole, bovine serum albumin (BSA), tween, palmitoyl 
CoA, clofibric acid (purity 97%), fenofibrate (≥ 99%), and gemfibrozil (≥ 99%) were 
purchased from Sigma-Aldrich (Switzerland), bezafibrate (≥ 99.3%) was kindly supplied 
by F. Hoffmann-La Roche Ltd (Switzerland). 
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Stock solutions of all pharmaceuticals were prepared in DMSO at a concentration of 
500 mM where soluble, otherwise substances were diluted corresponding to their 
solubility. For the different assays, stock solutions were diluted in the buffered cell 
culture medium (20 mM HEPES/pH 7.2) resulting in a maximal DMSO concentration of 
0.05%. Further concentrations were prepared by serial dilution.  
 
Cell culture 
The fish hepatoma cells PLHC-1 (Poeciliopsis lucida hepatoma cell) kindly supplied by 
L.E. Hightower (Ryan 1994) were grown in DMEM/F12 supplemented with 5% FBS  in 
a humidified incubator with 5% CO2 at 30°C. Cells were usually split every 4 days by 
dissociating with 0.05% (w/v) trypsin and 0.5 mM EDTA and subcultured at split ratios 
of about 1:6. For the different assays, cells were seeded on cell culture dishes with 
6 cm or 10 cm diameter (Milian, Switzerland).  
 
RT-PCR  
The PLHC-1 cells were lysed directly on the cell culture dish and homogenized using a 
QIAshredder Kit (Qiagen, Basel, Switzerland). RNA extraction was performed using an 
RNeasy Mini Kit (Qiagen, Basel, Switzerland). The concentration of the RNA was 
spectrophotometrically measured at 260 nm (NanoDrop® ND-1000 full-spectrum (220–
750 nm) spectrophotometer) and the quality was verified by measuring the ratio of 
absorption at 260 nm and 280 nm as well as on a RNA 6000 Nano LabChip Kit (Agilent 
Technologies, Basel, Switzerland). 1000 ng of the total RNA template was reverse-
transcribed using poly-dT-primer and Transcriptor Reverse Transcriptase (Roche 
Diagnostics, Basel, Switzerland). 
 
For the detection of PPARα, PPARβ, PPARγ and RxR, known sequences of all four 
receptors were aligned and degenerated primers were designed on conserved regions 
(Tab. 1). The amplification conditions consisted of initial denaturation at 94°C for 2 min, 
followed by 40 cycles of denaturation at 94°C for 30 sec, annealing for 60 sec, and 
elongation at 72°C for 60 sec. The final elongation was hold for 7 min at 72°C. A 
temperature gradient was performed in the range from 45°C to 60°C in order to find the 
best annealing temperature (Table 1).  
 
The PCR samples were loaded on a DNA 1000 LabChip (Agilent Technologies, Basel, 
Switzerland) and analyzed on an Agilent 2100 bioanalyzer (Agilent Technologies, 
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Basel, Switzerland). For sequencing, PCR samples were loaded and separated on a 
1.2% agarose gel and the bands of expected sizes were excised from the gel. The 
following digestion of the agarose pieces and the purification of the PCR products were 
performed using NucleoSpin® Extract II kit (Macherey-Nagel, Germany). The PCR 
products were custom-sequenced (Synergene Biotech GmbH, Switzerland). 
 
Expression analysis of PPARs 
PLHC-1 cells were exposed for 6 h to different fibrates. The cells were seeded on cell 
culture dishes (6 cm diameter) with a density of 10x105 cells/ml. After 24 h, the medium 
was changed and 24 h later fibrates were added. The concentrations were 100 μM 
clofibric acid, 100 μM gemfibrozil, 10 μM fenofibrate, and 10 μM bezafibrate. Cells 
exposed to the solvent DMSO were used as negative control. The concentration of the 
solvent DMSO was 0.1%. RNA was extracted and reverse transcription was performed 
as mentioned above using 1000 ng total RNA. 
 
Table 1. Primers designed for the detection of PPARα, PPARβ, PPARγ and RxR. Degenerated 
positions in the primer sequence are indicated in bold. Anopt: optimal annealing temperature. 
IUPAC-code: R=A/G, Y=C/T, S=C/G, D=A/G/T, B=C/G/T. 
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For real time PCR, specific primers for all three receptors were designed, with 
annealing temperature at 58°C and a resulting product of approximately 160 bp (Tab. 
2). β-actin was used as a housekeeping gene. Real time PCR amplification was 
performed on a RotorGeneTM 6000 (Corbett Life Sciences, Brisbane, Australia) using 
the FastStart SYBR Green System (Roche Diagnostics, Switzerland). The amplification 
conditions consisted of initial denaturation at 95°C for 10 min, followed by 50 cycles of 
denaturation at 95°C for 30 sec, annealing at 58°C for 45 sec, and elongation at 72°C 
for 45 sec. A melting curve analysis was performed after the run.  
 
Fatty-Acyl CoA Oxidase (FAO) Assay 
PLHC-1 cells were seeded on cell culture dishes (10 cm diameter) and 24 h later 
exposed to fibrates. The medium containing the fibrates was changed every day. After 
72 h, the cells were harvested with a rubber policeman (VWR, Switzerland) and lysed 
with lysis buffer (60 mM Trisma Base/pH 8.3, 0.25 M Sucrose, 1% Triton X-100 
containing one tablet of Protease Inhibitor Cocktail (Roche, Switzerland)) and by 
sonification twice for 15 sec (60%, 0.6 cycle). The lysate was centrifuged for 20 min at 
15’000g at 4°C. The amount of protein was measured using the BioRad Protein Assay 
(Bio-Rad, Switzerland) based on the Bradford dye-binding procedure (Bradford 1976).  
 
The FAO-assay (Small et al. 1985) was performed in a 96-well microplate. The reaction 
mixture contained 12 units/ml horseradish peroxidase, 0.05 mM di-chloro-di-hydro-
fluorescamine and 40 mM aminotriazole in 10 mM PBS/pH 7.4, 0.6 mg/ml BSA and 
0.02% Tween. Cell lysate was added to the reaction mixture with a final concentration 
of 400 μg/ml protein and preincubated for 5 min in the dark. The microplate was 
Table 2. Primers used for expression analysis of PPARα, PPARβ, and PPARγ as well as the 
housekeeping gene β-actin. The optimal annealing temperature is 58°C. 
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measured at 502 nm on a spectrophotometer (Tecan, Switzerland). To start the 
reaction 30 μM palmitoyl CoA was added to each well and the enzymatic reaction was 
monitored by measuring at 502 nm every 5 min during 1 h.  
 
Data analysis 
Sequence manipulations, analysis and multiple alignments were done using BLAST 
Internet service, BioEdit (version 5.0.1) and DNASIS MAX (version 2.05, Hitachi 
Software Engineering Co.). Sequences were submitted to GenBank (NIH genetic 
sequence database) and got the accession numbers EU180568 (PPARα), EU180569 
(PPARβ), EU180570 (PPARγ), EU180571 (RxR), and EU180572 (β-actin). 
 
All experiments were independently repeated three times and the results of typical 
experiments are shown. Expression analysis was performed using Rotor-Gene 6000 
Series Software (Corbett Life Sciences, Brisbane, Australia) and Excel. Data from the 
FAO-assay were analysed by one-way ANOVA (p-value < 0.05). 
 
 
Results 
Three PPARs and RxR are expressed in PLHC-1 
Sequences for the four receptors PPARα, PPARβ, PPARγ and RxR are not kown for 
P.lucida, the organism PLHC-1 cells are derived from, but the receptors have been 
described in various other organisms including fish. Therefore, known sequences were 
aligned and degenerated primers were designed on conserved regions of each 
receptor. Several primers and combination of primers as well as different annealing 
temperatures were tested. Table 1 shows the primer pairs and the corresponding 
annealing temperatures that resulted in PCR products of the expected sizes (Fig. 1).  
 
The three PCR products found for PPARα had sizes of 227 bp, 238 bp and 524 bp and 
the sequence showed a similarity of up to 86% (Dicentrarchus labrax and Takifugu 
rubripes) with other fish species (Fig. 1A). The sequence is a part of the ligand binding 
domain of the receptor an all helical domain. The translated sequence (Fig. 2A) 
revealed 82% identities and 92% positives with the human PPARα pointing at a high 
degree of conservation. 
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For PPARβ, PCR products were found of 229 bp, 448 bp and 636 bp with an overall 
similarity of up to 89% with Dicentrarchus labrax, Pagrus major, Scophthalmus 
maximus and Oryzias latipes (Fig 1B). A high conservation was also found for the 212 
amino acid long translated sequence (Fig. 2B) that comprised the ligand binding 
domain. Identities were up to 96% and positives up to 98% with fish species (Sparus 
aurata, Dicentrarchus labrax, Pagrus major) and 82% and 89% identities and positives, 
respectively, with human PPARβ. 
 
The smallest fragment was found for PPARγ with a total size of 313 bp equivalent to 
104 amino acids (Fig. 1C). The cDNA identities were as high as 90% (Dicentrarchus 
labrax) and the translated sequence (Fig. 2C) showed 96% identities and 98% 
positives with Platichthys flesus. The sequence covers a part of one of the two zinc 
finger domains that are an element of the DNA binding domain. Conserved cysteins 
are found at positions 2, 12, 15 and 20.  
 
Upon binding of a ligand, PPARs form a heterodimer with the retinoid X receptor (RxR). 
This complex binds to PPREs and activates the expression of target genes. Hence, 
RxR is a necessary prerequisite for the functionality of PPAR activation. A 530 bp 
partial cDNA was found with identities up to 88% to fish (Paralichthys olivaceus) and 
the translated sequence (Fig. 2D) that is a part of the ligand binding domain showed 
87% identities and 93% positives with the human RxR receptors. 
Figure 1: Results of RT-PCR for the three receptors PPARα (A), PPARβ (B), and PPARγ (C). 
PCR products were analyzed on a Bioanalyzer (Agilent Technologies, Switzerland). L: ladder; A: 
actin; 1: PPARα, fw/rv 1/1; 2: PPARα, fw/rv 2/2; 3: PPARα, fw/rv 2/3; 4: PPARβ, fw/rv 1/1; 5: 
PPARβ, fw/rv 2/2; 6: PPARβ, fw/rv 1/2; 7: PPARγ, fw/rv 1/1; 8: PPARγ, fw/rv 2/2 
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Alignments of all four receptors found in this study in PLHC-1 cells with fish sequences 
as well as human and mouse are shown in figure 2. 
 
A) 
 
 
B) 
 
Figure 2: Sequence alignments for PPARα (A), PPARβ (B), PPARγ (C) and RxR (D). 
Sequnces were aligned using DNASIS MAX (Hitachi Software Engineering Co.). PPARα, 
PPARβ, and RxR comprise the all helical ligand binding domain. PPARγ covers the last part 
of one of the two zinc finger domains that are an element of the DNA binding domain. 
Conserved cysteins are at position 2, 12, 15, and 20. Yellow: 100% identity, green: > 50% 
identity. 
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C) 
 
 
D) 
 
 
 
Expression analysis of PPARs 
Specific primers for expression analysis were designed based on the obtained 
sequences (Tab. 2). All primer pairs have an optimal annealing temperature of 58.0°C 
and give a PCR product between 161 bp and 166 bp. First, the relative expression of 
the three receptors was assessed. The highest expression level was found for PPARα 
(100%) followed by PPARγ (73% of PPARα). PPARβ was expressed 3 times less than 
PPARα (37%) (Fig. 3). 
 
To assess an induction of the PPAR-pathway, the three fibrates bezafibrate, fenofibrate 
and gemfibrozil as well as clofibric acid, the active metabolite of several fibrates, were 
chosen as they are ligands and inducers of mammalian PPARs. Confluent PLHC-1 
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cells were exposed to the different fibrates or the solvent control. An induction of 
PPARα and PPARγ was found for all four fibrates after 6 h of exposure, the expression 
level of PPARβ was not changed, however (Fig. 4B). Bezafibrate and clofibric acid 
revealed the strongest induction with 4.03-fold and 2.77-fold for PPARα and 10.45-fold 
Figure 3: Expression analysis of the three PPARs in PLHC-1 cells. The expression is indicated 
relative to PPARα. Shown are means ± standard deviation (n=3). 
Figure 4: Induction of PPAR expression in 
PLHC-1 cells after 6 h of exposition to 
10 μM bezafibrate, 10 μM fenofibrate, 
100 μM gemfibrozil, 100 μM clofibric acid. 
A) PPARα, B) PPARβ, C) PPARγ. Shown 
are means ± standard deviation (n=3). 
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and 2.74-fold for PPARγ (Fig. 4A/C), respectively. The exposure to fenofibrate resulted 
in a 2.65-fold and 2.30-fold induction of PPARα and PPARγ, respectively. Gemfibrozil 
was slightly more potent than fenofibrate. The induction of PPARα was 2.77-fold and of 
PPARγ 2.81-fold. However, no significant induction was found in cells that were 
exposed for 3 d, 7 d and 14 d to fibrates (data not shown). 
 
FAO activity 
As a consequence of peroxisome proliferation peroxisomal enzymes and proteins 
become higher expressed. FAO is an enzyme involved in the β-oxidation of fatty acids 
in the peroxisome. We exposed PLHC-1 cells to different concentrations of bezafibrate, 
clofibric acid, fenofibrate, and gemfibrozil and measured the FAO activity after 72 h. All 
fibrates showed an increased dose-dependent activity (Fig. 5). The most potent fibrates 
were gemfibrozil and bezafibrate with a maximal increase in FAO activity of 30% at a 
concentration of 50 μM and 5 μM, respectively. Clofibric acid showed a 16% higher 
activity than controls and the least effects were found for fenofibrate with a 7% increase 
at 2.5 μM. 
 
 
Discussion 
Our work describes for the first time the presence and functional activity of PPARs in 
an in vitro model system for aquatic organisms, the PLHC-1 cell line. A response by the 
PPAR pathway is only possible when the activated PPAR forms a heterodimer with the 
RxR receptor (Escher and Wahli 2000). We detected all three PPARs as well as RxR 
demonstrating that the prerequisite for a response by the PPAR pathway is given in the 
PLHC-1 cells. In addition, after exposure of fibrates to PLHC-1 cells, an induction of the 
expression of PPARα and PPARγ was found as well as an increased activity of the 
peroxisomal enzyme FAO that is involved in the β-oxidation pathway of fatty acids. 
 
We detected four partial sequences: The sequence of PPARγ covered the last part of 
one of the two zinc finger domains that are an element of the DNA binding domain. As 
expected, the sequence is highly conserved. The sequences of PPARα, PPARβ and 
RxR covered the all-helical ligand binding domain. The high similarities with the 
corresponding receptors of other fish species and even with humans indicate that these 
receptors still have the same or at least similar ligand specificities and, consequently, 
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similar roles within the cell. However, there are studies that show differences between 
mammalian and fish PPARs. Potent activators of mammalian PPARβ and PPARγ 
failed to induce these receptors of Takifugu rubripes in a reporter assay (Kondo et al. 
2007). Other studies found that synthetic compounds and fatty acids induced the 
transcriptional activities in Pleuronectes platessa and Sparus aurata of PPARα and 
PPARβ, identical as in other vertebrates. However, the activity of their PPARγs was not 
enhanced by these products (Leaver et al. 2005). Another difference found in fish is the 
numbers of PPARs. One of each of the three PPARs has been reported in mammals. 
However, there have been found four (two isoforms of PPARα) in Takifugu rubripes 
(Maglich et al. 2003). In addition to one PPARγ, Danio rerio has two PPARα as well as 
two PPARβ (Robinson-Rechavi et al. 2001). Even four PPARβ subtypes were recently 
described in Atlantic salmon (Salmo salar) assigned into two families, each containing 
two isotypes (Leaver et al. 2007).  
 
The expression level of PPARs has been investigated after exposure to ligands such 
as fibrates in Salmo salar and in Carrassius aurata (Mimeault et al. 2006; Ruyter et al. 
1997). A 1.8-fold increase in PPARγ expression was found after 3 d exposure to 
0.5 mM clofibric acid as well as 0.5 mM bezafibrate in Salmo salar (Ruyter et al. 1997). 
Figure 5: Increase in FAO activity after 72 h exposition to fibrates. A) Exposition to gemfibrozil 
(Gf); B) exposition to bezafibrate (Bf); C) exposition to clofibric acid (Ca); D) exposition to 
fenofibrate (Ff). Shown are means ± standard deviation (n=3). Significant values are marked 
with * (P < 0.05). 
PPARs in PLHC-1 Cells 
 116
Mimeault et al. (2006) found a decrease of the PPARβ expression level after 14 and 28 
days of exposure to 1500 μg/L (6 mM). The expression levels of PPARα and PPARγ 
were unchanged, however. We have found an increased expression of PPARα and 
PPARγ in PLHC-1 cells after exposure for 6 h to all four fibrates of up to 10-fold. 
However, no significant induction was found in cells that were exposed for 3 d, 7 d and 
14 d to fibrates (data not shown). The expression level of PPARβ remained 
unchanged. We assume that the fibrates bezafibrate, fenofibrate, gemfibrozil and the 
metabolite clofibric acid activated PPARα and that PPARα itself as well as PPARγ are 
regulated by PPARα. There is evidence that the expression of PPARα and of PPARγ is 
induced in the beginning upon activation of PPARα as first response and turns back to 
basal level later on. Our results suggest that PPARβ is not regulated by PPARα in the 
PLHC-1 cells. In summary we found in PLHC-1 cells that all fibrates designed to be 
ligands for PPARα enhanced the expression of PPARα and PPARγ. Further 
investigations with PPARβ and PPARγ specific ligands are necessary to characterize 
the functionality of these two receptors in the PLHC-1 cells. 
 
The FAO activity has widely been used as a measure of peroxisome proliferation 
(Cajaraville et al. 2003; Donohue et al. 1993; Ibabe et al. 2005a; Mimeault et al. 2006; 
Ortiz-Zarragoitia and Cajaraville 2005; Ruyter et al. 1997). In our study, the FAO 
activity turned out to be not very sensitive to the exposure of fibrates. We have found a 
maximal increase in FAO activity of up to 30% over controls. The next step is to 
investigate effects on the expression level of different peroxisomal enzymes like FAO, 
bifunctional enzyme, and thiolase, which is probably a more sensitive approach. 
 
There are an increasing number of compounds reported to occur in the aquatic 
environment. Some of them such as pharmaceuticals, are known to have a specific 
mode of action in mammals and are assumed to act similarly in aquatic organisms 
(Fent et al. 2006; Owen et al. 2007). Other substances have so far not been 
characterized and may have the potential to exhibit unexpected effects. In surface 
waters, there is usually a complex mixture of different compounds present and 
therefore the risk of mixture effects arises. To address this issue it is necessary to first 
understand the biochemical mechanisms in aquatic organisms and to develop 
appropriate tools to screen for effects of numerous single substances, but also of 
complex (environmental) mixtures. For this purpose, in vitro systems are promising 
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tools as they are easy to handle and produce more reproducible results than in vivo 
systems. 
 
For our study we have chosen the fish hepatoma cell line PLHC-1 as it has widely been 
used in ecotoxicology as an in vitro model system to study detoxification mechanisms 
involving phase I and phase II enzymes (Fent 2001). The induction of the phase I 
enzyme CYP1A1 has been used for the assessment of the toxic potential of polycyclic 
aromatic hydrocarbons (PAHs), for single substances but also for complex 
environmental mixtures (Fent and Batscher 2000). Recently, the two efflux transporters 
P-gp1 (ABCB1) and MRP3 (ABCC3) that export a wide range of xenobiotics out of the 
cells have been detected and functionally characterized (Caminada et al. submitted; 
Zaja et al. 2007). Furthermore, the PLHC-1 cells have been used for the study of heat 
shock proteins (Ryan and Hightower 1996), metallothionein induction (Schlenk and 
Rice 1998) and cytotoxicity (Caminada et al. 2006). Due to the presence of all three 
critical phases of the detoxification system the PLHC-1 cells have been proposed as a 
reliable in vitro model in aquatic toxicology (Zaja et al. 2007). So far, only the aryl 
hydrocarbon (Ah) receptor has known to be present and functional in the PLHC-1 cells. 
Our present study demonstrates that there are at least four more nuclear receptors 
present in PLHC-1 cells, which are functional. These findings make the PLHC-1 cells 
an even more interesting model system for the investigation of molecular mechanisms 
of environmental pollutants in aquatic systems.  
 
Our findings correlate also with those found in fathead minnow (Pimephales promelas) 
where we investigated effects of bezafibrate and clofibric acid after chronic exposure 
for 14 days and 21 days. The expression level of PPARα was not affected significantly 
after 14 and 21 days of exposition. In contrast, the FAO activity after exposition for 14 
days to clofibric acid was about 1.5 times higher in male fish than in controls (Weston 
et al. submitted). 
 
In conclusion, our study shows for the first time the presence of all three PPARs as well 
as the RxR in PLHC-1 cells. We confirm previous suggestions that this cell line is an 
appropriate in vitro model system for aquatic organisms. Furthermore, the fibrates 
bezafibrate, fenofibrate, gemfibrozil and clofibric acid induced the expression of PPARα 
as well as PPARγ and they increased also the activity of FAO. In surface waters, the 
maximal concentrations of these fibrates are 4 μg/L. The effects found in this in vitro 
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study were at concentrations between 1.8 mg/L to 25 mg/L, about a factor 1000 higher 
than environmental concentrations. Whether in vitro effects in fish cells are less 
sensitive than effects in vivo has to be further analyzed. Further studies are also 
necessary to assess the specificity of PPARs towards other environmental pollutants 
and to estimate effects of compound mixtures. 
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Abstract 
Human pharmaceuticals are a class of emerging environmental pollutants, which are 
designed to act on specific targets. Our interest focuses on the lipid lowering agent 
bezafibrate and clofibric acid that, among other natural ligand and xenobiotics, are 
involved in peroxisome proliferation. We analysed the effects on liver metabolisms of 
fish after 14 and 21 days exposure to several concentrations from 0.1 to 106.7 mg/L 
bezafibrate, and 1.07, 10.75 and 108.91 mg/L clofibric acid, respectively, focussing in 
particular on peroxisome proliferator activating receptors and related enzymes. In 
addition we determined reproductive parameter such as egg production and 
vitellogenin induction to test the hypothesis, whether these human pharmaceuticals 
may be also linked to reproductive and developmental toxicity. We investigated 
whether both the expression of PPARα and the fatty-acyl oxidase (FAO) activity are 
affected in liver of fathead minnows. No effects were found in fish exposed to 
bezafibrate, in both mRNA expression of PPARα and FAO level at all concentration 
tested. Male fathead minnows exposed to clofibric acid showed an increased in FAO 
activity at 108.91 mg/L. This was not found in females and could not be related to an 
increase in PPARα expression. In addition a non significant decrease in egg production 
after 21 days of exposure to 1.07- 108.91 mg/L clofibric acid was found. In this study 
we demonstrate that the two lipid lowering agents did not significantly affect the 
parameter investigated at the concentrations tested, nor at environmentally relevant 
concentrations. 
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Introduction 
The awareness of potential environmental risks of human pharmaceuticals has 
increased in the last decade, as a considerable number of diverse medicinal products 
have been detected in the aquatic environment with concentrations that may reach 
several µg/L. Pharmaceuticals are designed to elicit a biological response in humans, 
but for most of these contaminants, potential toxic effects on aquatic organisms are not 
known, in particular after long-term exposure. In recent years it has become 
increasingly clear that it is not sufficient for the assessment of ecotoxicological hazard 
and risks to assess acute toxicity only. It is important to investigate the possible chronic 
effects of human pharmaceuticals on aquatic organisms. In addition, it is important to 
investigate these effects by focussing on target biomolecules and the histopathology of 
the organs (Fent et al. 2006). This was demonstrated for the non-steroidal 
antiinflammatory compound diclofenac, affecting liver and kidneys in fish similarly as in 
humans (Schwaiger et al. 2004). We proposed a concept of toxicity evaluation of 
pharmaceuticals in aquatic organism by focussing on their mode of action (Fent et al. 
2006). In regarding the mechanisms of action that may be similar in mammals and fish, 
more information on adverse effects may be gained than performing classical toxicity 
tests. Therefore, analysis of ecotoxicological effects should be performed following a 
mechanism-based concept. 
 
Amongst the most ubiquitously pharmaceuticals found in aquatic environment are the 
blood-lipid lowering agents bezafibrate and clofibric acid, the latter being the main 
metabolite of clofibrate, etollynifibrate and etofibrate. Bezafibrate occurred in sewage 
treatment plants effluents and surface water with maximal concentrations of 4.6 µg/L 
(Ternes 1998) and 3.1 µg/L (Stumpf et al. 1996). Clofibric acid has been found in 
sewage treatment effluents at maximal concentration of 1.6 µg/L (Ternes 1998) and at 
a maximal concentration of 0.55 µg/L in surface water (Buser et al. 1998). So far, for 
bezafibrate only acute toxicity data in Daphnia magna (EC50>200 mg/L) has been 
reported (Hernando et al. 2004). Clofibric acid has been analysed only for subchronic 
toxicity with LOEC for algae of 150 mg/L, for Cerodaphnia dubia of 2.56 mg/L and of 
140 mg/L in early life stage test of zebrafish (Ferrari et al. 2003). Acute toxicity on 
different organisms (Nunes et al. 2004) including oxidative stress has been reported 
(Nunes et al. 2006). In rats, fibrates have been found to induce peroxisome 
proliferation, which is strongly correlated to hepatocarcinoma (Qu et al. 2001). However 
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this has not been demonstrated in primates or fishes. As in mammals fibrates were 
found to interact with peroxisome proliferator-activated receptors (PPARs) in fish 
(Cajaraville et al. 2003; Ibabe et al. 2005; Ruyter et al. 1997) and mussels (Cajaraville 
et al. 2003). PPARs belong to the nuclear receptor superfamily and dimerize with the 
retinoid-X receptor to promote the expression of several lipid regulatory proteins by 
binding to a regulatory region of the target gene (Staels et al. 1998). PPARs are known 
to stimulate the proliferation of peroxisomes (Cajaraville et al. 2003; Escher and Wahli 
2000), and as a consequence the activity of some of the specific peroxisome proteins 
is increased. Three subtypes of PPARs have been described in diverse animals such 
as mammals (Schoonjans et al. 1996), amphibians (Dreyer et al. 1992) and fishes 
(Andersen et al. 2000; Leaver et al. 1998; Ruyter et al. 1997). PPARα, PPARβ or δ and 
PPARγ, which different functions have been associated to, different tissue distributions 
in fishes has been described. In fish PPARα was mainly expressed in tissues 
catabolizing fatty acids such as liver, proximal tubules of kidney and enterocytes, 
whereas PPARβ is less specifically expressed, being found in different tissues (Ibabe 
et al. 2002). An increase in the PPARγ mRNA expression was demonstrated in 
hepatocytes of salmon exposed to fibrates (Ruyter et al. 1997). Besides, some 
organochlorine pesticides (Cajaraville et al. 2003), plasticizers (Ortiz-Zarragoitia and 
Cajaraville 2005) and perfluorooctanoic acid (Oakes et al. 2004) may activate PPARs 
in fish both in vivo and in vitro, therefore increasing the interest of using PPARs as 
biomarker for environmental pollution.  
 
The fatty acyl-CoA oxidase (FAO) is an enzyme found only in peroxisomes and it plays 
a key role in the β-oxidation of fatty acid. An increased activity of the FAO has been 
found in primary hepatocytes of salmon (Salmo salar, (Ruyter et al. 1997)) and in 
rainbow trout and Japanese medaka (Scarano et al. 1994) after exposure to fibrates. 
The specific peroxisome membrane protein PMP70 was also found to be increased 
after exposure to a peroxisome proliferator in fish (Ackers et al. 2000). In a different 
study performed in our laboratory on fish hepatocytes we found a light increase in FAO 
activity after 72 hours exposure to 5 µM of bezafibrate and 100 µM of clofibric acid, 
respectively as well as a first increase in PPARα expression after 6 hours exposure to 
bezafibrate and clofibric acid, followed by a recovery of this receptor after 7 to 14 days 
(Caminada et al. submitted). 
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In our present study we investigate effects of bezafibrate (BF) and clofibric acid (CA) 
on fathead minnows (Pimephales promelas) after chronic exposure for 14-21 days by 
focussing on known target molecules of fibrates in order to evaluate the potential 
ecotoxicological effects of this important group of pharmaceuticals. Effects on PPARα 
expression and on FAO activity were determined after 14 or 21 days of exposure to 
different concentrations of these compounds in three different experiments. The aim 
was to better understand potential ecotoxicological effects of the blood-lipid lowering 
agents bezafibrate and clofibric acid on fish, and in addition, the role of their target 
biomolecules as potential biomarkers for environmental pollution.  
 
 
Materials and methods 
Chemicals 
Bezafibrate (purity > 99%) was kindly supplied by F.Hoffmann-La Roche Ltd. (Basel, 
Switzerland). Clofibric acid (>99 %), fenoxycarb (>98 %) and dibutyl phthalate 
(DBP>98 %) were purchased from Sigma-Aldrich (Buchs, Switzerland). Ethanol and 
DMSO were purchased from TJ Backer (Backer Ltd, Switzerland). Chemicals used in 
the different assays are described below in the specific chapters. 
 
Analytical determinations 
Analysis of experimental water samples was performed for all experiments. For fish in 
experiment A different volumes of samples were extracted using a Strata Screen-A 
cartridge (500 mg/6 mL, 8B-S019-HCH, Phenomenex). Conditioning and equilibration 
were performed prior to sample loading with 5  mL of MeOH and 5 mL 50 mM 
phosphate buffer (pH 7), respectively. The rate of sample loading was kept at 4-
8 mL/min. The analytes were eluted with a solution of 1 % concentrated HCl in 70 % 
1:1 MeOH/ACN. The extracts were dried under a stream of N2 at 40°C for 1-1.5 h, and 
at 55°C for 1-2 h, and subsequently dissolved with 1 to 2 mL of 40 % ACN/MilliQ water. 
For experiment B and C the samples were either diluted 1 : 10 (CA or BF 100 mg/L) or 
directly analysed (CA 1 and 10 mg/L) without prior extraction.  
 
20 µL of extracts or sample were injected in a HPLC (Hewlett Packard HP 1090 or 
1050), both equipped with a Spherisorb RP-C18 250 x 4.6 mm column, with a flow rate 
of 1 mL/min. The mobile phase consisted of a binary mixture of MilliQ water and 
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acetonitril. The linear gradient program began at 5 % ACN hold for 1 minute to end at 
40 % ACN after 8 minutes. The peaks were detected after 8 minutes for CA and after 
11.5 minutes for BF and were determined by UV detection at 225 nm. 
 
Fathead minnows 
Acclimatisation: Adult fathead minnows (Pimephales promelas) for experiment A were 
purchased from Osage Catfisheries Inc. (Osage Beach, MO, USA) and were kept in a 
water tank (300 L) for 3 weeks for acclimatisation prior to the beginning of the 
experiment. Two batches of fishes were delivered and kept separately. Fish of one 
batch were raised in the laboratory (Lab reared fish, LR), whereas the other batch was 
raised in an outdoor pond (pond fish, P) until delivering. Both batches were kept in the 
laboratory for acclimatisation prior to the experiment, each batch in a separate 300 L 
water tank. Fathead minnows for experiments B and C were cultured in house 
(Springborn Smithers). Temperature (25±2°C) and daylight photoperiod (16 h) were 
held constant during the acclimatisation period. The water tanks were supplied with a 
carbon filtration system. 
 
Experimental design 
The experimental procedure was the same for all the experiments. It was adapted from 
Kunz et al. (2006) and conducted by a semi-static procedure (Kunz and Fent 2006). 
For the experiments, reconstituted tab water with alkalinity range of 25-30 mg/L CaCO3 
and conductivity of 500 µS/cm was used. The experiments were conducted at a 
constant temperature of 25 ± 1°C. BF solutions were prepared the day prior to the 
water renewal and kept under agitation overnight, whereas CA solutions were freshly 
prepared the day when water renewal took place. Every 48 h, aquaria containing BF, 
CA or DHP were completely renewed. After 24 h a known volume of solution was 
soaked and renewed with fresh solution to eliminate food residuals and faeces. In each 
aquarium two steel tunnels were added. Fishes were fed twice daily with commercial 
flakes (Tetramin, Germany). Mortality, swimming behaviour as well as eggs production 
were recorded daily. Dissolved oxygen and pH were recorded twice during the renewal 
from fresh (0 h) and old solution (48 h). A number of 12 male, 6 male and 6 female for 
experiments A and C, and 8 fishes, 4 male and 4 female, in experiment B were 
randomly distributed in stainless steel aquaria containing BF, DBP, CA solutions or 
control water. The aquaria were filled with 15 L water containing different concentration 
of BF and CA or water control for experiment A and C, and with 10 L for experiment B. 
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Plastic top covers were used to avoid aeration, and air was delivered through air 
pumps connected to an appropriate plastic tube ending in a Pasteur pipette that was 
dept into water.  
 
Experiment A: For each batch of fish (P and LR) two replicates of four concentrations 
of bezafibrate with a separation factor of 10 were applied. As a positive control, dibutyl 
phthalate (DBP 0.5 mg/L prepared in < 0.01 % DMSO) was chosen according to 
effects on FAO activity found in the literature (Ortiz-Zarrgoitia et al. 2005). The 
experiment was conducted in a climate chamber and exposure lasted 14 days. 
 
For analysis of actual BF concentrations, 1 L of each water samples were collected of 
control and the different BF dose groups at time 0 and 48 hours during the 14 days 
exposure period. This occurred at day 0, 2, 6, 8, 10, 12, whereas aliquots of the fresh 
stock solution of 100 mg/L were collected at each water renewal. Water samples were 
extracted and analyzed as described above. 
 
Experiment B: Two replicates of 100 mg/L bezafibrate and two replicates of a water 
control were applied. During the 14 days of exposure the aquaria were kept in a water 
bad at 25°C. 
 
For chemical analysis of actual BF concentrations, 100 mL of each water samples were 
collected of control and the 100 mg/L BF dose group at time 0, 24 and 48 hours. This 
occurred at day 0 and 8 during the 14 days exposure period. Control water samples 
were directly injected to the HPLC for analysis, whereas bezafibrate samples were 
diluted 1 : 10 with fish medium prior to injection. 
 
Experiment C: Three replicates of 1, 10 and 100 mg/L of CA and three replicates of a 
water control were applied. The experiment was conducted in a climate chamber were 
temperature was kept at 25°C. The exposure lasted for 21 days. 
 
For analysis of actual CA concentrations, 50 mL of water were collected of control and 
the different CA dose groups at time 0, 24 and 48 hours during the 21 days exposure 
period. This occurred at day 0, 2, 6, 8, 10, 12. Controls and samples from doses CA 1, 
and 10 mg/L were directly injected to the HPLC for analysis, whereas from the dose CA 
100 mg/L samples were diluted 1 : 10 with tap water prior to injection. 
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Termination of experiments: At the end of the exposure period, the fishes were 
anesthetized with 100 mg/L MS-222 (tricaine, Fluka) and the lengths and the weights 
were measured. Blood was collected with 20 or 50 µL heparinised capillary tubes 
(KABE Labortechnik GmbH, Nümbrecht-Elsenroth, Germany) from the caudal vein and 
kept on ice for a maximum of 3 hours. 20 µL at 2 units/mL of protease inhibitor 
(Aprotinin, Fluka AG, Buchs, Switzerland) were added to each blood sample. Plasma 
was collected after centrifugation (10 min at 3000 rcf and 4°C) and stored at -80°C until 
analysis. Fishes were then dissected to collect livers. Depending on the analysis to be 
performed, livers were either directly fast-frozen in liquid nitrogen for FAO activity 
measurement or given to a RNA later solution (Qiagen, for quantitative rtRT-PCR) 
which was let soak into livers overnight at room temperature according to the 
manufacture protocol. All livers were then stored at -80°C until analysis was performed. 
 
Vitellogenin, FAO activity and PPARα expression: 
Vitellogenin determination: Vitellogenin analysis was performed with a commercial 
ELISA kit (Biosense Laboratories, Bergen, Norway) in experiment A following the 
instruction of the manufacturer. The kits were provided with monoclonal antibodies 
against vitellogenin in order to perform a sandwich ELISA analysis. Briefly, purified 
vitellogenin supplied in the kits was freshly prepared every day of analysis as standard 
for vitellogenin quantification. Fish plasma samples were first diluted with sample buffer 
delivered with the commercial kit to achieve a 1:2 ratio of plasma/buffer. Further 
dilution steps were prepared as follows: 1:5000; 1:500000; 1:5000000 for female 
plasma and 1:50; 1: 5000; 1:500000 for male plasma. Measurements were performed 
in duplicate and colour was measured at 450 nm in a spectrophotometric microtiter 
plate reader (Tecan, Infinite M200, Switzerland). As first screening fish from water 
control, positive control and 100 mg/L BF dose were analysed. 
 
FAO activity. The activity of fatty acyl oxidase (FAO) was measured according to the 
method of Small (Small et al. 1985), with some minor modifications of the protocol 
(Ortiz-Zarragoitia and Cajaraville 2005; Ruyter et al. 1997). Livers were let thaw on ice, 
weighed with an analytical scale and placed in 100 µL of ice cold buffer (0.6 M TRIZMA 
base, 0.25 M sucrose, 0.01 % TritonX-100) and a protease inhibitor cocktail 
(F.Hoffmann-La Roche, Switzerland). Livers were homogenised with an ultrasonic 
homogenisator (Labsonic, Satorius AG, Germany) and supernatants were collected 
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after centrifugation at 600 rcf for 20 minutes. Before starting the reaction, the amount of 
proteins was measured by a BioRad protein assay. Briefly, liver samples were 
prepared at 400 µg/mL protein concentration in a dilution buffer (PBS at pH 7.4 with 
0.02 % Tween and 0.6 mg/mL BSA) and added in triplicate on a microtiter plate. 40 µL 
of reagent mixture (12 units/mL horseradish peroxidise, 0.05 mM 2’,7’-
dichlorodifluorescein diacetate, 0.015 mM FAD and 40 mM aminotriazole, all chemicals 
purchased from Sigma-Aldrich, Buchs, Switzerland) were then added to each sample, 
and incubated in the dark for 5 minutes prior to measurement at 502 nm. 10 µL of 
palmitoyl CoA (Sigma-Aldrich, Buchs, Switzerland) at a final concentration of 30 µM 
were then added to start the reaction and the kinetics of the enzyme (product 
formation) was monitored for 1 hour (13 cycles of 5 minutes) at 502 nm using a 
spectrophotometric microtiter plate reader (Tecan, Infinite M200, Switzerland). A serial 
dilution of dichlorofluorescein standard was used to quantify the amount of 
dichlorofluorescein produced from dichlofluorescein diacetate during the reaction. The 
FAO activity is expressed as nM DCF/min*mg protein. 
 
PPARα expression: RNA were extracted from liver samples with a commercial kit 
(RNeasy extraction kit, Qiagen Switzerland) and according to the manufacture protocol. 
Extracted RNA were resuspended in 35 to 45 µL of nuclease free water (Qiagen, 
Switzerland). The reverse transcription reaction was carried out according to the 
manufacturer protocol with a reverse transcriptase (Roche Diagnostic, Switzerland) 
The same initial concentration of 0.1 µg/µL RNA was taken for each sample to be 
transcribed, and was ensured by a spectrophotometric measure of RNA concentration 
at 260 nm (NanoDrop ND-1000 full-spectrum (220-750 nm) spectrophotometer, Witec, 
Switzerland). For the reverse transcription, polydT primer (Roche Diagnostic, 
Switzerland) were used for a non-specific transcription of whole RNA into cDNA. A first 
set of degenerated primers previously designed for PLHC-1 cell was used to clone the 
PPARα and the β-actin cDNA of fathead minnows (Caminada et al. submitted), which 
were subsequently sequenced (Synergene Biotech GmbH, Switzerland) and submitted 
to gene bank (accession number EU195886 and EU195887, respectively). The 
purification procedure for sequence analysis is described elsewhere (Caminada et al, 
submitted). According to the sequence obtained, a second set of primer was designed 
to get a shorter band for each gene for the quantitative PCR. The sequences of the 
primers were 5’-GCGTCCTGCATGAATAAAGA-3’, 5’-GTCCAGCTCGAGAGCGTT-
3’for PPARα, and 5’-TCCGTAAGGATCTGTATGCC-3’, 5’-
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GATCCAGACGGAGTATTTGC-3’ for β-actin (Microsynth, Switzerland). These set of 
primers were tested with standard Corbett PCR machine (45 cycles of 30 seconds at 
94°C, 45 seconds at 55°C and 45 seconds at 72 °C) and analyzed on a DNA chip 1000 
(Bioanalyzer, Agilent technologies, Switzerland) prior to start with the quantitative PCR 
analysis. The bands were detected at 158 bp for β-actin and at 150 bp for PPARα. No 
unspecific amplifications seemed to occur. 
After reverse transcription the resulting cDNA samples were then diluted for real time 
analysis. A standard dilution sequence (1 : 20 to 1 : 5120, with a factor 4 of separation 
between each step) as well as a 1 : 320 dilution of each sample were prepared for both 
β-actin (housekeeping gene for normalization) and PPARα. The fluorescent dye 
FastStart SYBR Green (Roche Diagnostic, Switzerland) was chosen for the real time 
procedure. The real time PCR program was performed with 50 cycles and an annealing 
temperature of 58 °C for 45 seconds. At the end a melting procedure for quality 
analysis was also performed between 50 and 95 °C, and 1°C/5 seconds. All the real 
time reactions were performed on a Corbett RotorGene TM 6000 (Corbett Life 
Sciences, Australia). 
 
Table 1 gives a summary of the experiments performed and the respective endpoints 
analyzed. 
 
Statistical analysis: 
An analysis of variance test (ANOVA) was performed to determine the effects of 
bezafibrate and clofibric acid on investigated parameter. An effect was chosen as 
significant if p<0.05. 
Table 1: Summary of experiments performed and endpoints analyzed. 
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Results 
Chemical analysis: The chemical analysis of water sample of all fish experiments 
showed that the concentrations of BF and CA were close to nominal values and did not 
decrease during the renewal period of 48 hours. This was the case in all the treatments 
(p>0.05). Therefore mean levels in each dose group were taken as exposure 
concentrations. The analysis of water control did not show any contamination. 
 
Weight, length and egg production: Both the fibrates analyzed in this study did not 
interfere nor with the weight nor the length of fathead minnows. In Table 2 the effects 
on condition factor (CF=105*W/L3, where W is the weight of the fish expressed in 
grams, and L is the length expressed in millimetres) are summarized for fish exposed 
to BF and CA, respectively. As both adult female and male fish were kept in aquaria, 
mating could take place Fish exposed to 101.56 mg/L BF in experiment A produced 
eggs just twice (data not shown). Also in experiment B fish of all groups did not 
produced enough eggs to perform a statistical analysis. Here the sporadic egg 
production was found in different groups, but the egg production events were lower 
than 5 times (data not shown). Interestingly, by fish exposed to CA the egg laying 
seemed to be affected, even if this effect was not significant (Figure 1). Fish exposed to 
1.07 and to 10.75 mg/L CA showed a tendency to decreased egg production 
(p=0.052), whereas fishes exposed to 108.91 mg/L CA did not significantly differ 
compared to control fish (p=0.08). This lack of significance may be explained by the 
Table 2: Condition factors of experiments A, B and C represented as mean±SD of male and 
female fish. Difference between male and female at 10.75 mg/L CA is significantly increased 
for male (**p=0.03). BF – Bezafibrate; CA – Clofibric acid; DBF-dibuthyl phthalate 0.5 mg/L. 
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fact that, out of three replicates just two produced eggs during the exposure period of 
21 days, whereas in the control fish egg production took place in all three replicates. 
Table 3 summarizes data on egg production in experiment C including the last day 
when eggs were produced. However, no significant effects were found. 
 
Plasma vitellogenin: Vitellogenin concentration in blood of male and female was 
analysed in experiment A. No induction of vitellogenin was found in experiment A 
(Figure 2 a, b). 
 
FAO activity: FAO activity expressed as nM DCF/min*mg protein in liver was measured 
in the male fish of experiment A, and in male and female fish of experiment C. A 
statistical analysis demonstrated that there was no difference in FAO activity between 
pond and labor reared fishes in experiment A. No statistically significant effects on FAO 
activity in fish were observed after 14 days of exposure to BF (Figure 3a). In contrast, 
Figure 1: Egg production of control fish (CON) and fish exposed to three different 
concentrations (1.07 mg/L, 10.75 mg/L, 108.91 mg/L) of clofibric acid (CA) during 21 days. 
Statistically not significant (p>0.05 for all the treatments). 
Table 3: Egg production and last day of egg laying (mean±SD) of fish exposed to clofibric 
acid in experiment C. 
No significant effects were found, although a tendency to a decreased production of eggs 
occurs (p=0.052) at 1.07 mg/L CA and 10.75 mg/L CA. 
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exposure to 108.91 mg/L CA for 21 days let to a significant increase in FAO activity in 
male fish (p=0.04) but this was not the case in female fish (Figure 3b). In male fish the 
effect was not completely dose-dependent. Even if fish exposed to 108.91 mg/l CA 
showed a statistically significant increase in the FAO activity compared to both control 
and 10.75 mg/L CA (p=0.041), this was not the case when compared to 1.07 mg/L CA 
(p>0.05). When male and female were pooled there was a significant increase in FAO 
activity of fish exposed to 108.91 mg/L CA compared to control (p=0.015) and to 
10.75 mg/L CA (p=0.036). The activity of FAO of male fish exposed to 108.91 mg/L of 
CA was 1.5-times higher than that of control fish. In pooled male and female fish, this 
effect at 108.91 mg/L CA was 1.3 fold higher compared to control fish. Relative 
activities are shown in Table 4.  
 
PPARα expression: PPARα expression was measured in fishes of experiment B and C. 
The expression was normalised for RNA concentration and the housekeeping gene β-
actin. As shown in Figure 4a BF does not seem to affect the expression of PPARα 
(p>0.05) at the tested concentration of 106.7 mg/L BF. Males and female were 
analysed separately and in both cases, there was not a significant increase of PPARα 
Figure 2: Plasma vitellogenin concentrations in control fish (CON), the positive control dibutyl 
phthalate (0.5 mg/L) and fish exposed to 101.56 mg/L bezafibrate (BF). Plasma VTG of male (A) 
and females (B) as means ± SD. No significant induction of plasma VTG has been found both in 
male and female, p>0.05. 
Table 4: Relative FAO activity in fish exposed to clofibric acid of experiment C. 
A significant increase in FAO activity was found in male fish exposed to 108.91 mg/L CA 
(*p=0.042). 
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expression. Also for CA there was not a clear induction of PPARα expression. In Figure 
4b PPARα expression of fish exposed to CA were shown for male and female 
separately. Males showed an increased expression at 1.07 and 108.81 mg/L CA, but 
this was not significant. 
 
 
Discussion 
In this study, effects of bezafibrate and clofibric acid have been assessed in fathead 
minnows after chronic exposure for 14 and 21 days. To our knowledge effects of these 
lipid lowering agents have not yet been investigated so far in fathead minnows, in 
particularly focussing on their mode of action. The blood lipid lowering agent 
bezafibrate and the parent compounds of clofibric acid are widely used in medicine to 
Figure 3: FAO activity in liver of fish. Male fish exposed to bezafibrate of experiment A (A) 
and male and female fish exposed to clofibric acid of experiment C (B). Shown are means ± 
SD. FAO activity of male fish exposed to clofibric acid at 108.91 mg/L is significantly 
increased (*p<0.05). 
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treat lipidemic disease such as hypercholesteremia and to prevent heart attack. These 
pharmaceuticals belong to the class of fibrates which are known to bind to peroxisome 
proliferating activating receptors (PPAR). These are nuclear receptors which enter the 
nucleus, heterodimerize with the RXR receptor and promote both the expression of 
different genes involved in lipid metabolisms, e.g. fatty acyl oxidase, and the 
proliferation of peroxisomes. Substances such as perfluoroctanoic acid and phthalates 
have been found to be PPAR activator (Ibabe et al. 2005) and exposure of aquatic 
organisms to such compounds showed increased FAO activity or PPAR expression. 
PPAR agonists may be also related to reproductive and developmental toxicity (Ackers 
et al. 2000). 
 
Both bezafibrate and clofibric acid have been found in the environment in concentration 
that reach several µg/L in sewage treatment effluents and in surface water (Buser et al. 
1998; Stumpf et al. 1996; Ternes 1998).  
Figure 4: PPARα expression in liver of male and female fish relative to housekeeping gene β-
actin. (A) Fish exposed to bezafibrate of experiment B. (B) Fish exposed to clofibeic acid of 
experiment C. Data as means ± SD. No significant effects were found.
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The data presented in this study indicate that bezafibrate does not seem to affect any 
of the parameter chosen at fairly high concentrations, which are orders of magnitudes 
higher than environmental concentration. For clofibric acid, however a small increase 
(1.5-fold) of the fatty acyl oxidase activity was found at 108.91 mg/L. Ortiz-Zarragoitia 
et al. (2004) found an increase in the FAO activity of fish exposed to perfluoroctanoic 
acid, which is also known to be a PPAR receptor agonist. Scarano (1994) investigated 
the effects on FAO activity on rainbow trout and medaka. The activity we found was 
lower compared to the activity measured by Scarano (1994). In fact, even in control fish 
we found, in both experiment, an activity, which was four times less (0.6-
0.8 nmol/min*mg protein in our study compared to 2.5 nmol DCF/mg*protein in 
Scarano et al.). Scarano (1994) found an increase of FAO activity in rainbow trout, this 
effect appeared only if the data were analyzed in nmol DCF/mg liver. We decided that 
normalization on protein concentration was more reliable for our aim. Ruyter et al. 
(1997) analyzed effects on FAO activity of rainbow trout hepatoma cell lines exposed to 
bezafibrate and clofibric acid. These authors found a higher FAO activity, with values 
ranging from 2.5 to 4.35 for CA, and to 4.075 for BF compared to our data and they 
found a significant increase after exposure to both substances. In case of gemfibrozil 
FAO activity was not affected in fish (Mimeault et al. 2006). The results in our study for 
CA correspond to those found in an in vitro study with PLHC-1 cell lines, where an 
induction in FAO activity was found at 100 µM CA (Caminada et al. submitted). 
However, the induction found in vitro in PLHC-1 after exposure to BF was not 
confirmed in our in vivo study. 
 
The increase in FAO activity by CA was not paralleled by an increase in PPARα 
expression. Whether this is a reflection of an early up-regulation of PPARα expression 
as in vitro in PLHC-1 cells, followed subsequently by a down-regulation of this receptor, 
remains an open question. At the same time it is not known, whether the induction of 
this nuclear receptor and of regulatory proteins of fatty acid oxidation are subject to 
similar regulation processes and timing. It is also possible that, by increasing the 
sensitivity of the real-time method by using for example probes such as TaqMan 
smaller variations of PPARα may be detected. 
 
PPAR receptors belong to DNA receptors, enter the nucleus when activated by a 
ligand and after dimerization with the RxR receptor. By binding to the DNA the 
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expression of different enzymes involved, among other cellular functions, in fatty 
oxidation, is enhanced. An increase in PPARγ expression was found by Ruyter (1997), 
where a 1.6 fold increase in PPARγ receptor was found after exposure to BF and CA in 
hepatoma cell lines of rainbow trout (Ruyter et al. 1997). On the other hand, Mimeault 
(2006) did not find any increase in the expression of PPARα in Goldfish after 14 and 28 
days of exposure to 1.5 and 1.500 µg/L gemfibrozil. It is possible that a 14 to 21 days 
exposure to fibrates in fish is too long to detect an induction at receptor level. Support 
for this hypothesis is provided by our in vitro study (Caminada et al. submitted), in 
which an induction of PPARα and PPARγ was found in PLHC-1 cell lines after a short-
term (6 hours), but not after a long-term (7 to 14 days) exposure to bezafibrate and 
clofibric acid. A comparison between in vivo and in vitro data both found in the literature 
and obtained in our laboratory seem to demonstrate that a first short term induction of 
PPARα may occur followed by a rapid recovery. The induction of enzyme seems, on 
the other hand, to had longer-lasting effect in the cells. 
 
Another interesting result of the exposure to CA, was the decrease of egg production, 
even if this was not significant. This effect may be related to the known decrease on 
plasma testosterone of goldfish exposed to a drug of the fibrates family, gemfibrozil 
(Mimeault et al. 2005) and even on sperm amount and motility of fish exposed to CA 
(Runnalls et al. 2007). If the non significant decrease in egg production found in our 
experiment could be related to other reproductive effects such as sperms motility 
remains unclear and need to be further investigated. Whether indirect effects on 
reproduction of females occur via negative interaction with lipid metabolism remains 
open. This can only be investigated by pertinent reproductive experiments. The lack of 
egg production after exposure to BF in experiment A and B can be only explained as 
follows. For experiment A fish were almost two years old, and were previously used for 
breeding, which could explain the lack of reproduction in all groups. On the other hand, 
in experiment B the fish were slightly older than 6 months, and they could have been 
too young for reproduction. Vitellogenin was not induced in male or female fish 
exposed to BF. 
 
None of the parameters analyzed in our study seemed to significantly affect fish 
exposed to BF and CA (except FAO activity at high CA concentration). Furthermore, 
the effects were found at several orders of magnitude higher concentration than found 
in the environment maximal concentration found in wastewater treatment plants 
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effluents are 4.6 µg/L and 1.6 µg/L for BF and CA, respectively (Buser et al. 1998; 
Ternes 1998). Therefore it seems that these two lipid-lowering agents do not pose a 
risk for fish with respect to the endpoints determined in our study related to the mode of 
action of these drugs. This does not necessary rule out the possibility of unexpected 
effects that may occur as in case of other pharmaceuticals (Runnalls et al. 2007). 
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General discussion 
The results of the different studies in chapter two to six are discussed in detail in the 
corresponding chapters. Here, the findings are summarized and discussed in general 
terms including their relevance within the field of ecotoxicology and towards the risk 
assessment of pharmaceuticals in the environment. 
 
This dissertation is focused on effects of human pharmaceuticals towards aquatic 
organisms. Residues of pharmaceuticals are regularly found in surface waters in the 
range of ng/L to μg/L. At polluted sites, aquatic organisms are exposed during their 
whole lifetime to a variety of micro-pollutants, but the risks of permanent exposure to 
environmental xenobiotics are largely unknown. Pharmaceuticals are designed to 
exhibit specific modes of action at often low concentrations on target biomolecules in 
humans. Current data indicate that most of the targets are also present in lower 
organisms. Therefore, pharmaceuticals may have similar modes of action and effects 
in fish as in humans. 
 
So far, most ecotoxicological studies have focused on established endpoints such as 
acute toxicity, effects on the detoxification system (phase I and phase II), induction of 
heat shock proteins, etc. This approach is not sufficient enough for the investigation of 
potential chronic effects of substances interacting specifically with defined targets like 
receptors, enzymes and transporters in the cell. Therefore, a mechanism-based 
approach is necessary. As only little is known about the presence and function of these 
targets in aquatic organisms, they have to be found and characterized first.  
 
In this dissertation, several studies are performed to elucidate cellular mechanisms of 
pharmaceuticals in fish. The cytotoxicity of environmentally important pharmaceuticals 
in in vitro model systems are assessed and correlated with results from Daphnia 
magna and fish. Further, we succeeded in selecting a doxorubicin-resistant PLHC-1 
subclone (PLHC-1/dox) characterized in the overexpression of P-glycoprotein 
(ABCB1). This transporter plays a crucial role in detoxification processes and its 
modulation can essentially change the intracellular concentration of compounds. The 
data demonstrate the presence of a classical multidrug resistance phenotype in a non- 
mammalian cell system. A subsequent study shows that several pharmaceuticals affect 
the multidrug resistance mechanism in PLHC-1/wt and PLHC-1/dox cells. Finally, we 
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demonstrated the presence of the receptor based PPAR-system in PLHC-1 cells and 
analyzed effects mediated by fibrates on the expression of these receptors as well as 
on the activity of a peroxisomal enzyme. In the following a short summary of the 
different achievements with the most important conclusions are given. 
 
Cytotoxicity of pharmaceuticals 
We evaluated the in vitro cytotoxicity of 34 common pharmaceuticals from different 
classes and with different modes of action using the mitochondrial MTT reduction and 
NR uptake assays in the two fish cell lines, PLHC-1 and RTG-2. Cytotoxicity was found 
for 21 pharmaceuticals with no significant difference between the MTT and NR assays. 
The comparison of the cell lines revealed that PLHC-1 cells were slightly more 
sensitive to cytotoxic effects than the RTG-2 cells. We demonstrated that the 
cytotoxicity of pharmaceuticals correlated with their LogD values at physiological 
conditions (pH 7.0). A correlation between the in vitro data and in vivo data was found 
for Daphnia magna, but not for fish due to insufficient and heterogeneous data.  
 
The findings provide an indication that in vitro cytotoxicity assays with fish cell lines are 
suitable for the first screening of the acute in vivo toxicity of pharmaceuticals and 
possibly other compounds, thereby contributing to the reduction of in vivo experiments. 
The EC50-values of the pharmaceuticals showing a correlation with their LogD 
indicates that the cytotoxic effect is probably due to non-specific toxicity or narcosis. 
However, some pharmaceuticals like doxorubicin and fluoxetine did not correlate with 
their LogD value pointing at a specific mode of toxic action.  
 
Effects of pharmaceuticals on the MDR/MXR mechanism 
We were able to select a highly doxorubicin-resistant PLHC-1 subclone (PLHC-1/dox) 
by culturing wild type cells in the presence of doxorubicin. We demonstrate that a 
specific, P-gp1 mediated doxorubicin resistance mechanism is present in the PLHC-1 
fish cell line. In addition, the fact that low micromolar concentrations of specific 
inhibitors may completely reverse a highly expressed doxorubicin resistance points to 
the fragility of P-gp1 mediated MXR defence mechanism in fish. The data demonstrate 
for the first time the presence of a classical multidrug resistance phenotype in non-
mammalian cells. 
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The aim of our subsequent work was the analysis of a series of pharmaceuticals for 
their potential to interact and modulate the activity of xenobiotic efflux transporters from 
the ABCB and ABCC sub-family in the PLHC-1 fish cell line (PLHC-1/wt) and the 
doxorubicin resistant PLHC-1 subclone (PLHC-1/dox). Our work revealed significant 
inhibitory effects of environmentally relevant pharmaceuticals on ABC transporters, 
demonstrating that this class of compounds interacts with the MDR/MXR mechanism in 
fish. Our findings correspond well with data from mammalian systems indicating that 
the specificity and roles of the efflux transporters are similarly in fish.  
 
Detection and characterization of PPARs in PLHC-1 cells and fathead minnows 
This piece of work aimed at the detection and characterisation of the receptor-based 
PPAR-system in the fish cell line PLHC-1. We found all three PPARs (PPARα, PPARβ 
and PPARγ) present in the cells as well as the retinoid X receptor (RxR) that forms a 
heterodimer with the activated PPAR-receptor, and thus, is necessary for a response. 
The sequences showed high similarities to other known sequences in fish, especially 
with Dicentrarchus labrax and Sparus aurata. In expression analysis, the highest 
expression level was found for PPARα followed by PPARγ and PPARβ. Upon 
exposure to different fibrates for 6 h, the expression level of PPARα and PPARγ was 
induced up to ten-fold. Further, an increased activity of the peroxisomal enzyme fatty 
acyl oxidase was found that is involved in the β-oxidation pathway of fatty acids and 
that is regulated by PPARα. These results demonstrate for the first time the presence 
and function of PPARs in a fish cell line. 
 
Our interest in the following study focused on biochemical effects on the liver of fish 
after 14 and 21 days exposure to bezafibrate and clofibric acid, respectively, focussing 
in particularly on PPARs and peroxisomal enzymes. In addition we monitored 
reproductive parameter such as egg production and vitellogenin induction to investigate 
the hypothesis whether the effects of these human pharmaceuticals may be also linked 
to reproductive toxicity. Male fathead minnows exposed to clofibric acid showed an 
increase in FAO activity at the highest concentration only; this effect was not found in 
female and could not be related to an increase in PPARα expression. This indicates 
that in vitro and in vivo results are comparable, but only to a certain extent. Effect 
concentrations and even mechanistic parameters (induction of PPARα) diverge due to 
different exposures and time-scales. In addition, a non-significant decrease in egg 
production after 21 days of exposure to clofibric acid was found.  
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A comprehensive evaluation of the potential risk of pharmaceuticals to the (aquatic) 
environment demands a mechanism based approach to account the specific modes of 
action of compounds. Pharmaceuticals exhibit often important side effects besides their 
therapeutic properties. Unexpected effects in lower organisms may also appear due to 
biological differences in pharmacodynamcis, pharmacokinetics and physiology. Only 
chronic toxicity investigations using more specific toxicity parameters will lead to a 
more meaningful ecological risk assessment. Regarding the amount of substances to 
be evaluated and the many different targets to be taken into account, in vitro studies of 
pharmaceuticals are important for screening, elucidating the modes of action in non-
target organisms, and designing specific in vivo studies.  
 
A comparison of effects of fibrates in the PLHC-1 cells with effects in vivo was 
performed. Pronounced effects on the expression of fibrates as well as on the FAO-
activity were found in vitro, whereas in vivo only an effect on the FAO-activity was 
measured. These studies reveal two important aspects: first, we could prove our 
mechanism-based hypothesis that pharmaceuticals act on the same targets as in 
mammals; in our case, fibrates are ligands of PPARα in PLHC-1 cells. Second, the cell 
line was a sensitive and appropriate tool to detect the receptors and to establish 
assays for the investigations of their effects. In contrast, standardized protocols for in 
vivo investigations are not found to be sensitive enough to find specific effects. Instead, 
the protocols have to be adapted in order to find both relevant exposure times and 
endpoints. The in vitro system allows a better characterization of the involvement of 
PPARs, whereas the in vivo study actually represents a more realistic exposure 
situation. Knowledge from in vitro studies helps to design the more complex in vivo 
experiments.  
 
Knowledge on targets like receptors with which pharmaceuticals interact as well as 
toxicological mechanisms in aquatic organisms is lacking to a large extent. Therefore, 
such knowledge is gathered in this dissertation as a basis for further toxicological 
studies. In the field of multidrug resistance/multixenobiotc resistance, we did the first 
step towards the development of more appropriate model systems by selecting an 
ABCB1 overexpressing subclone. It is the first time that a specific P-gp1 mediated 
doxorubicin resistance mechanism has been shown to be present in cells derived from 
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an aquatic organism. In ongoing studies, we are trying to select further subclones 
overexpressing other kinds of transporters like multidrug resistance-related proteins 
(MRP1, MRP3) and breast cancer resistance protein (BCRP) involved in the efflux of 
xenobiotics. The successful selection of additional subclones will allow a better 
understanding of the biochemical mechanisms involved in multidrug resistance 
mechanisms in aquatic organisms and facilitate the characterisation of the role and 
specificities of these transporters in aquatic organisms. Subject of forthcoming studies 
is also the cloning, transfection and expression of selected fish ABC-transporters in 
appropriate systems like insect cells allowing more specific molecular-biological 
investigations. 
 
Peroxisome proliferator-activated receptors (PPARs) play important functions during 
the development of an organism, but also in the receptor mediated regulation of the 
fatty acid metabolism, lipid homeostasis, differentiation of adipocytes and epithelial 
tissues. Further, in mice and rats, but not in humans, it has been shown that PPARα is 
involved in the hepatocarcinogenesis mediated by fibrates. It is not known whether 
carcinogenesis mediated by PPARα activation can occur in fish. The detection and 
functional characterisation of PPARs in PLHC-1 cells allows further investigations of 
the processes regulated by PPARs in fish. Together with the knowledge of MDR 
mechanism and induction of CYP1A1 in PLHC-1 cells there are currently several 
elements that may have implications on carcinogenesis. As xenobiotics having the 
potential to interact with targets involved in carcinogenic processes are present in the 
aquatic environment, investigations of these processes in fish may gain more 
importance in future research. The PLHC-1 cell line could represent a reliable tool for 
such studies. 
 
In conclusion, this dissertation gives new insights into the interaction of 
pharmaceuticals on the cellular level with different targets like ABC-transporters and 
PPARs. The PLHC-1 cells are found to be a reliable in vitro model system for the 
investigation of biochemical and molecular-biological mechanisms in fish. Our findings 
that different efflux transporters as well as the three PPAR- and the RxR-receptor are 
present and functional in this cell line - in addition to the already characterized function 
of the aryl hydrocarbon (Ah) receptor involved in the regulation of CYP1A expression – 
indicates that many of the metabolic pathways still work similarly as in vivo. Therefore, 
this cell line is very promising in further research on the investigation of the modes of 
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action of environmentally relevant pharmaceuticals and other xenobiotics on the 
cellular level.  
 
In terms of environmental practice, cytotoxicity assays in fish cell lines can be a 
valuable tool in the risk assessment to estimate and rank the acute toxicity of 
compounds in order to minimize acute toxicity tests in vivo. They may be included in a 
tiered approach to assess the ecotoxicity of pharmaceuticals, but may also gain 
importance in the toxicity assessment of chemicals in the future strategy of the 
European Union within the REACH concept. However, for this purpose further 
validation is needed in ring studies with a broader set of compounds and in respect to 
the correlation with in vivo data. 
 
Cytotoxicity in fish cells occured at concentrations of about 1’000’000 higher than 
environmental concentrations. Moreover, effects of single compounds on efflux 
transporters and PPARα induction in cell lines and fish occurred at concentrations that 
are a factor 1000 higher than ambient levels. However, mixtures of compounds acting 
on the same targets usually exhibit an additive nature, e.g. all individual components 
contribute to the overall effect of a mixture. This implies that the overall effect exceeds 
the highest individual effect of the mixture’s components. Further, as found for the 
efflux transporters, interactions of certain pharmaceuticals with these transporters 
leads to inhibition of efflux activity, and therefore compound mixtures may increase the 
toxicity to environmental pollutants resulting in a more than additive or synergistic 
phenomenon. These considerations are of particular importance for the environmental 
hazard and risk assessment of pharmaceuticals, because it indicates that 
concentrations of single chemicals that show no effect when applied singly may 
provoke (substantial) effects when acting in combination. 
 
 
Outlook  
Our studies reveal new insights towards a mechanism based approach in the 
evaluation of ecotoxicological effects of pharmaceuticals in in vitro systems for aquatic 
organisms. Our mechanism-based research focused on the characterisation of 
multidrug resistance proteins and PPARs and showed that pharmaceuticals interact 
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with these targets. This allows a better understanding of these processes and 
mechanisms on the cellular level.  
 
The effects found in our in vitro studies occurred only at concentrations of about a 
factor 1000 higher than environmental concentrations, but they may contribute to the 
overall toxicity of a mixture. For further studies aimed at a better risk assessment of 
these compounds we propose the following issues to be addressed:  
• What are the specific interactions of other environmental pollutants (including 
pharmaceuticals) towards the investigated targets? 
• What other cellular targets are affected by pharmaceuticals? 
• What effects do compound mixtures and environmental samples exhibit on 
these targets? 
• How do in vitro effects in fish cells correlate with in vivo effects in fish?  
 
These questions are addressed in ongoing projects in our laboratory. The results from 
the in vitro assays of this dissertation are the basement for the design of further in vivo 
investigations. They will reveal whether in vitro effects in fish cells are less (or more) 
sensitive than effects in vivo. Moreover, this will indicate what the cellular effects found 
will signify for aquatic organisms. The in vitro system used in this study has the 
disadvantage that it is derived from a rarely used fish in ecotoxicology (topminnow, 
Poeciliopsis lucida). So far, in vivo experiments in our laboratory were performed with 
fathead minnow (Pimephales promelas). However, the best characterized and most 
often used model system for aquatic organisms represents the zebrafish (Danio rerio). 
It is widely used by developmental geneticists and it was the first aquatic organism 
whose genome was sequenced. Therefore, zebrafish will be used in our laboratory for 
future in vivo investigations. In order to expand mechanism based investigations, this 
model system can further be used for toxicogenomic analysis using microarray 
techniques.  
 
Pharmaceuticals represent only a small fraction of numerous different xenobiotics 
found in the environment. Further studies should focus on the specificity of the targets 
characterized in this dissertation towards other environmental pollutants. During this 
dissertation, different mechanisms were investigated using single compounds or dual 
mixtures. However, environmental samples usually contain a complex mixture of 
different compounds that may be able to increase the biological potency. To address 
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this question, effects of compound mixtures and of environmental samples on specific 
targets should be investigated in future studies. 
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Abstract 
Low levels of human medicines (pharmaceuticals) have been detected in many countries in 
sewage treatment plant (STP) effluents, surface waters, seawaters, groundwater and some 
drinking waters. For some pharmaceuticals effects on aquatic organisms have been 
investigated in acute toxicity assays. The chronic toxicity and potential subtle effects are only 
marginally known, however. Here, we critically review the current knowledge about human 
pharmaceuticals in the environment and address several key questions. What kind of 
pharmaceuticals and what concentrations occur in the aquatic environment? What is the fate in 
surface water and in STP? What are the modes of action of these compounds in humans and 
are there similar targets in lower animals? What acute and chronic ecotoxicological effects may 
be elicited by pharmaceuticals and by mixtures? What are the effect concentrations and how do 
they relate to environmental levels? Our review shows that only very little is known about long-
term effects of pharmaceuticals to aquatic organisms, in particular with respect to biological 
targets. For most human medicines analyzed, acute effects to aquatic organisms are unlikely, 
except for spills. For investigated pharmaceuticals chronic lowest observed effect 
concentrations (LOEC) in standard laboratory organisms are about two orders of magnitude 
higher than maximal concentrations in STP effluents. For diclofenac, the LOEC for fish toxicity 
was in the range of wastewater concentrations, whereas the LOEC of propranolol and fluoxetine 
for zooplankton and benthic organisms were near to maximal measured STP effluent 
concentrations. In surface water, concentrations are lower and so are the environmental risks. 
However, targeted ecotoxicological studies are lacking almost entirely and such investigations 
are needed focusing on subtle environmental effects. This will allow better and comprehensive 
risk assessments of pharmaceuticals in the future.    
 
Key words: Pharmaceuticals – Ecotoxicological Effects – Environmental Toxicity – Chronic 
Effects – Environmental Risk Assessment 
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Introduction 
It came as a surprise when an unusually high death rate among three species of vulture in India 
and Pakistan was reported in 2004 to be caused by diclofenac, a widely used analgesic and 
antiinflammatory drug (Oaks et al. 2004). The Oriental white-backed vulture (Gyps bengalensis) 
is one of the most common raptors in the Indian subcontinent and a population decline of >95% 
makes this species as being critically endangered. Whereas a population decline has started in 
the 1990s, recent catastrophic declines also involve Gyps indicus and Gyps tenuirostris across 
the Indian subcontinent (Prakash et al. 2003; Risebrough 2004). High adult and subadult 
mortality and resulting population loss is associated with renal failure and visceral gout, the 
accumulation of uric acid throughout the body cavity following kidney malfunction. A direct 
correlation between residues of diclofenac and renal failure was reported both by experimental 
oral exposure and through feeding vultures diclofenac-treated livestock. Hence, the residues of 
diclofenac were made responsible for the population decline (Oaks et al. 2004). This drug has 
recently come into widespread use in these countries as a veterinary medicine, but is also 
widely used as in human medicine since the 1970s. Vultures are natural scavengers feeding on 
carrion of wildlife and domestic livestock and cattle. The three vulture species continue to 
decline in Pakistan, India, Bangladesh and southern Nepal. Apart from this severe case, never 
having been anticipated, potential ecotoxicological effects of drug residues in the environment 
on wildlife are largely unknown.  
 
Pharmaceuticals are a class of emerging environmental contaminants that are extensively and 
increasingly being used in human and veterinary medicine. These chemicals are designed to 
have a specific mode of action, and many of them for some persistence in the body. These 
features among others make pharmaceuticals to be evaluated for potential effects on aquatic 
flora and fauna. The current investigations are mainly driven by advances in environmental 
residue analysis, particularly after the establishment of chemical analysis methods able to 
determine more polar compounds such as liquid chromatography-tandem mass spectrometry, 
which allows the identification of trace quantities of polar organic pollutants without 
derivatization (Daughton and Ternes 1999; Kolpin et al. 2002; Kümmerer 2004). Accordingly, 
many environmental analyses have been performed in various countries, which are summarized 
by various reports  (e.g. Daughton and Ternes 1999; e.g. Halling-Sorensen et al. 1998; 
Kümmerer 2004). These monitoring studies demonstrate that drug residues in treated 
wastewater and surface water are very widespread.  
 
In contrast, only little is known about ecotoxicological effects of pharmaceuticals on aquatic and 
terrestrial organisms and wildlife, and a comprehensive review on ecotoxicological effects is 
lacking. Aquatic organisms are particularly important targets, as they are exposed via 
wastewater residues over their whole life. Standard acute ecotoxicity data have been reported 
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for a number of pharmaceuticals, however, such data alone may not be suitable for specifically 
addressing the question of environmental effects, and subsequently in the hazard and risk 
assessment (Fent 2003). The current lack of knowledge holds in particular for chronic effects 
that have only very rarely been investigated. In spite of the sizeable amounts of human drugs 
released to the environment, concise regulations for ecological risk assessment are largely 
missing. Only in the last few years, regulatory agencies have issued detailed guidelines on how 
pharmaceuticals should be assessed for possible unwanted effects on the environment. The 
first requirement for ecotoxicity testing as a prerequisite for registration of pharmaceuticals was 
established in 1995 according to the European Union (EU) Directive 92/18 EEC and the 
corresponding “Note for Guidance” (EMEA 2005) for veterinary pharmaceuticals. The European 
Commission released a draft guideline (Directive 2001/83/EC) specifying that an authorization 
for a medicinal product for human use must be accompanied by an environmental risk 
assessment (EMEA 2005). The U.S. Food and Drug Administration (FDA) published a guidance 
for the assessments of human drugs; according to this, applicants in the U.S.A. are required to 
provide an environmental assessment report when the expected introduction concentration of 
the active ingredient of the pharmaceutical in the aquatic environment is ≥ 1 µg/L (FDA-CDER 
1998), which corresponds to about 40 tons as a trigger level. In contrast, environmental 
assessments of veterinary pharmaceuticals is required by the U.S. FDA since 1980 (Boxall et al. 
2003). 
 
The objective of our paper is to compile and critically review the present knowledge about the 
environmental occurrence and fate of human pharmaceuticals in the aquatic environment, to 
discuss potential mechanisms of action based on knowledge from mammalian studies, and to 
describe the acute and chronic ecotoxicological effects on aquatic organisms. We also identify 
major gaps in the current knowledge and future research needs. We concentrate on 
pharmaceuticals used in human medicine, some of which are also applied in veterinary 
medicine, thereby focusing on environmentally important compounds belonging to different drug 
categories, namely non-steroidal antiinflammatory drugs, beta-blockers, blood lipid lowering 
agents, cancer therapeutics and neuroactive compounds. These classes differ for their modes 
of actions and were chosen because of their consumption volumes, toxicity and persistence in 
the environment. We will not address the environmental effects of antibiotics and biocides 
(Daughton and Ternes 1999; Halling-Sorensen et al. 1998; Hirsch et al. 1999), hormones (used 
in contraceptives and in therapy) (Damstra et al. 2002) and special veterinary pharmaceuticals 
(Boxall et al. 2003; Montforts et al. 1999) as the cited reports provide detailed information. 
 
The current knowledge indicates that residues of pharmaceuticals at trace quantities are 
widespread in aquatic systems. Pharmaceuticals in the environment are suggested to pose only 
a low risk for acute toxicity. For chronic effects, the situation may be different, but there is a 
considerable lack of information. Investigation of multigenerational life-cycle effects or at various 
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life stages is lacking, although many aquatic organisms are exposed for their entire life. There is 
a need to focus on long-term exposure assessment regarding specific modes of action of 
pharmaceuticals to better judge the implications of pharmaceutical residues in aquatic systems. 
Only after filling these gaps, more reliable environmental risk assessments with much lower 
uncertainty can be performed.  
 
 
Sources  
The consumption of pharmaceuticals is substantial. In the European Union (EU) about 3’000 
different substances are used in human medicine such as analgesics and antiinflammatory 
drugs, contraceptives, antibiotics, beta-blockers, lipid regulators, neuroactive compounds and 
many others. Also a large number of pharmaceuticals are used in veterinary medicine, among 
them antibiotics and antiinflammatory.  Sales figures are relatively high as reported for several 
countries (Table 1). In England, Germany and Australia, the amounts for the most frequently 
used drugs are in the hundreds of tons per year (Huschek et al. 2004; Jones et al. 2002; Oaks 
et al. 2004). The pattern of consumed pharmaceuticals for the different countries is not identical 
and some drugs may be forbidden or replaced by related drugs. However, as listed in Table 1, 
some drugs are regularly documented within the most frequently applied range: the class of 
non-steroidal antiinflammatory drugs (NSAID) including acetylsalicylic acid (e.g. 836 t in 
Germany in 2001), paracetamol (e.g. 622 t in Germany in 2001), ibuprofen (e.g. 345 t in 
Germany in 2001), naproxen (e.g. 35 t in England in 2000) and diclofenac (86 t in Germany in 
2001), the oral antidiabetic metformin (e.g. 517 t in Germany 2001) and the antiepileptic 
carbamazepine (e.g. 88 t in Germany 2001). Data representing the annual sales or 
consumptions include mainly prescribed drugs, some include also sales over-the-counter, some 
a mixture of both, and internet sales are not included. Therefore, the real amounts of applied 
drugs is uncertain, but probably significantly higher for some of the pharmaceuticals reported 
than the figures in Table 1. Figuring out the annual consumption of a certain drug is difficult and 
often based on estimates. For example, based on sales, estimates of the U.S. production of the 
antiepileptic carbamacepine (which is also used for other treatments) ranged from 43 t in 2000 
to 35 t in 2003 (Thaker 2005). 
 
Pharmaceuticals are excreted after application in their native form or as metabolites and enter 
aquatic systems via different ways. The main pathway from humans is ingestion following 
excretion and disposal via wastewater. Municipal wastewater is therefore the main route that 
brings human pharmaceuticals after normal use and disposal of unused medicines into the 
environment. Hospital wastewater, wastewater from manufacturers and landfill leachates (Lilius 
et al. 1994) may contain significant concentrations of pharmaceuticals. Pharmaceuticals not 
readily degraded in the sewage treatment plant (STP) are being discharged in treated effluents 
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resulting in the contamination of rivers, lakes, estuaries and rarely, groundwater and drinking 
water. Where sewage sludge is applied to agricultural fields, contamination of soil, run-off into 
surface water but also drainage may occur. In addition, veterinary pharmaceuticals may enter 
aquatic systems via manure application to fields and subsequent runoff, but also via direct 
application in aquaculture (fish farming). Of environmental concern is not necessarily a high 
production volume of a certain pharmaceutical per se, but the environmental persistence and 
critical biological activity (e.g. high toxicity, high potency for effects on biological key functions 
such as reproduction). As exemplified by the synthetic steroid hormones in contraceptive pills, 
such as 17-ethinylestradiol (EE2), the annual production lies in a couple of hundreds 
kilograms per year in the EU, yet it is extremely potent, quite persistent in the environment and 
shows estrogenic activity in fish at 1-4 ng/L, or lower. Hence, pharmaceuticals having 
environmental relevance share the following properties: often, but not always, high production 
volume combined with environmental persistence and biological activity, mainly after long-term 
exposure. 
 
 
Fate in the environment 
The behaviour and fate of pharmaceuticals and their metabolites in the aquatic environment is 
not well known. The low volatility of pharmaceuticals indicates that distribution in the 
environment will occur primarily through aqueous transport, but also via food chain dispersal. In 
wastewater treatment, two elimination processes are generally important: adsorption to 
suspended solids (sewage sludge) and biodegradation. Adsorption is dependent on both 
hydrophobic and electrostatic interactions of the pharmaceutical with particulates and 
microorganisms. Acidic pharmaceutical such as the NSAID acetylsalicylic acid, ibuprofen, 
fenoprofen, ketoprofen, naproxen, diclofenac and indomethacin having pKa values ranging from 
4.9 to 4.1, as well as clofibric aid, bezafibrate (pKa 3.6) and gemfibrozil occur as ion at neutral 
pH, and have little tendency of adsorption to the sludge. But adsorption increases with lower 
pH. At neutral pH, these negatively charged pharmaceuticals therefore occur mainly in the 
dissolved phase in the wastewater. For these compounds and the antitumor agent ifosfamide 
sorption by non-specific interactions seems not to be relevant (Buser et al. 1998b; Kümmerer 
2004). In general, sorption of acidic pharmaceuticals to sludge is suggested to be not very 
important for the elimination of pharmaceuticals from wastewater and surface water. Therefore, 
levels of pharmaceuticals in digested sludge and sediments are suggested to be relatively low, 
as was demonstrated in several monitoring studies (Daughton and Ternes 1999; Urase and 
Kikuta 2005). However, basic pharmaceuticals and zwitterions can adsorb to sludge to a 
significant extent, as has been shown for fluoroquinolone antibiotics (Golet et al. 2002).  For the 
hydrophobic EE2 (log Kow 4.0) sorption to sludge is likely to play a role in the removal from 
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wastewater. Degradation in sludge seems not significant.  As a consequence, EE2 occurs in 
digested sludge, where concentrations of 17 ng/g were reported (Temes et al. 2002). 
 
In case a pharmaceutical is occurring mainly in the dissolved phase, biodegradation is 
suggested to be the most important elimination process in wastewater treatment. It can occur 
either in aerobic (and anaerobic) zones in activated sludge treatment, or anaerobically in 
sewage sludge digestion. In general, biological decomposition of micro-pollutants including 
pharmaceuticals increases with increase in hydraulic retention time and with age of the sludge 
in the activated sludge treatment. For example, diclofenac was shown to be significantly 
biodegraded only when the sludge retention time was at least 8 days (Kreuzinger et al. 2004). In 
contrast, data from Metcalfe et al. (2003) indicate that the neutral drug carbamazepine, which is 
hardly biodegradable, is only poorly eliminated (normally less than 10%), independent from 
hydraulic retention times. Pharmaceuticals are often excreted mainly as non-conjugated and 
conjugated polar metabolites. Conjugates can, however, be cleaved in sewage treatment plants 
(STP), resulting in the release of active parent compound as shown for estradiol (Daughton and 
Ternes 1999; Panter et al. 1999), and the steroid hormone in the contraceptive pill, 17α-
etinylestradiol (D'Ascenzo et al. 2003). 
 
Studies on the elimination rates during the STP process are mainly based on measurements of 
influent and effluent concentrations in STPs, and they vary according to the construction and 
treatment technology, hydraulic retention time, season and performance of the STP. Some 
studies (Carballa et al. 2004; Daughton and Ternes 1999; Stumpf et al. 1999) indicate 
elimination efficiencies of pharmaceuticals to span a large range (0-99%). The average 
elimination for specific pharmaceuticals varied from only 7-8% for carbamazepine  (Clara et al. 
2004; Daughton and Ternes 1999; Heberer 2002) up to 81% for acetylsalicylic acid, 96% for 
propranolol, and 99% for salicylic acid (Daughton and Ternes 1999; Heberer 2002). Lowest 
average removal rates were found for diclofenac (26%), the removal of bezafibrate was 51%, 
but varied significantly between STPs, and high removal rates were found for naproxen (81%) 
(Lindqvist et al. 2005). Table 2 shows that removal rates are variable, even for the same 
pharmaceutical between different treatment plants. Very high total elimination of 94-100% of 
ibuprofen, naproxen, ketoprofen and diclofenac was found in 3 STP in the U.S.A. (Hollert et al. 
2000). Efficient removal took place mainly in the secondary treatment step (51-99% removal), 
whereas in the primary treatment only 0-44% were removed. X-ray contrast media (diatrizoate, 
iopamidol, iopromide, iomeprol), to the contrary, were not significantly eliminated (Daughton and 
Ternes 1999). Also, the anticancer drug tamoxifen (antiestrogen) was not eliminated (Roberts 
and Thomas 2005). This variation in elimination rates is not surprising, since pharmaceuticals 
form a heterogeneous group consisting of compounds with diverse chemical properties. 
Independent from the chemical characteristics of the compounds, the efficiencies of various 
STPs also vary for the same compound due to their equipment and treatment steps but also to 
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other factors such as temperature and weather. For instance, diclofenac showed largely 
different elimination rates between 17% (Heberer 2002) and 69% (Daughton and Ternes 1999), 
and 100% (Hollert et al. 2000).  
 
Once in surface waters, biotransformation through biodegradation occurs, but abiotic 
transformation reactions are probably more important. Whereas hydrolysis is generally 
negligible for environmentally relevant human drugs, photodegradation sometimes plays an 
important role at the water surface. Photolysis has been shown to be the main removal process 
for diclofenac in surface water (Buser et al. 1998b). For additional pharmaceuticals 
(sulphamethoxazole, ofloxacin and propranolol) laboratory experiments indicate direct and 
indirect photolysis as an important removal process (Andreozzi et al. 2003b). Carbamazepine 
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and clofibric acid, both compounds that are marginally processed in STP, have been shown to 
undergo slow photodegradation in salt- and organic free water with estimated half-lives in the 
range of 100 days at latitudes of 50°N in winter (Andreozzi et al. 2003b). The efficiency of 
photodegradation depends, besides substance properties, on the strength of the solar 
irradiation, and therefore on latitude and season, and on constituents present in the water that 
may act as photosensitizers generating hydroxyl radicals and singlet oxygen (i.e. nitrates, humic 
acids). Some adsorption to particles may occur. Laboratory batch studies to characterize the 
sorption behaviour of carbamazepine, diclofenac and ibuprofen in sandy sediments show that 
sorption coefficients were generally quite low (Scheytt et al. 2005). Diclofenac and ibuprofen are 
carboxylic acids with pKa values of 4.16 and 4.52 and these weak acids are negatively charged 
at pH of ambient water and sediment.  
 
There are no information about the bioaccumulation potential of pharmaceuticals in biota or 
food webs with the exception of diclofenac, accumulating in the prey of vultures (Oaks et al. 
2004), fluoxetine, sertraline and the SSRI metabolites norfluoxetine and desmethylsertraline 
detected in fish (Brooks et al. 2003). Diclofenac bioconcentration factors were 10-2’700 in the 
liver of fish and 5-1’000 in the kidney, depending on exposure concentrations (Schwaiger et al. 
2004). 
 
A few cases were reported, where pharmaceuticals were detected in drinking water (Heberer 
and Stan 1996) and groundwater (Daughton and Ternes 1999; Lilius et al. 1994). Ozonation, 
granulated activated carbon, and advanced oxidation have been shown as efficient removal 
processes. In drinking water, this has been shown for diclofenac, while clofibric acid and 
ibuprofen were oxidized in laboratory experiments mainly by ozone/H2O2 (Zwiener and Frimmel 
2000). The elimination of selected compounds (bezafibrate, clofibric acid, carbamazepine, 
diclofenac) during drinking water treatment was investigated in laboratory experiments and 
waterworks (Daughton and Ternes 1999). No significant removal was observed in batch 
experiments with sand, indicating low sorption properties and persistence. Flocculation using 
iron(III) chloride was ineffective, but ozonation was in some cases very effective in eliminating 
these polar pharmaceuticals. However, clofibric acid was stable and not eliminated, even with 
filtration using granular activated carbon, which was effective for the other compounds. The 
removal of pharmaceuticals and other polar micropollutants can therefore only be assured using 
more advanced techniques such as ozonation, activated carbon or membrane filtration 
(Daughton and Ternes 1999). However, the economic consequences have to be evaluated 
carefully before investing into these advanced treatment technologies on a larger scale. 
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Environmental concentrations 
The occurrence of pharmaceuticals was first reported in the U.S.A. in treated wastewater, were 
clofibric acid in the range of 0.8-2 µg/L was found (Garrison et al. 1976). Subsequently, 
pharmaceuticals were detected in the U.K. in 1981 in rivers up to 1 µg/L (Richardson and 
Bowron 1985), and ibuprofen and naproxen were identified in wastewaters in Canada (Rogers 
et al. 1986). In the last few years, knowledge about the environmental occurrence of 
pharmaceuticals has increased to a large extent due to new analytical techniques able to 
determine polar compounds at trace quantities. This also holds for the steroid hormones 
contained in contraceptive pills such as 17-ethinylestradiol (EE2), which is linked to biological 
effects in fish (Desbrow et al. 1998; Stumpf et al. 1996). Data on environmental concentrations 
up to 2004 have been compiled and reviewed (e.g. Daughton and Ternes 1999; e.g. Halling-
Sorensen et al. 1998; Heberer 2002; Kümmerer 2004). Here, we give a summary on 
environmental concentrations focusing on most recent analytical data with the ultimate aim to 
relate them to ecotoxicological data. First, we give a general overview on the occurrence of 
pharmaceuticals in general and in different environmental media, and subsequently present 
data on the different pharmaceutical classes. 
 
Recent studies reported concentrations of a wide range of about 80-100 pharmaceuticals from 
many classes of drugs (antiinflammatory, beta-blockers, sympathomimetics, antiepileptics, lipid 
regulators, antibiotics etc.) and some of their metabolites in many countries in treated sewage, 
rivers and creeks, seawater, groundwater and even drinking water.  Ternes (1998) reported on 
the occurrence of 32 pharmaceuticals belonging to different medicinal classes in German 
municipal STP effluents, river and stream waters. 20 different drugs and 4 corresponding 
metabolites including antiinflammatory drugs (salicylic acid, diclofenac, ibuprofen, indometacine, 
naproxen, phenazone), lipid regulators (bezafibrate, gemfibrozil, clofibric acid, fenofibric acid), 
beta-blockers (metoprolol, propranolol) and carbamazepine were found to be ubiquitously 
present in streams and river water in the ng/L range. In an extended monitoring study 
concentrations of 95 micro-pollutants in water samples of 139 streams downstream of urban 
areas and livestock production across the U.S.A. were detected (Kolpin et al. 2002). In some 
sites as many as 38 of the targeted 95 compound were detected in a single water sample 
(average number of compounds in a sample was seven). Among the most frequently detected 
compounds were steroids (although some data had to be withdrawn subsequently), an insect 
repellant (N,N-diethyltoluamide), caffeine, triclosan (an antimicrobial compound), antibiotics, a 
fire retardant, 4-nonylphenol and some pharmaceuticals. Analysis of the distribution of different 
drugs in the river Elbe and its tributaries between the source and the city of Hamburg, Germany, 
showed the presence of many pharmaceuticals. The main substances found were diclofenac, 
ibuprofen, carbamazepine, various antibiotics and lipid regulators  (Wiegel et al. 2004). A similar 
contamination pattern was found in Italy in the river Po and Lambro (Calamari et al. 2003) 
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where at all sampling sites atenolol, bezafibrate, furosemide, and antibiotics were found and 
ranitidine, clofibric acid, diazepam were often detected. Kolpin et al. (2004) collected water 
samples upstream and downstream of selected towns and cities in Iowa, U.S.A., during high-, 
normal- and low-flow conditions to determine the contribution of urban centres to concentrations 
of pharmaceuticals and other organic wastewater contaminants in streams under varying flow 
conditions. Prescription drugs were only frequently detected during low-flow conditions.  
 
Environmental concentrations of pharmaceuticals were mainly reported in STP effluents and in 
surface water in many countries, often at locations near STPs (Ashton et al. 2004; Gross et al. 
2004; Halling-Sorensen et al. 1998; Kolpin et al. 2002). The occurrence of selected 
pharmaceuticals was also reported in the Tyne estuary in the U.K. with concentrations ranging 
from 4 to 2370 ng/L (Roberts and Thomas 2005). Figure 1 gives a summary on the 
concentrations of most frequently assessed pharmaceuticals in wastewater and surface water 
reported so far. In STP effluents a number of different pharmaceuticals occur at concentrations 
generally in the ng/L to µg/L range. In rivers, lakes and seawaters, they are in the ng/L range 
(Ashton et al. 2004; Buser et al. 1998b; Hollert et al. 2000; Kolpin et al. 2002; Weigel et al. 
2002). The rather persistent antiepileptic carbamazepine, and clofibric acid, a metabolite of the 
Figure 1: Concentration of pharmaceuticals in treated wastewater (a) and surface water (b). References:
(Andreozzi et al. 2003b; Calamari et al. 2003; Daughton and Ternes 1999; Gross et al. 2004; Halling-
Sorensen et al. 1998; Hollert et al. 2000; Jones et al. 2002; Kolpin et al. 2002; Kümmerer 2004; Lindqvist 
et al. 2005; Metcalfe et al. 2003a; Metcalfe et al. 2003b; Oaks et al. 2004; Quintana et al. 2005; Roberts 
and Thomas 2005; Stackelberg et al. 2004; Stuer-Lauridsen et al. 2000; Tauxe-Wuersch et al. 2005; 
Weigel et al. 2004; Wiegel et al. 2004) 
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lipid lowering agents clofibrate, etofibrate and etofyllin clofibrate, have been detected with few 
exceptions in STP effluents, freshwater (rivers and lakes) and even in seawater (Buser et al. 
1998b; Weigel et al. 2002). In surface water, carbamazepine is found with maximal 
concentrations of 1.2 µg/L (Wiegel et al. 2004) and clofibric acid at 0.55 µg/L (Daughton and 
Ternes 1999). Carbamacepin contamination is widespread. In 44 rivers across the U.S.A. 
average levels were 60 ng/L in water and 4.2 ng/mg in the sediment (Thaker 2005). Frequently, 
the analgesic ibuprofen and its metabolites were detected in STP effluents (Boyd et al. 2003; 
Buser et al. 1999; Daughton and Ternes 1999; Weigel et al. 2004), in surface water of up to 1 
µg/L (Kolpin et al. 2002), and in seawater (Hollert et al. 2000; Weigel et al. 2004). In a 
monitoring study in the U.K. propranolol (median level 76 ng/L) was always found in STP 
effluents, whereas diclofenac (median 424 ng/L) was found in 86%, ibuprofen (median 3086 
ng/L) in 84%, mefenamic acid (median 133 ng/L) in 81%, dextropropoxyphene (median 195 
ng/L) in 74%, and trimethoprim (median 70 ng/L) in 65% of the samples (Ashton et al. 2004). In 
the corresponding receiving streams, fewer compounds and lower levels were found. 
 
Some drinking waters (Heberer and Stan 1996; Putschew et al. 2000; Stackelberg et al. 2004; 
Stumpf et al. 1999; Zuccato et al. 2000), groundwaters (Daughton and Ternes 1999; Lilius et al. 
1994), and landfill leachates (Lilius et al. 1994) contain pharmaceuticals in the ng/L range, in 
some cases up to µg/L. Phenazone, propiphenazone and clofibric acid were found in samples 
of potable water collected in the vicinity of Berlin, Germany (Heberer and Stan 1997; Reddersen 
et al. 2002). Several polar pharmaceuticals such as clofibric acid, carbamazepine, and X-ray 
contrast media can occur in groundwater. In the following, current knowledge about major 
pharmaceuticals of different therapeutic classes is summarized. 
 
Analgesics and antiinflammatory drugs. The widely used non-steroidal antiinflammatory 
drugs (NSAID) ibuprofen, naproxen, diclofenac and some of their metabolites (e.g. hydroxyl-
ibuprofen and carboxy-ibuprofen) are very often detected in sewage and surface water. Ternes 
(1998) reported levels in sewage exceeding 1 µg/L, and in effluents of conventional STP 
(mechanical clarification and biological treatment) concentrations often approach or exceed 0.1 
µg/L in the U.S.A. (Gross et al. 2004). The deacylated, more active form of acetyl salicylic acid, 
salicylic acid, has been found in many municipal wastewaters at levels up to 4.1 µg/L (Daughton 
and Ternes 1999), 13 µg/L (Farré et al. 2001; Heberer 2002) or even 59.6 µg/L with median 
levels of 3.6 µg/L (Metcalfe et al. 2003a). However, salicylic acid may also derive from other 
sources. Similar to acetyl salicylic acid, acetaminophen (paracetamol) is well removed from 
STP. However, up to 10 µg/L (median 0.11 µg/L) acetaminophen has been found in 24% of 
samples from U.S. streams (Kolpin et al. 2002). The analgesic codeine was detected in 7% of 
samples at median concentrations of 0.01 µg/L. 
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In many countries diclofenac was frequently detected in wastewater in the µg/L range, and in 
surface water at lower levels (Buser et al. 1998b; Daughton and Ternes 1999; Farré et al. 2001; 
Heberer 2002; Heberer and Stan 1997; Sedlak and Pinkston 2001; Stumpf et al. 1999). This 
also holds for ibuprofen (Buser et al. 1999; Daughton and Ternes 1999; Heberer and Stan 
1997; Stumpf et al. 1999). Sometimes, high levels of up to 85 µg/L (Farré et al. 2001), or 24.6 
µg/L (median 4.0 µg/L) were detected in STP effluents (Metcalfe et al. 2003a). In Norway, 
ibuprofen and its metabolites occurred in all sewage samples, and in seawater at 
concentrations of 0.1-20 µg/L (sum of ibuprofen and metabolites) (Weigel et al. 2004). In U.K. 
estuaries maximal concentration of 0.93 µg/L (median 0.05 µg/L) occurred (Hollert et al. 2000). 
Ibuprofen is significantly removed during sewage treatment, and metabolites such as hydroxy-
ibuprofen occur in STP effluents. Kolpin et al. (2002) found ibuprofen in 10% of stream water 
samples with maximal concentrations of 1 µg/L (median 0.2 µg/L). In two stormwater canals 
levels of ibuprofen were up to 674 ng/L and of naproxen up to 145 ng/L (Boyd et al. 2004). 
Naproxen was also found at much higher level in Canadian STP effluents with median levels of 
12.5 µg/L and maximal levels of up to 33.9 µg/L (Metcalfe et al. 2003a). Moreover, several other 
analgesics have been detected in sewage and surface water, but also in ground water and 
drinking water samples.    
 
Beta-blockers. Several beta-blockers were identified in wastewater (Daughton and Ternes 
1999; Sedlak and Pinkston 2001). Propranolol, bisoprolol and metoprolol were found at highest 
levels (0.59 µg/L, 2.9 µg/L and 2.2 µg/L respectively in surface water), with lower levels of 
nadolol (in surface water) and betaxolol (0.028 µg/L in surface water) (Daughton and Ternes 
1999). Propranolol, metoprolol and bisoprolol have also been found in surface water, and 
sotalol in groundwater (Sacher et al. 2001).  
 
Blood lipid lowering agents. Clofibric acid, the active metabolite from a series of widely 
used blood lipid regulators (clofibrate, etofyllin clofibrate, etofibrate) belongs to the most 
frequently found and reported pharmaceutical in monitoring studies. It has been found in 
numerous wastewaters, surface waters, in seawater (Buser et al. 1998a; Daughton and Ternes 
1999; Stumpf et al. 1996), and at rather high concentrations in groundwater (4 µg/L) (Heberer 
and Stan 1997) and drinking water (0.07-0.27 µg/L) (Heberer and Stan 1997; Stumpf et al. 
1996). Bezafibrate occurred in maximal concentrations of up to 4.6 and 3.1 µg/L (median 2.2 
and 0.35 µg/L, respectively) in wastewater and surface water, respectively (Daughton and 
Ternes 1999; Stumpf et al. 1996). In addition, gemfibrozil, clofibric acid and fenofibric acid 
(metabolite of fenofibrate) have also been detected in sewage up to the µg/L level and in 
surface water (Daughton and Ternes 1999; Farré et al. 2001; Heberer 2002; Stumpf et al. 
1999). Gemfibrozil was detected in 4% of streams at maximal levels of 0.79 µg/L (Kolpin et al. 
2002). 
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Neuroactive compounds (antiepileptics, antidepressants). Of this category, the 
antiepileptic carbamazepine was detected most frequently and in highest concentration in 
wastewater (up to 6.3 µg/L) (Daughton and Ternes 1999), and at lower levels in other media 
(Andreozzi et al. 2003b; Heberer et al. 2002; Metcalfe et al. 2003b; Wiegel et al. 2004). 
Carbamazepine was found in every Canadian STP effluent sample at concentration up to 2.3 
µg/L (Metcalfe et al. 2003b). This compound was found to occur ubiquitously in the river Elbe 
and its tributaries, Germany (Wiegel et al. 2004), exceeding 1 µg/L in other German surface 
waters (Daughton and Ternes 1999; Heberer 2002) and occurred in groundwater (Daughton 
and Ternes 1999; Sacher et al. 2001; Seiler et al. 1999). In U.S. rivers average levels were 60 
ng/L in water and 4.2 ng/mg in the sediment (Thaker 2005). Carbamacepine was also found at 
average levels of 20.9 ng/mg solids of STP.  Diazepam was present in 8 of 20 STP in Germany 
at relatively low concentrations of up to 0.04 µg/L (Daughton and Ternes 1999) whereas in 
Belgium it was found at concentration up to 0.66 µg/L (van der Ven et al. 2004). The 
antidepressant fluoxetine was also detected in STP effluents samples in Canada (Metcalfe et al. 
2003a), and in U.S. streams, median concentrations of 0.012 µg/L were estimated (Kolpin et al. 
2002). Primidone, an antiepileptic drug, has also been detected in sewage up to 0.6 µg/L 
(Heberer 2002). 
 
Antineoplastics and antitumor agents. Pharmaceuticals used in cancer chemotherapy occur 
primarily in hospital effluents and only at lower concentrations in municipal wastewater. 
Ifosfamide and cyclophosphamide occur in concentrations of up to 4.5 µg/L in hospital 
wastewaters (Steger-Hartmann et al. 1997), and at ng/L in municipal wastewater (Kümmerer 
2004; Steger-Hartmann et al. 1997). The occurrence of the antiestrogen tamoxifen used in 
breast cancer therapy was reported in U.K. wastewater, where concentrations in STP effluents 
ranged between 146-369 ng/L (Roberts and Thomas 2005). Tamoxifen was not reduced in the 
STP, and even found in estuarine waters (Tye estuary) at concentrations ranging from 27-212 
ng/L with a median level of 53 ng/L (Hollert et al. 2000; Roberts and Thomas 2005). 
 
Various other compounds. Many additional pharmaceuticals have been detected in 
sewage and surface water (Daughton and Ternes 1999; Heberer 2002; Kolpin et al. 2002). Here 
only a few of them will be mentioned. The stimulant caffeine and the nicotine metabolite cotinine 
were generally present in STP effluents and surface waters contaminated by drugs (Metcalfe et 
al. 2003b). Caffeine was generally found in U.S. streams at maximal levels of 6.0 µg/L (median 
0.1 µg/L) (Kolpin et al. 2002) and this compound can even serve as an anthropogenic marker in 
aquatic systems due to its ubiquity in surface water, seawater (Weigel et al. 2004), and also in 
groundwater (Figure 1). The antiacid cimetidine and ranitidine were estimated to occur in U.S. 
streams at concentrations of 0.58 µg/L and 0.01 µg/L, respectively, and they were detected at a 
frequency of 10 % and 1%, respectively (Kolpin et al. 2002). X-ray contrast media are very 
persistent. Iopamidol has been found in municipal wastewater as high as 15 µg/L, in surface 
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water (0.49 µg/L) and groundwater (Daughton and Ternes 1999; Putschew et al. 2000). 
Iopromide was detected at 2-4 µg/L in surface water, and up to 21 µg/L in STP (Putschew et al. 
2000), but showed degradation in the laboratory (Steger-Hartmann et al. 2002). Hospital 
wastewater was also a source of gadolinium (Kümmerer 2004). The antidiabetic compound 
metformin was observed in 5% of stream water samples with estimated levels of 0.11 µg/L 
(Kolpin et al. 2002). Bronchodilators (β2-sympathomimetics terbutalin and salbutamol) were also 
detected in sewage in a few cases not exceeding 0.2 µg/L (Daughton and Ternes 1999). 
 
Steroidal hormones have been reported on in many reports, and in our review we only 
summarize knowledge about the synthetic estrogen EE2 and mestranol contained in 
contraceptive pills. These steroids have been found in numerous studies in many countries in 
Europe, Canada, the U.S.A., Japan, Brazil etc. both in wastewater and surface water. A survey 
in the U.S.A. showed that maximal and median EE2 concentrations were as high as 831 and 73 
ng/L, respectively, and levels of mestranol were 407 and 74 ng/L, respectively (Kolpin et al. 
2002). They were detectable in 16 % and 10 % of the streams sampled.  Generally, median 
concentrations are much lower being in the range of non detectable up to 9 ng/L in treated 
wastewater in several countries (Baronti et al. 2000). Typical wastewater effluent concentrations 
are 0.5 ng/L and they are even lower in surface water. However, these concentrations must put 
into the perspective of their high biological activity accounting for potential estrogenic effects in 
fish.  
 
Exposure and fate models are increasingly being used to estimate environmental 
concentrations without analytical chemical measurements. Some exposure models have been 
developed for drugs (e.g. PhATE), others have been extended from general chemicals to 
pharmaceuticals (e.g. EPIWIN, GREAT-ER). These tools have been developed both for 
estimation of predicted environmental concentrations (PEC) and the behaviour of 
pharmaceuticals in the environment. A pharmaceutical assessment and transport evaluation 
model (PhATE) was developed to estimate concentrations of active pharmaceutical ingredients 
in U.S. surface waters (Sanderson et al. 2004). The PhATE model uses some for most 
hydrologic regions of the U.S. representative watersheds. For European surface waters an 
exposure simulation was developed for pharmaceuticals with the GREAT-ER (Geo-referenced 
Regional Exposure Assessment Tool for European Rivers) model, a tool developed for use 
within ecological risk assessment (ERA) schemes and river basin management (Schowanek 
and Webb 2002). The GREAT-ER software calculates the distribution of PEC’s of consumer 
chemicals in surface waters, for individual stretches, as well as representative average PEC’s 
for entire catchments. The system uses an ARC/INFO-ArcView (®ESRI) based Geographical 
Information System (GIS) for data storage and visualization, combined with simple 
mathematical models for prediction of the fate of chemicals. 
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For some estimates, measured environmental concentrations (MEC) are in agreement with the 
estimated PEC’s, however, often, they are not as large differences occur between the models 
and the real world situation. The main reason is that different assumptions are made, which not 
always correspond to the real conditions in the environment. Consumption figures, metabolism 
in the organism, removal during sewage treatment plants and fate in the environment contain all 
uncertainties that may result in inappropriate estimates of PEC’s. Moreover, detailed situations 
at a given site is not reflected by models integrating large geographical areas. Poor prediction 
performance of current models for many pharmaceuticals is one of the outstanding scientific 
issues with regard to the question of pharmaceuticals in the environment. It is hoped that the 
models are improving by further refining the mentioned uncertainties and may be developing to 
a useful and readily applicable regulatory tool (Sanderson et al. 2004).  
 
 
Modes of actions in humans and mammals and occurrence of 
target biomolecules in lower vertebrates and invertebrates 
Here, we briefly summarize the modes of actions of pharmaceutical classes and ask, whether or 
not similar target receptors and biomolecules exist in lower vertebrates and invertebrates. 
Knowledge about similar targets exists primarily for fish. In general, very little is known about 
possible counterparts of human target biomolecules of pharmaceuticals in invertebrates. In 
addition, some of the side effects in humans are discussed, giving hints to possible adverse 
effects in lower animals.  
 
Analgesics and non-steroidal antiinflammatory drugs (NSAID). Non-steroidal 
antiinflammatory drugs act by inhibiting either reversibly or irreversibly one or both of the two 
isoforms of the cyclooxygenase enzyme (COX-1 and COX-2), which catalyze the synthesis of 
different prostaglandins from arachidonic acid (Vane and Botting 1998). Classical NSAID inhibit 
both COX-1 and COX-2 at different degrees, whereas new NSAID act more selectively on COX-
2, the inducible form responsible for the inflammatory reactions. Differences in binding site size 
are responsible for the selectivity of these drugs (Gierse et al. 1999; Kurumbail et al. 1997; 
Penning et al. 1997). NSAIDS are commonly used to treat inflammation and pain and to relieve 
fever, and sometimes they are also used for long-term treatment of rheumatic diseases. 
 
Prostaglandins play a variety of physiological roles according to their cells source and target 
molecules. They are known to be involved in process such as inflammation and pain, regulation 
of blood flow in kidney, coagulation processes and synthesis of protective gastric mucosa 
(Mutschler 1996; Smith 1971; Vane 1971). Since NSAID inhibit non-specifically prostaglandin 
synthesis, most side effects, at least after long-term treatment, are related to the physiological 
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function of prostaglandins. In the kidney, prostaglandins are involved in maintenance of the 
equilibrium between vasoconstriction and vasodilatation of the blood vessel that supply 
glomerular filtration. Renal damages and renal failure after chronic NSAID treatment seems to 
be triggered by the lack of prostaglandins in vasodilatation-induction. Gastric damages are 
thought to be caused by inhibition of both COX isoforms (Wallace 1997; Wallace et al. 2000). In 
contrast, liver damages are apparently due to building of reactive metabolites (e.g. acyl 
glucuronides) rather than inhibition of prostaglandins synthesis (Bjorkman 1998).  
 
The mode of action of paracetamol is not yet fully elucidated. It seems that this drugs acts 
mainly by inhibiting the cyclooxygenase of the central nervous system and it does not have 
antiinflammatory effects, because of the lack of inhibition of peripheral cyclooxygenase involved 
in inflammatory processes. Adverse effects of paracetamol are mainly due to formation of 
hepatotoxic metabolites, primarily N-acetyl-p-benzoquinone imine, synthesized when the 
availability of glutathione is diminished in liver cells. Acetaminophen widely used in many 
analgesic/antipyretic medications induces proliferation of cultured breast cancer cells via 
estrogen receptors without binding to them, but has no estrogenic activity in rodents (Harnagea-
Theophilus et al. 1999). The consequences of these observations are not clear. 
 
In fish an inducible COX-2 homologue has been found to be expressed in macrophages in 
rainbow trout (Oncorhynchus mykiss) and the translation product of the COX gene was found to 
have a high homology of 83-84% and 77% to its human counterpart COX-2 and COX-1, 
respectively (Zou et al. 1999). Also in goldfish, macrophages express a COX enzyme, which is 
an equivalent to mammalian COX-2 (Zou et al. 1999). A COX-1 and COX-2 homologue was 
cloned from brook trout ovary (Roberts et al. 2000), and recently, a shark COX was cloned in 
dogfish Squalus acanthias having 68% and 64% homology to mammalian COX-1 and COX-2, 
respectively (Chong et al. 2000). Prostaglandins are formed in a diverse range of vertebrates 
and invertebrates. However, in lower invertebrates such as corals, their synthesis is 
independent of COX, involving other enzymes (Song and Brash 1991). In arthropods and 
molluscs, COX-like activity is apparently responsible for the formation of prostaglandins, but 
these enzymes have not been purified and characterized (Pedibhotla et al. 1995). In birds, 
prostaglandins play a role in the biosynthesis of egg shells and treatment with the COX-inhibitor 
indometacine resulted in egg shell thinning (Lundholm 1997).  
 
Beta-blockers. Beta-blocker act by competitive inhibiting beta-adrenergic receptors and they 
are used in the treatment of high blood pressure (hypertension), and to treat patients after heart 
attack to prevent further attacks. The adrenergic system is involved in many physiological 
functions such as regulation of the heart oxygen need and beating, vasodilatation mechanisms 
of blood vessels, and bronchodilation. Furthermore, the adrenergic system is also known to 
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interact with carbohydrate and lipid metabolisms, mainly in response to stress needs such as 
starvation (Jacob et al. 1998).  
 
β-Adrenoceptors are 7-transmembrane receptor proteins coupled with different G-proteins that 
ultimately enhance the synthesis of the second messenger signaling molecules cAMP (Rang et 
al. 2003). According to medical needs beta-blockers may selectively inhibit one or more β-
receptors types; for example β2-blockers are used to treat hypertension avoiding cardiac effects, 
since this receptor subtype is not found in the heart. Selectivity is based on difference in 
chemical groups added to compounds that are able to enhance the interactions with amino 
acids of the transmembrane domains. Some of the beta-blockers (e.g. propranolol, a beta1-
adrencoceptor antagonist) have the ability to cause cell membrane stabilization, whereas other 
(e.g. metoprolol) have no membrane stabilizing activity (Doggrell 1990). Side effects of this 
therapeutic class are mainly bronchoconstriction and disturbed peripheral circulations (Hoffman 
and Lefkowitz 1998; Scholze 1999). Due to their lipophility they are supposed to pass the blood 
brain barrier and to act in the central nervous system (Soyka 1984, 1985).  
 
β-Adrenoceptors where found in fish (Oncorhynchus mykiss) liver, red and white muscle with a 
high degree of sequence conservation with other vertebrate homologues. They are also 
supposed to play similar role as in humans (Nickerson et al. 2001). The presence of a β2-
adrenoceptor subtype was also suggested by binding studies to occur in liver membranes of 
other fish and amphibians. β2-Adrenoceptors of rainbow trout (Nickerson et al. 2001) show a 
high degree of amino-acid sequence conservation with other vertebrate β2-adrenoceptors. Frog- 
(Devic et al. 1997) and turkey β1-adrenoceptors (Yardeny et al. 1986) are similar to mammalian 
β1-adrenoceptors. In rainbow trout, the β2-adrenoceptor gene is highly expressed in the liver, 
red and white muscle, with lower expression in gills, heart, kidney and spleen (Nickerson et al. 
2001). Clenbuterol or ractopamine that function in mammals as β-agonist were found in rainbow 
trout to show a somewhat different reaction. Clenbuterol displayed only partial agonist activities 
and the small effects of ractopamine may be related to low affinity for the trout β2-adrenoceptor. 
Agonist regulation of the trout hepatic β2-adrenoceptors may involve down-regulation of the 
receptors without affecting responsiveness (Dugan et al. 2003). Differences in the structure and 
function of the receptors may be responsible for differences in the affinity with β-blockers and 
mechanisms triggered by these drugs.  
 
Whereas mammals have 3 α2adrenoceptors, five distinct α2-adrenoceptor genes have been 
found expressed in zebrafish (Ruuskanen et al. 2005). Localization of the α-adrenoceptos in 
zebrafish shows marked conservation when compared with mammals. The α2-adrenergic 
system is functional in zebrafish as demonstrated by marked locomotor inhibition and lightening 
of skin color induced by the specific α2-adrenoceptor agonist dexmedetomidine, similar to 
mammals. Both effects were antagonized by the specific α2-adreneceotor antagonist 
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atipamezole. The α-adrenoceptor agonists medetomidine and clonidine are being investigated 
as potential antifouling agents preventing the settlement of barnacles on ship halls (Dahlstrom 
et al. 2004). Settlement of larvae is inhibited at low concentrations of 0.25-2.5 µg/L. Additional 
pharmacological and biochemical investigations on α- and β-adrenoceptors of fish and other 
lower organisms are needed.  
 
Blood lipid lowering agents. There are basically two types of anti-lipidemic drugs, namely 
statins and fibrates, the latter have been targeted analytically more often in the aquatic 
environment than the former. Both types are used to decrease the concentration of cholesterol 
(statins and fibrates) and triglycerides (fibrates) in the blood plasma. Statins as inhibitors of 
cholesterol synthesis act by inhibiting the 3-hydroxymethylglutaril coenzym A reductase (HMG-
CoA), responsible for the limiting step in the cholesterol synthesis, namely the conversion of 
HMG-CoA to mevalonate (Laufs and Liao 1998). As a consequence of the intracellular 
cholesterol depletion, the expression of LDL receptors in hepatocyte membranes is increased 
and therefore, the resorption of LDL-cholesterol from blood plasma. Due to interactions of 
statins with mevalonate metabolism, multiple additional effects occur (antiinflammatory, 
antioxidative). There is also evidence that statins affect juvenile hormone synthesis in insects 
(Debernard et al. 1994), as fluvastatin completely suppressed its biosynthesis in vitro, and in the 
mandibular organo of lobsters (Li et al. 2003). 
 
In contrast, effects of fibrates are mediated, at least in part, through alterations in transcription 
of genes encoding for proteins controlling lipoprotein metabolism. Fibrates act probably by 
activating the lipoprotein lipase enzyme, which is mainly responsible for the conversion of very 
low density lipoprotein (VLDL) to high density lipoproteins (HDL), decreasing therefore plasma 
triglycerides concentration (Staels et al. 1998). Binding of fibrates to peroxisome proliferator-
activated receptors (PPARs), nuclear receptors known to be activated during different cellular 
pathways, stimulates the expression of several lipid regulatory proteins such as, for example, 
the lipoprotein lipase (Staels et al. 1998). To date, three subtypes of PPAR have been 
described; PPARα is involved in peroxisome proliferation and plays a pivotal role in controlling 
hepatic lipid metabolism (Schoonjans et al. 1996), whereas PPARβ has diverse roles in basic 
lipid metabolism, and PPARγ plays a key role in the differentiation of adipocytes (Kersten et al. 
2000). Heterodimerization of PPAR’s with the retinoid X receptor and their binding to response 
elements in the promoter regions of genes leads to their activation.  
 
Fibrates stimulate cellular fatty acid uptake, conversion to acetyl-CoA derivatives, and 
catabolism by the beta-oxidation pathways, which, combined with a reduction in fatty acid and 
triglyceride synthesis, results in a decrease in VLDL production (Staels et al. 1998). Hepatic 
damages may occur after chronic exposure to fibrates in rat (Castano et al. 1994) (and this is 
thought to be related to inhibition of mitochondrial oxidative phosphorylation (Keller et al. 1992). 
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Furthermore, fibrates caused in rodents a massive proliferation of peroxisomes (Hess et al. 
1965). Strong correlation between fibrates exposure and hepatocarcinogenicity in rodents were 
found, while this was not observed in humans (Cajaraville et al. 2003). These findings increase 
the interest for ecotoxicological impact of this therapeutic class of drugs. 
 
PPAR genes have been found in fish such as plaice (Leaver et al. 1998) and Atlantic salmon 
(Ruyter et al. 1997) and zebrafish (Ibabe et al. 2002). Fish PPARs display an amino acid 
sequence identity of 43-48 % to the human and amphibian PPARγ (Andersen et al. 2000). All 
PPAR forms have been found in zebrafish, and PPARα was mainly expressed in hepatocyte 
and tissues that catabolize high amounts of fatty acids (Ibabe et al. 2002).  Furthermore, PPARγ 
was shown to be induced in response to clofibrate and benzafibrate in salmon hepatocytes 
(Ruyter et al. 1997), although their PPARγ seem to be less responsive than PPARγ of rodents 
(Andersen et al. 2000). All three PPAR receptors were found to already been expressed in the 
larval stage, with a similar tissue distribution pattern to that found in adult zebrafish (Ibabe et al. 
2005a). Activators of PPARα include a variety of endogenously present fatty acids, leukotrienes 
and hydroxyeicosatetraenoic acids and drugs, such as fibrates (Cajaraville et al. 2003). PPARβ 
activators include fatty acids, prostaglandin A2 and prostacyclin. PPARγ is the most selective 
receptor and prostaglandin J2 has been described to be a specific ligand (Ibabe et al. 2005b). In 
isolated zebrafish hepatocytes, mRNA of both PPARα and PPARγ was induced by clofibrate at 
0.5-2 mM, although to a low extent (Ibabe et al. 2005b). The physiological and toxicological 
roles of PPAR’s have yet to be investigated, and their involvement in potential effects of lipid 
lowering drugs is not yet known. With regard to invertebrates, no information is currently 
available on the existence of PPARs, although extensive searches for nuclear receptors in 
cnidarians and platyhelminthes have been performed (Escriva et al. 1997). 
 
Neuroactive compounds (antiepileptics, antidepressants). Among the many drugs 
interacting with the central nerve system (CNS), only a few will be considered as with respect to 
its occurrence in the aquatic environment. Antiepileptic drugs act on the CNS by decreasing the 
overall neuronal activity. This can be achieved either by blocking voltage-dependent sodium 
channels of excitatory neurons (e.g. carbamazepine), or by enhancing of inhibitory effects of the 
GABA neurotransmitter by binding on a specific site in the gamma subunit of the corresponding 
receptor (e.g. diazepam, member of benzodiazepine family) (MacDonald and Olsen 1994; 
Rogers et al. 1994; Study and Barker 1981). Evidence of the occurrence of the GABA system in 
fish (Oncorhynchus mykiss, (Cole et al. 1984; Meissl and Ekstrom 1991))  was found, whereas 
no studies have been found indicating the occurrence of sodium voltage dependent channels in 
fish or lower invertebrate.  
 
Fluoxetine is a widely used antidepressant, which acts by inhibiting the re-uptake of serotonin. 
This neurotransmitter is involved in many mechanisms, namely hormonal and neuronal, and it is 
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also important in functions such as food intake and sexual behavior. A pump directs serotonin 
from the synapse space back to the presynapse, and serotonin re-uptake inhibitors (SSRI) 
inhibit this pump, thus increasing the serotonin level in the synapse space. Serotonin as a 
neurotransmitter occurs in lower vertebrates and invertebrates (Chong et al. 2000), however, 
the effects associated with this transmitter are different, and so are possibly the effects of SSRI. 
Serotonin mediates, among others, endocrine functions in aquatic organisms such as fingernail 
claims (Sphaerium striatinum, (Chong et al. 2000)) and Japanese medaka (Oryzias latipes, 
(Brooks et al. 2003; Chong et al. 2000)). Fluoxetine and sertraline and the SSRI metabolites 
norfluoxetine and desmethylsertraline have been detected in fish sampled from wild in the U.S., 
and therefore reflect a bioaccumulation potential (Brooks et al. 2003). Whether the accumulated 
levels of 1.6 ng/g fluoxenine and 4.3 ng/g sertraline found in brain have effects on the nervous 
system of fish has yet to be investigated. 
 
Cytostatics compounds and cancer therapeutics. Another potential interesting class of 
compound is represented by cytostatic pharmaceuticals interacting with cell proliferation. There 
are different modes of actions of the different compounds. For example methotrexate acts as a 
potent inhibitor of the folate dehydroreductase enzyme, which is responsible for the purine and 
pyrimidine synthesis (Rang et al. 2003; Schalhorn 1995). Doxorubicin is an intercalating 
substance inducing DNA-strand brakes (in humans, heart arrhythmia may be a side effect). 
Tamoxifen as an anti-estrogenic drug is used for breast cancer treatment and acts by 
competitive inhibiting the estrogenic receptor at least in mammary gland (Rang et al. 2003).  
 
Various compounds. Cimetidine and ranitidine are compounds, which act by inhibiting the 
histamine receptors type 2 in the gastric system, thus inhibiting the acid secretion (antacid). 
These drugs are used to treat gastric ulceration. Since H2-histamine receptors are found also in 
the brain, both drugs may elicit central nervous system reactions and side effects (Cannon et al. 
2004). Peitsaro (2000) demonstrated the presence of H3-histamin receptors in central nervous 
system of zebrafish (Danio rerio), but the lack of histamine in the periphery of this fish was also 
reported. However, interspecies differences may occur; cod and carp seem to have histamine 
and H2-receptors in the periphery (Peitsaro et al. 2000). 
Metformin is an antidiabetic agent, which mechanisms of actions are not well understood. It 
seems that this drugs acts by increasing the cellular use of glucose and inhibiting the 
gluconeogenesis. Metformin seems to act on insulin receptor by direct stimulation of the insulin 
receptor or indirectly through inhibition of tyrosine phosphatase (Holland et al. 2004). 
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Ecotoxicological effects 
Pharmaceuticals are designed to target specific metabolic and molecular pathways in humans 
and animals, but they often have important side effects too. When introduced into the 
environment they may affect the same pathways in animals having identical or similar target 
organs, tissues, cells or biomolecules. As shown above, certain receptors in lower animals 
resemble those in humans, others however, are different or lacking, which means that dissimilar 
modes of actions may occur in lower animals. It is important in this respect to recognize that for 
many drugs, their specific modes of actions are not well known and often not only one, but 
many different modes of actions occur. Among other reasons, this makes specific toxicity 
analysis in lower animals difficult to perform. Despite this, toxicity experiments should be 
targeted and designed for specific targets of the pharmaceutical even in lower vertebrates and 
invertebrates, based on the hypothesis of similarity of modes of actions. However, current 
toxicity testing is not designed in this way, rather general and established test systems and 
traditional organisms according to guidelines are being used and traditional end points such as 
mortality are assessed.  
 
Thus far, ecotoxicity testing merely provided indications of acute effects in vivo in organisms of 
different trophic levels after short-term exposure, and only rarely after long-term (chronic) 
exposures. These data are ultimately used for ecological risk assessments. Because of animal 
welfare and screening purposes, in vitro analyses are becoming more important, but they are 
not sufficient for assessing the toxicological profiles of a compound, particularly as a basis for 
risk analysis (Fent 2001). Beyond laboratory investigations, some mathematical models were 
developed to estimate or predict ecotoxicological effects. The most often applied quantitative 
structure activity relationship (QSAR) program is ECOSAR (online 
http://www.epa.gov/oppt/newchems/sarman.pdf) (Sanderson et al. 2004). Despite serious 
drawbacks such as an inadequate structure coverage for pharmaceuticals, the program has 
been repeatedly applied to estimate pharmaceutical baseline toxicities (Cleuvers 2005; Jones et 
al. 2002; Sanderson et al. 2004). Both methods are helpful in estimating potential toxicity or the 
behavior of a compound in the environment, but they cannot replace in vivo or in vitro assays.  
 
The current literature about ecotoxicological effects of human pharmaceutical deals mainly with 
the acute toxicity in standardized tests and it is generally focused on aquatic organisms. The 
influence of environmental parameters such as pH on toxicity has only rarely, or not yet been 
investigated. Such studies would be of importance for instance for acidic pharmaceuticals that 
may induce different toxicities depending on speciation at different ambient pH. Moreover, 
effects of drug metabolites have rarely been investigated. Phototransformation products of 
naproxen, for instance, showed higher toxicities than the parent compound, while genotoxicity 
was not found (Isidori et al. 2005).  At contaminated sites, aquatic life is exposed over the entire 
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life cycle to these compounds. Chronic effects are less investigated and often even related to 
relative short-term exposures. However, long-term exposures are needed for an accurate 
environmental risk assessment. Here we summarize the current ecotoxicological data, focusing 
on specific modes of action of different therapeutic classes of pharmaceuticals, and covering 
many differences in methods, species and time of exposure. These data are then related to 
environmental levels in order to assess the potential hazard for the different classes of 
pharmaceuticals and identify current research and knowledge gaps.  
 
Acute effects 
Pharmaceuticals are assessed for their acute toxicity by traditional standard tests according to 
established guidelines (e.g. OECD, U.S. EPA, ISO) using established laboratory organisms 
such as algae, zooplankton and other invertebrates and fish. Acute toxicity data of 
pharmaceuticals were compiled by Hallig-Sorensen et al. (1998) and Webb (2001), whereby in 
the latter, a list of about 100 human pharmaceuticals from different sources is given. By 
comparing different trophic levels, Webb (2001) suggested that algae were more sensitive to 
the listed pharmaceuticals than Daphnia magna, and fish were even less sensitive. However, 
such generalizations do not focus enough on the different modes of actions of a given 
pharmaceutical, and hence, differences in toxicity in different phyla. In the attempt to compare 
the different classes of pharmaceuticals in terms of acute toxicity, Webb (2001) noted that the 
most toxic classes were antidepressants, antibacterials and antipsychotics, but the range of 
responses within each of these categories was large, typically several orders of magnitude. In 
our present review, we provide and summarize additional and new data and discuss its 
ecotoxicological relevance covering different classes of human pharmaceuticals. The data 
originate from different sources, and studies were performed under different quality criteria (i.e. 
nominal versus measured exposure concentrations), making comparisons difficult.  
  
Analgesics and non-steroidal antiinflammatory drugs (NSAID). In general, toxicity data vary 
for each pharmaceutical, however, diclofenac seems to be the compound having highest acute 
toxicity within the class of NSAID, since for all the tests performed the effect concentrations 
were below 100 mg/L (Figure 2). Short-term acute toxicity was analyzed in algae and 
invertebrates (Cleuvers 2003; Webb 2001), phytoplankton was found to react more sensitive 
[lowest EC50 (96 h) = 14.5 mg/L, (Ferrari et al. 2004)] than zooplankton [lowest EC50 (96h) = 
22.43 mg/L, (Ferrari et al. 2004)]. There is no correlation between the acute toxicity in Daphnia 
and the lipophilicity as represented by log Kow (Figure 3). In general, not much is known about 
the acute toxicity to fish.  
 
Beta-blockers. As shown in Figure 2, the acute toxicity of beta-blockers is not extensively 
studied, with the exception of propranolol. This compound shows the highest acute toxicity and 
highest log Kow as compared to other beta-blockers (Figure 3). This and the fact that it is a 
Ecotoxicology of Human Pharmaceuticals 
 178
strong membrane stabilizer, whereas other investigated beta-blockers are not, may in part 
explain its higher toxicity (Doggrell 1990; Hutchinson et al. 2003). Comparison of toxicity is 
difficult in this case, since other beta-blockers, except metoprolol, were only analyzed in D. 
magna (Hernando et al. 2004). Metoprolol and verapamil caused the acceleration of the heart 
beat rate at low concentration, but lowered it at high concentrations in D. magna (Villegas-
Navarro et al. 2003). For propranolol it seems that phyto- and zooplankton are more sensitive 
than fish. Ceriodaphnia dubia [EC50 (48 h) = 0.8 mg/L, (Ferrari et al. 2004)] displayed higher 
sensitivity than D. magna [EC50 (48 h) = 1.6 mg/L, (Hutchinson et al. 2003)] or other zooplankton 
organisms. Within phytoplankton, the microorganism Synechococcus leopolensis reacted most 
sensitive [EC50 (96 h) = 0.668 mg/L, (Ferrari et al. 2004)].  
 
Blood lipid lowering agents. Similar to beta-blockers, acute toxicity of lipid lowering agents is 
not extensively reported. Clofibrate showed LC50 values in the range of 7.7 to 39.7 mg/L and 
can be classified as harmful to aquatic organisms. The fish Gambusia holbrooki [LC50 (96 h) = 
7.7 mg/L, (Nunes et al. 2004)] seems the most sensitive organism to acute clofibrate 
Figure 2: Acute toxicity of 24 different pharmaceuticals, belonging to different therapeutic classes to 
aquatic organisms. EC50 and LC50 for different organisms and different endpoint and exposure time are 
summarized. See text for details. References: (Brooks et al. 2003; Calleja et al. 1993, 1994; Chong et al. 
2000; Cleuvers 2003, 2004; Ferrari et al. 2004; Halling-Sorensen et al. 1998; Henry et al. 2004; Henschel 
et al. 1997; Hernando et al. 2004; Hutchinson et al. 2003; Isidori et al. 2005; Kümmerer 2004; Lilius et al. 
1994; Marques et al. 2004a, 2004b; Nunes et al. 2004; Villegas-Navarro et al. 2003; Webb 2001) 
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concentrations studied so far. The known rodent peroxisome proliferator gemfibrozil injected to 
rainbow trout led to significant increases in fatty acyl-CoA oxidase (FOA) activity at doses of 46-
152 mg/kg/day (Scarano et al. 1994). Significant dose-related increases in peroxisomal FOA 
were observed after exposure of rainbow trout primary hepatocytes to clofibric acid, and 
ciprofibrate, but not with gemfibrocil (Donohue M. et al. 1993). The in vitro activity in these fish is 
weak. 
 
Neuroactive compounds (antiepileptics, antidepressants). The serotonin re-uptake inhibitor 
fluoxetine is apparently the most acute toxic human pharmaceutical reported so far with acute 
toxicity ranging from EC50 (48 h, alga) = 0.024 mg/L (Brooks et al. 2003) to LC50 (48 h) = 2 mg/L 
(Kümmerer 2004). For benthic organisms, acute toxicity is in the range of 15-43 mg/kg sediment 
[Chironomus tentans LC50 (10 d) = 15.2 mg/kg, Hyalella azteca LC50 (10 d) = 43 mg/kg, (Brooks 
et al. 2003)]. Fluoxetine seems to stronger affect phytoplankton than other aquatic organisms. 
 
Diazepam and carbamazepine, both antiepileptics, can be classified as potentially harmful to 
aquatic organisms, because most of the acute toxicity data are below 100 mg/L. For both 
compounds it seems that D. magna is affected more than other species, but the reasons for the 
higher susceptibility is not known. Acute toxicity of carbamazepine was found at 17.2 mg/L in 
Daphnia and at 34.4 mg/L in midges, but growth was inhibited at 12.7 mg/L in Daphnia and at 
9.2 mg/L in midges (Thaker 2005). 
 
Figure 3: Relation between acute toxicity (LC50) of analgesics and antiinflammatory drugs (y=0.0082x-
0.0034; R2=0.1202; ANOVA not significant) (a) and β-blockers (y=0.1386x-0.1709; R2=0.4301; ANOVA 
significant; p<0.02) (b) and octanol-water partition coefficients of the compounds (LogKow); calculated and 
measured values are given in different symbols. Acute toxicity of Daphnia magna refers to immobilisation 
after 48 hours (LC50 value). References: Acute toxicity: (Brooks et al. 2003; Calleja et al. 1993; Cleuvers 
2003, 2004; Ferrari et al. 2004; Halling-Sorensen et al. 1998; Henschel et al. 1997; Hernando et al. 2004; 
Hutchinson et al. 2003; Lilius et al. 1994; Marques et al. 2004a, 2004b; Villegas-Navarro et al. 2003). 
LogKow, in between parenteses: acetylsalicylic acid (1.13) (Sanderson et al. 2004); salicylic acid (2.26) 
(Hansch et al. 1995); diclofenac (4.51), ibuprofen (3.97) (Avdeef et al. 1998); naproxen (3.18) (Cleuvers 
2004); paracetamol (0.49) (Henschel et al. 1997); atenolol (0.5) (Griffin et al. 1999); betaxolol (2.98) 
(Sanderson et al. 2004); metoprolol (2.15), propranolol (3.56) (Hardman et al. 1996); sotalol (0.24) 
(Hansch et al. 1995). 
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Cytostatic compounds and cancer therapeutics. Acute toxicity of methotrexate on highly 
proliferative species, namely the ciliate Tetrahymena pyriformis, indicated acute effects [EC50 
(48 h) = 45 mg/L, (Henschel et al. 1997)]. Teratogenicity in fish embryos was observed at even 
higher concentrations [EC50 (48 h) = 85 mg/L, (Henschel et al. 1997)].  
 
The acute toxicity data summarized in Figure 2 shows that 17% of the pharmaceuticals 
displayed an acute toxicity below 100 mg/L, and for fluoxetine, all toxicity values were below 10 
mg/L. On the other hand, 38 % of the pharmaceuticals such as acetylsalicylic acid, betaxolol, 
sotalol, bezafibrate, gemfibrozil, bezafibrate, cimetidine and ranitidine displayed LC50 values 
higher than 100 mg/L, which, according to EU-Directive 93/67/EEC (Commission of the 
European Communities, 1996), are classified as not being harmful for aquatic organisms. The 
other pharmaceuticals (45%) displayed a considerable variability of acute toxicity values, 
spreading over a wide range, thus making a classification difficult. 
 
Variability of data both within the same and between different species is obvious. Different 
actual exposure concentrations (only nominal concentrations were used in the determination of 
the endpoints), different sensitivities of used clones, different laboratory performances are 
among the reasons for variability within the same species (for example, clofibric acid toxicity in 
D. magna varies between 72 and 200 mg/L; the LC50 (48h) of acetyl salicylic acid varies 
between168 mg/L (Calleja et al. 1994) and 1468 mg/L (Lilius et al. 1994); the LC50 (24h) of 
diazepam varies between 9.6 mg/L (Calleja et al. 1993) and 10‘000 mg/L (Calleja et al. 1994). 
Depending on the quantity and quality of data, ranges of acute toxicity values span one to two 
orders of magnitude, in some cases such as propranolol or diazepam, the species differences 
are quite large, spanning 3-4 orders of magnitude. When different categories are compared, a 
tendency of lower LC50 (EC50) values is found for beta-blockers and neuroactive drugs as 
compared to antiinflammatory drugs or various other compounds.  
 
Often, acute toxicity is related to non-specific mode of actions, and not to mechanisms involving 
specific target molecules. The compounds are thought to interact with cellular membranes 
leading to unspecific membrane toxicity. This general mechanism may be only one, additional 
ones (e.g. oxidative stress) come into play with particular pharmaceuticals. We evaluated 
whether the acute toxicity data of the different classes of pharmaceuticals correlate with the log 
Kow of the compound, as the lipophilicity determined by log Kow is an important parameter for 
membrane toxicity. However, no correlation was found between the log Kow of pharmaceuticals 
of a certain category or of all pharmaceuticals, and the acute toxicity either of a certain species, 
a group of organisms, or all of them. The best relation between measured and estimated log Kow 
of one class of pharmaceuticals and acute toxicity in one species, Daphnia magna, is depicted 
in Figure 3. Reasons for the variability of the data are probably based on laboratory differences, 
nominal concentration differences, clone susceptibility differences, but also on the fact that log 
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Kow may not be the best model for lipophilicity. This holds in particular for ionizable compounds, 
where the pH-dependent speciation is of significant influence (Brüschweiler et al. 1995; Looser 
et al. 1998). 
 
In conclusion, acute toxicity to aquatic organisms is unlikely to occur at measured 
environmental concentrations, as acute effects concentrations are 100 to 1000 higher than 
residues found in the aquatic environment. For example, the lowest acute effect concentration 
of fluoxetine was 20 µg/L, whereas the highest estimated environmental concentration was 0.01 
µg/L; the lowest acute effect of salicylic acid was 37 mg/L, whereas the highest environmental 
concentration was ~60 µg/L. Therefore, acute toxicity is only relevant in case of spills.  
 
Chronic effects 
Many aquatic species are continuously exposed over long periods of time or even over their 
entire life cycle. Evaluation of the chronic potential of micro-pollutants, e.g. pharmaceuticals, is 
therefore important. However, there is a lack of chronic data, and where available, chronic 
toxicity is marginally known. The available chronic data do often not investigate the important 
key targets, nor do they address the question in different organisms. Toxicity experiments are 
usually performed according to established guidelines. More specific investigations including 
analysis of possible targets of the pharmaceutical, or over different life stages, are lacking, or 
have only rarely been performed. Moreover, life cycle analyses are not reported, except for EE2 
(Länge et al. 2001; Parrott and Blunt 2005), and toxicity to benthic and soil organisms have very 
Figure 4 : Chronic toxicity of 10 different pharma-
ceuticals, belonging to different therapeutic 
classes. Given are lowest observed effect 
concentrations (LOEC) and no observed effect 
concentrations (NOEC) for different aquatic 
organism, different endpoints and exposure times. 
See text for details. References: (Brooks et al. 
2003; Cleuvers 2004; Ferrari et al. 2004; Henry et 
al. 2004; Hutchinson et al. 2003; Kümmerer 2004; 
Marques et al. 2004a, 2004b; Schwaiger et al. 
2004; Triebskorn et al. 2004; Webb 2001). 
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rarely been evaluated. In this chapter, we review the current literature according to the different 
pharmaceutical classes and summarize the data in Figure 4.  
 
The best knowledge exists for the synthetic steroid EE2 contained in contraceptive pills, 
showing estrogenic effects at extremely low and environmentally relevant concentrations. This 
steroid has been shown in many fish to induce estrogenic effects at extremely low 
concentrations. Exposure of fathead minnows over their life cycle indicates reproductive effects 
at low concentrations of EE2 (Länge et al. 2001). The NOEC values of the F0 generation F1 
embryo hatching success and larval survival were ≥ 1 ng/L. Male fish exposed to EE2 at 4 ng/L 
failed to develop normal secondary sexual characteristics and the sex ratio was altered. No 
testicular tissue was observed in any fish exposed to EE2 at 4 ng/L. A recent study shows 
vitellogenin (VTG) induction in fathead minnows with an EC50 value as low as 1 ng/L; EE2 was 
25-30 times more potent than estradiol (Brian et al. 2005), confirming previous reports on VTG 
induction at concentrations between 0.1 and 1 ng/L (Pawlowski et al. 2004). Decreased egg 
fertilization and sex ratio (skewed toward females), both of which were significantly affected at 
extremely low concentrations of 0.32 ng/L EE2 (Parrott and Blunt 2005). The next most 
sensitive parameter was demasculinization (decreased male secondary sex characteristic 
index) of males exposed to an EE2 concentration of 0.96 ng/L. Full life cycle exposure of 
zebrafish to 3 ng/L EE2 lead to elevation of VTG and caused gonadal feminization in all 
exposed fish and thus inhibited reproduction (Fenske et al. 2005). Life-long exposure of 
zebrafish to 5 ng/L in the F1 generation caused a 56% reduction in fecundity and complete 
population failure with no fertilization. Infertility in the F1 generation was due to disturbed sexual 
differentiation with males having no functional testes and intersex gonads (Nash et al. 2004).  
 
In hazard and risk assessment, the ratio between acute to chronic toxicity is often taken for 
evaluation of chemicals. For pharmaceuticals, this is difficult, because only very rarely, a 
systematic analysis of a given drug in both acute and chronic toxicity in a single species is 
performed. Apart from EE2, there are only a few NSAID, from which acute to chronic ratios can 
be deduced. Table 3 shows that even for similar drugs, these ratios in Daphnia magna vary by 
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two orders of magnitude. For all other drugs, only partial information is available on a given 
species. Ratios derived on the basis of a number of different species are not accurate, giving 
questionable information. The examples in table 3 confirm again that chronic toxicity cannot be 
derived from acute toxicity by simple calculations. This is often neglected in risk assessment.  
 
Analgesics and non-steroidal anti-inflammatory drugs. NSAID inhibit the synthesis and 
release of prostaglandins via COX inhibition and these compounds are the most consumed 
category of drugs. About NSAID commonly found in the aquatic environment, most chronic data 
are reported. Acetyl salicylic acid affected reproduction in D. magna and D. longispina at 
concentrations of 1.8 mg/L (Marques et al. 2004a). Diclofenac is commonly found in wastewater 
at median concentration of 0.81µg/L (Daughton and Ternes 1999) whereas the maximal 
concentration in wastewater and surface water is up to 2µg/L (Daughton and Ternes 1999; 
Schwaiger et al. 2004; Stumpf et al. 1996). Traditional chronic toxicity studies with diclofenac 
were reported in invertebrates (Ferrari et al. 2004). A recent study demonstrated chronic 
histopathological effects in rainbow trout after 28 days of exposure. At the LOEC of 5 µg/L renal 
lesions (degeneration of tubular epithelia, interstitial nephritis) and alterations of the gills 
occurred in rainbow trout (Schwaiger et al. 2004), and subtle subcellular effects even at 1 µg/L 
(Triebskorn et al. 2004). Impairment of renal and gill function is likely to occur after long-term 
exposure. The kidney was also found to be a target of diclofenac in vultures, acute renal failure 
was probably the reason for the visceral gout (Oaks et al. 2004) and the occurrence of 
extensive deposits of uric acid on and within internal organs (Oaks et al. 2004). In zebrafish 
embryos, no effect of diclofenac on embryonic development was observed, except delayed 
hatching at 1 and 2 mg/L (Hallare et al. 2004). Additional side effects of diclofenac have been 
observed in humans in the liver with degenerative and inflammatory alterations (Banks et al. 
1995), in lower gastrointestinal tract and in the esophagus (Bjorkman 1998), but not in fish.  
 
Beta-blockers. As fish contain β2-receptors in heart and liver (Gamprel et al. 1994) and 
probably in reproductive tissues (Haider and Baqri 2000), unspecific antagonists such as 
propranolol may be active in fish. In fact, propranolol indicated chronic toxicity not only on the 
cardiovascular system, but also on reproduction. The no-observed-effect-concentration (NOEC) 
and lowest-observed-effect-concentration (LOEC) of propranolol affecting reproduction in C. 
dubia were 125 and 250 µg/L, and reproduction was affected after 27 days of exposure in 
Hyalella azteca at 100 µg/L (Hutchinson et al. 2003). In fish O. latipes, significant changes in 
plasma steroid levels occurred after 14 days of exposure. The number of eggs released by fish 
was reduced at 0.5 µg/L after a 4-week exposure to 0.5 and 1 µg/L, but not at 50 and 100 µg/L 
(Hutchinson et al. 2003). No alteration in vitellogenin levels was observed. It was suggested that 
alteration in sex steroids let to decreased oxytocin excretion, which could decrease the number 
of eggs released. Propranolol was also analysed in invertebrates. LOEC and NOEC for different 
organisms span several orders of magnitude (Figure 4), partly due to differences between 
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laboratories, but also species differences. These data should be compared to the environmental 
concentrations; propranolol, metoprolol and nadolol were identified in U.S. wastewater samples 
up to 1.9, 1.2 and 0.36 µg/L, respectively (Hutchinson et al. 2003).  
 
Blood lipid lowering agents. Data on this class of compounds are rare. Fibrates have been 
evaluated by traditional toxicity tests. The following NOEC were found for clofibric acid in C. 
dubia [NOEC (7 days) = 640 µg/L], the rotifer B. calyciflorus [NOEC (2 days) = 246 µg/L], and in 
early life stages of zebrafish [NOEC (10 days) = 70 mg/L] (Ferrari et al. 2004). Gemfibrozil 
occurred in blood plasma of goldfish after exposure over 14 days at 113-times higher levels 
than in water (bioconcentration factor of 113). Plasma testosterone was reduced by over 50% 
after exposure to 1.5 and 10 mg/L, as well as levels of steroid acute regulatory protein transcript 
in goldfish testes (Mimeault et al. 2005).   
 
Neuroactive compounds. Most data were reported for the antiepileptic carbamazepine and 
serotonin reuptake inhibitors (SSRI), other neuroactive compounds were very rarely or not 
evaluated (Figure 4). Traditional toxicity tests showed chronic toxicity of carbamazepine in C. 
dubia [NOEC (7 days) = 25 µg/L], in the rotifer B. calyciflorus [NOEC (2 days) = 377 µg/L], and 
in early life stages of zebrafish [NOEC (10 days) = 25 mg/L] (Ferrari et al. 2004). 
Carbamazepine is considered carcinogenic in rats but is not mutagenic in mammalian cells. 
Sublethal effects occurred in Daphnia at 92 µg/L and the lethal concentration in zebra fish was 
43 µg/L (Thaker 2005).  In a study with the cnidarian Hydra vulgaris, diazepam was shown to 
inhibit polyp regeneration at 10 µg/L (Pascoe et al. 2003).  
  
Most chronic studies focussed on SSRI. Serotonin is a neurotransmitter found in lower 
vertebrates and invertebrates, and SSRI may adversely influence the function of the nervous 
and associated hormonal systems of these organisms as well. Besides having important 
functions as a neurotransmitter, serotonin may directly act on the immune system, alters 
appetite, influences behavior and modulates sexual function. The role of serotonin in 
reproduction varies between different phyla and effects of SSRI as well. Fong (1998) found that 
SSRI (fluvoxamine, paroxetine) led to induction (at 10 nM to 100 µM) and fluoxetine to 
potentiation (at 5 µM, and if co-applied with 7-100 µM serotonin, but not at other concentrations) 
of parturition in fingernail clams. Fong (1998) found an induction of spawning in zebra mussels 
by fluvoxamine concentrations as low as 0.032 µg/L. Induction of mussel spawning point to an 
interference with serotonin action, as in invertebrates, serotonin may stimulate ecdysteroids, 
ectysone and juvenile hormone, responsible for controlling oogenesis and vitellogenesis (Nation 
2002). A reproductive stimulation was also found in D. magna exposed to 36 µg/L fluoxetine for 
30 days, and in C. dubia fecundity was increased at 56 µg/L (Flaherty et al. 2001), but reduced 
in another study (Brooks et al. 2003). An evaluation of 5 SSRI (fluoxetine, fluvoxamine, 
paroxetine, citalopram, sertraline) showed negative effects on C. dubia reproduction by 
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reduction of the number of neonates or brood per female after 7-8 days of exposure. For the 
most active compound, sertraline, the LOEC was 45 µg/L and the NOEC 9 µg/L (Henry et al. 
2004). Fluoxetine has been detected in sewage and stream water at concentrations of 12 ng/L 
(Kolpin et al. 2002) and 99 ng/L (Metcalfe et al. 2003b), respectively. 
 
In medaka (O. latipes), serotonin induced oocyte maturation (Iwamatsu et al. 1993), but a 
contrary action was reported in mummichog (F. heteroclitus) (Cerda et al. 1998). Serotonin was 
indicated to potentiate effects of gonadotropin-releasing hormone on gonadotropin release from 
the pituitary (Oaks et al. 2004). When medaka were exposed for 4 weeks to fluoxetine 
concentrations of 0.1-5 µg/L, vitellogenin plasma content, plasma steroids, fecundity, egg 
fertilization or hatching rate were not affected (Brooks et al. 2003). This indicates no 
reproduction impairment in this fish up to 5 µg/L fluoxetine. Taken together the chronic effects of 
SSRI on reproduction of fish and invertebrates are not yet clear, interference with reproduction 
occurred at much higher concentrations than measured in surface waters.  
 
Chronic data on various other compounds are lacking, although they have been shown to occur 
in considerable amounts in surface waters (Figure 2). This holds in particular for fish. For the 
anticancer compound, tamoxifen, chronic data are found for Acartia tonsa [EC50=49 µg/L, 
(Andersen et al. 2001)]. Various morphological and developmental effects (early embryonic 
mortality) were induced in sea urchin embryos after exposure to 10-8 to 10-5 M tamoxifen, which 
corresponded to oxidative stress. ROS production was increased and lead to oxidative damage 
and  it is thought to represent a pro-oxidant mode of action explaining carcinogenicity in humans 
and rodents (Pagano et al. 2001).   
 
The antiandrogenic compound flutamide and aromatase inhibitor fadrazole were also analysed 
for effects in fish, mainly as a positive controls for the evaluation of effects suspected for other 
environmental chemicals. Short-term reproduction assays in fathead minnows show that 
flutamide at 0.9 mg/L significantly reduced male sex characteristics in male fish. Fadrozole 
significantly inhibited ovarian growth and induced testis growth at 0.05 and 0.96 mg/L after 21 
days, and inhibited VTG in females and induced VTG synthesis in males (Panter et al. 2004).   
Flutamide at 0.5 mg/L also reduced fecundity of the fish after 21 days. Embryo hatch was 
reduced and alterations in godadal histology were observed (Jensen et al. 2004). Ovaries from 
females indicated a decrease in mature oocytes and males exhibited spermatocyte 
degeneration and necrosis. Concentration-dependent VTG and testosterone increase were 
observed in females. Flutamide had an antiandrogenic effect and reduced fecundity, yet at 
rather high concentrations. Moreover, in adult male guppy, reduction in ejaculated sperms, 
reduced sex coloration and smaller testes occurred. The male courtship behaviour was also 
disrupted at 1 and 10 mg/kg in feed (Baatrup and Junge 2001). The aromatase inhibitor 
fadrozole reduced fecundity after 21 days at water concentrations of 10 and 50 µg/L and 
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inhibited brain aromatase activity (Ankley et al. 2002).  In females a concentration dependent 
reduction in plasma estradiol and VTG was observed. In males, androgens in plasma were 
significantly increased and resulted in a marked accumulation of sperm in the testes.  
 
 
In vitro studies 
Several pharmaceuticals have been investigated in in vitro systems. They were mainly analyzed 
for acute cytotoxicity in fish cell lines and in primary fish cell cultures. Cytotoxicity of clofibrate, 
fenofibrate, carbamazepine, fluoxetine, diclofenac, and propranolol to the fish cell line PLHC-1 
(hepatoma cells derived from topminnow) and primary cultures of trout hepatocytes was 
reported (Laville et al. 2004). Fibrates are known to enhance β-oxidation of lipids, which 
increases the amount of reactive oxidative species (ROS) in cells. Fenofibrate [EC50 (24 h) = 
3.25 mg/L] and clofibrate [EC50 (24 h) = 0.46 mg/L] were the most active compounds (Laville et 
al. 2004). Cytotoxicity was higher in PLHC-1 than in primary hepatocytes. Oxidative stress is 
thought to be responsible for the cytotoxicity, at least for these fibrates (Laville et al. 2004). 
Cytotoxicity of fluoxetine [EC50 (24 h, PLHC-1) = 1.73 mg/L] was also mediated in part by 
oxidative stress. Besides cytotoxicity and ROS production, the pharmaceuticals were analyzed 
for their potential to induce cytochrome P4501A monooxygenase activity (CYP1A), which can 
be regarded as important for chronic toxicity. Among the tested drugs, the β-adrenergic receptor 
antagonist propranolol was the only CYP1A inducer in primary hepatocytes, the other 6 
pharmaceuticals lead to inhibition of basal activity (Laville et al. 2004). 
 
Furthermore, Henschel et al. (1997) evaluated the cytotoxicity of salicylic acid, paracetamol, 
clofibrinic acid and methotrexate to BF-2 fish cell line (fibroblasts derived from bluegill sunfish). 
For three out of four compounds the concentrations inducing in vitro cytotoxicity were lower as 
compared to in vivo studies with highly proliferating ciliates. The particular mode of action of 
methotrexate [EC50 (48 h) = 3 mg/L, (Henschel et al. 1997)] may negatively interact with cell 
proliferation and therefore survival. Sensitivity of cells to toxicants may vary within species, as 
demonstrated by a direct comparison between cytotoxicity on fish and rat cell lines (Rau et al. 
2004), or depending on their origin, e.g. PLHC-1 cell lines are more sensitive than trout primary 
hepatocytes (Laville et al. 2004). Some of the differences may be based on the difference in the 
ability of the cells to metabolize toxicants. These in vitro studies indicate their usefulness for the 
acute toxicity evaluation, but also for investigations of the modes of action of pharmaceuticals 
including chronic toxicity parameters. Among the advantages of in vitro systems based on fish 
cells or reporter gene systems are their potential for screening and first evaluation of potential 
toxicity (Fent 2001). They are important alternatives to animal testing able to identify general 
toxicity and specific cellular targets and processes, and they are economic. 
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Toxicity of pharmaceutical mixtures and community effects 
There are only a few studies dealing with the effects of mixtures of pharmaceuticals. Cleuvers 
(2003, 2004) has evaluated the ecological potential of antiinflammatory drugs and of diverse 
acting pharmaceuticals in different sets of biotests using different aquatic organisms. A mixture 
of NSAID (diclofenac, ibuprofen, naproxen, acetylsalicylic acid) has been evaluated using acute 
Daphnia and algal tests. Toxicity of the mixture was found at concentrations at which the single 
compound showed no or only little effects. The mixture toxicity followed the concept of 
concentration addition, which means that the concentrations of each compound behaved in an 
additive fashion.  
 
Acute toxicity tests using D. magna, alga (Desmodesmus subspicatus) and macrophyte (Lemna 
minor) were performed to analyze for acute toxicity of 9 drugs having different modes of action 
(clofibric acid, carbamazepine, ibuprofen, propranolol, metoprolol, diclofenac, naproxen, 
captopril, metformin). The combined effects of two substances, clofibric acid and 
carbamazepine, followed the concept of concentration addition in the Daphnia test, whereas in 
the algal tests, the concept of independent action was adequate. When a combination of 
NSAID, ibuprofen and diclofenac, was analyzed, the effect on algae followed the concentration 
addition concept, whereas for Daphnia, the combination effect was stronger. These data 
indicate that for the acute toxicity of these pharmaceuticals, concentration addition can be 
assumed, which means that the concentration of each individual pharmaceutical has to be 
added for the combination effects. This implies that compounds occurring at concentrations 
below their individual NOEC can nevertheless contribute to the total effect of the mixture. 
 
Only few pharmaceuticals have been analysed in ecologically more realistic model ecosystems, 
namely, microcosms and mesocosms. In two recent studies, outdoor aquatic microcosms of a 
total volume of 12’000 L containing water and sediment were used to analyze the effects of 
combination of pharmaceuticals. (Sanderson et al. 2004) evaluated the effects of combinations 
of 8 pharmaceuticals at 3 concentration levels on macrophytes Lemnea gibba and Myriophyllum 
sibiricum over a 35 days period. Atorvastatin, a blood lipid regulator, was among antibiotics the 
pharmaceutical eliciting phytotoxicity. Using similar microcosms effects on phyto- and 
zooplankton were assessed after exposure for 35 days at 3 concentrations to two 
pharmaceuticals (ibuprofen, fluoxetine) and an antibiotic (ciprofloxacin) (Brooks et al. 2003). 
The microcosms contained periphyton, phytoplankton, zooplankton, algae and benthic 
communities, and in addition, juvenile sunfish were exposed in mesh cages. Species 
abundance and number of phytoplankton and zooplankton were affected at the medium (60-100 
µg/L each compound), and high treatment level (600-1000 µg/L each), whereas at the low 
treatment (6-10 µg/L each), only trends were visible, but no significant effects occurred. 
Unexpected high lethality occurred in fish at the high and medium treatments, lethality was 
observed in plants in addition to decreased growth. Decreased diversity of both phytoplankton 
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and zooplankton communities and increased abundance of both communities may have 
important ecological implications. However, the cause of the decline in diversity and the other 
effects was unclear (whether caused directly or indirectly and by what pharmaceutical having 
different modes of action). Maximal concentrations of ibuprofen, fluoxetine and ciprofloxacin 
detected in the U.S. were 1.0, 0.012 and 0.03 µg/L, respectively (Kolpin et al. 2002). Richards et 
al. (2004) concluded that a low probability exists that these three pharmaceuticals are currently 
present in surface waters at concentrations negatively affecting aquatic communities. By 
comparing calculated whole-body therapeutic doses – and not human and fish plasma levels - 
the authors note that all responses occurred at levels well below the equivalent 
pharmacologically active concentrations in mammals. Concentrations of pharmaceuticals in fish 
can reach significantly higher concentrations in plasma than in the ambient water (Mimeault et 
al. 2005).  
 
 
Comparison of environmental concentrations and ecotoxicolo-
gical effects concentrations 
The potential risk of a substance to the environment is often characterized by comparing the 
Predicted Environmental Concentration (PEC) with the Predicted No Effect Concentration 
(PNEC). PEC of pharmaceuticals are often estimated using calculations, which include usage or 
Figure 5: Comparison between maximal concentrations of pharmaceuticals in treated wastewater and 
their chronic toxicity in aquatic organisms. (a) Lowest observed effect concentrations (LOEC). (b) No 
observed effect concentrations (NOEC) for different aquatic organism, different endpoints and exposure 
times. References see Figure 1 (wastewater concentrations) and Figure 4 (chronic toxicity). 
a b 
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sales figures, population density, wastewater production and dilution in watersheds to generate 
likely concentrations in surface waters (Bound and Voulvoulis 2004; Halling-Sorensen et al. 
1998; Jones et al. 2002; Sanderson et al. 2004; Straub 2002). Due to the lack of experimental 
data (in particular chronic) in the public domain on the ecotoxicity of pharmaceuticals, 
estimation of PNEC, and therefore hazard and risk assessment, is difficult or even impossible to 
perform. In the open literature or databases, for less than 1% of pharmaceuticals data are 
available, and only a small number of new pharmaceuticals have been undergone risk 
assessment using ecotoxicological tests (Halling-Sorensen et al. 1998; Jones et al. 2002; 
Sanderson et al. 2004) In the absence of experimental data, information is often derived from 
Quantitative Structure-Activity Relationships (QSAR) predictions, for example by applying the 
EPA’s ECOSAR program (Jones et al. 2002; Sanderson et al. 2004). While being a pragmatic 
approach for identifying hazards or prioritizing critical substances, this concept is not sufficiently 
precise for accurate hazard and risk assessments of pharmaceuticals.  
 
Here, we summarize and compare the currently available empirical data in the open literature 
on maximal STP effluent concentrations with chronic LOEC and NOEC concentrations of 
individual pharmaceuticals (Figure 5). This approach is based on experimental data allowing to 
prioritize pharmaceuticals according to their ecotoxicological potential and to gain knowledge 
about the worst case situation. As can be deduced from Figure 5, LOEC and NOEC values of 
the pharmaceuticals for different aquatic organisms are about one to two orders and two orders 
of magnitude, respectively, higher than maximal concentrations in STP effluents. For diclofenac, 
the LOEC for fish toxicity was in the range of wastewater concentrations, whereas the LOEC of 
propranolol and fluoxetine for zooplankton and benthic organisms were near to maximal 
measured STP effluent concentrations. This shows that for diclofenac, propranolol and 
fluoxetine the margin of safety is narrow, and chronic effects at highly contaminated sites can 
not be completely ruled out, in particular, when the combined effects of pharmaceutical mixtures 
are taken into account. However, median sewage effluent concentrations are lower and dilution 
in receiving waters result in lower levels in surface waters reducing the environmental risk. It 
should be noted, however, that more experimental data on chronic toxicity and on the 
bioaccumulation potential is needed to fully judge the environmental risk posed by individual 
pharmaceuticals.  
 
 
Discussion 
Pharmaceuticals have been tested in traditional ways. A set of mainly acute toxicity tests using 
traditional species such as an algae (mainly Scenedesmus quadricauda), zooplankton (Daphnia 
magna) and fish (species according to OECD guidelines) has been performed. In general, only 
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very few pharmaceuticals have been assessed for acute and chronic toxicity in fish. Moreover, 
only a few pharmaceuticals have been analyzed for chronic toxicity, again in the traditional way 
according to guidelines (OECD, US EPA). Based on these studies, no one would probably have 
been able to anticipate the current population decline of three species of vultures due to 
diclofenac exposure. Furthermore, these tests alone are not sufficient for deriving an accurate 
profile of the possible hazards and risks of the pharmaceutical in question. Current tests cover 
only a small set of laboratory organisms, which are often not sensitive enough and often not 
able to unravel adverse effects of pharmaceuticals. As a consequence, more specific tests are 
needed. Only chronic toxicity investigations using more specific toxicity parameters will lead to a 
more meaningful ecological risk assessment. The following working hypotheses should be 
addressed in future ecotoxicological investigations: 
 
1. Pharmaceuticals as biologically active compounds may have similar (chronic) effects in 
non-mammalian animals (and even plants) as in mammals as target receptors and/or 
biomolecules are similar and conserved during evolution. Therefore, similar adverse 
(chronic) effects as in humans and mammals may occur in lower vertebrates and 
invertebrates. 
2. Some pharmaceuticals may have unexpected (chronic) effects in lower organisms due to 
biological differences in pharmacodynamics, pharmacokinetics and physiology. 
3. In vitro studies of pharmaceuticals are important for screening, elucidating the modes of 
action in non-target organisms, and designing specific in vivo studies.  
 
One approach to address these hypotheses is to include histopathological investigations in 
chronic fish toxicity studies. By focusing on specific tissues and organs, more detailed answers 
about possible adverse effects may be obtained. This is exemplified by a study on chronic 
effects of diclofenac in fish (Schwaiger et al. 2004; Triebskorn et al. 2004). Another approach is 
to use the existing knowledge about possible side effects of the compound of interest in 
mammals and humans for the design of specific analysis in aquatic organisms. Furthermore, 
known drug-drug interactions in humans may be relevant for compound mixtures in the 
environment. Both are based on the hypothesis that targets of the pharmaceutical may be 
identical or similar in lower organisms as receptors, biochemical pathways and enzymes are 
conserved in evolutionary terms. This holds true for nuclear steroid receptors that are very 
similar in organisms of different evolutionary levels (Sanderson et al. 2004), nuclear 
peroxisome-proliferator activated receptors (PPAR’s) (Escriva et al. 1997), adrenoceptors such 
as β1- and β2-receptors (Nickerson et al. 2001), but also for insulin receptor, insulin-like growth 
factor and glucagon receptors being present in lower vertebrates and invertebrates (Villegas-
Navarro et al. 2003). Also, basic mechanisms like signal transduction, cell division, and key 
metabolizing enzymes such as cytochrome P450s are conserved in a large variety of organisms 
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(Nelson et al. 1996). As a consequence, analysis of pharmaceuticals should specifically be 
directed to  
• specific and identical targets (biomolecules, tissues, organs): target specificity  
• known adverse side effects in humans and mammals: side effect specificity 
• general chronic effects for accounting physiological differences: species specificity 
 
Our proposed strategy for future research on the ecotoxicology of pharmaceuticals is 
exemplified by a few examples. When the ecotoxicity of NSAID is studied, effects on inhibition 
of prostaglandin synthesis and COX inhibition should be addressed in lower organisms, and at 
the same time, on side effects already known in mammals. Diclofenac has been known for 
causing side effects on the kidney (and other organs such as liver) in mammals, subsequently 
being found in vultures (Oaks et al. 2004), and fish (Schwaiger et al. 2004). Cardiovascular 
pharmaceuticals should be analyzed for their possible effects on the cardiovascular system in 
lower vertebrates. Lipid lowering agents such as fibrates are also known to act by enhancing or 
reducing PPAR (Kliewer et al. 1997). These nuclear receptors play key roles in the catabolism 
and storage of fatty acids and are important for blood lipid regulation. Indeed, PPAR’s are 
affected in amphibians (Kliewer et al. 1997) and fish by clofibrate, benzafibrate and fenofibrate 
(Ruyter et al. 1997).  
 
Beta-blockers bind to the beta-adrenergic receptors and block its activation by physiological 
agonists. These receptors are located in mammals in many tissues including heart, and its 
blockade causes a decrease in heart rate and contraction. Beta-blockers differ in specificity to 
the different receptor subtypes, some are non-specifically acting on β1- and β2- receptors (e.g. 
propranolol), while others are specific for the β1-receptor subtype (e.g. atenolol). In D. magna, 
heart beat rate, fecundity and biomass were reduced after chronic exposure to 0.11 mg/L 
(Dzialowski et al. 2003), although it is not know whether β2-receptors occur. Long-term 
exposure to propranolol reduced reproduction in C. dubia at 250 µg/L and in H. azteca at 
100 µg/L (Hutchinson et al. 2003). 
 
A class of anti-hyperlipidemic drugs inhibit their target enzyme hydroxymethylglutaryl-CoA 
reductase (HMG-CoA reductase) in mammals (Seiler 2002). Whether these enzymes are also 
inhibited in lower animals should be addressed in future investigations. Surprisingly, atorvastatin 
was even found in a plant (duckweed, Lemna gibba) to have effects, but the mode of action is 
unclear (Sanderson et al. 2004). 
 
Many antineoplastic drugs used in cancer therapy have a high mutagenic and cancerogenic 
potential. Parent compounds are often bioactivated leading to formation of mutagenic 
metabolites (e.g. cyclophosphamide, ifosfamide). In case organisms in the environment are able 
to metabolize these pharmaceuticals, enhanced mutation frequencies and cancer risk will result. 
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In addition, these drugs often have significant side effects on humans such as nausea, 
cytotoxicity, reduction in proliferation of cells in various tissues etc. One would expect 
mutagenicity and cancerogenicity to occur in exposed aquatic organisms as well. However, 
such studies are lacking besides the analysis of hospital wastewater, in which the genotoxic 
potential was based on antibiotics such as ciprofloxacin (Hutchinson et al. 2003).  
 
It should be noted, however, that besides known targets additional or other target tissues and 
organs may be affected alternatively.  This would result in unexpected effects not targeted by 
the investigations. Examples are effects on sex hormones in blood plasma of fish and reduced 
reproduction in C. dubia and H. azteca induced by the beta-blocker propranolol after long-term 
exposure  (Hutchinson et al. 2003), and the effects of serotonin-reuptake inhibitors on 
reproduction of mollusks (Chong et al. 2000). As the effects of the antiestrogen tamoxifen 
indicate, pharmaceuticals may have not only one, but multiple modes of action, such as 
oxidative damage in addition in case of tamoxifen (Pagano et al. 2001). This fact complicates 
the strategy to analyze for chronic effects. However, many of these unexpected chronic 
responses will be elucidated in the context of careful chronic toxicity analyses including 
histopathology and reproduction. However, such analyses are more expensive and probably 
only justified for important pharmaceuticals occurring in significant concentrations in the 
environment. But in the light of the limitations of traditional (acute) toxicity testing for use in 
environmental risk assessment, more specific toxicity analyses should be performed in 
forthcoming studies, taking full advantage of the available knowledge that is generated during 
the pharmaceutical drug development process (e.g. mechanisms of action, pharmacokinetic 
behaviour and metabolism, target organs and side effects in mammals).  
 
In vitro studies are important for screening and evaluation of possible cellular targets in 
ecotoxicology (Fent 2001). They are also important in the reduction of animal experiments, in 
conjunction with other proposed new strategies (Hutchinson et al. 2003). Effects of 
pharmaceuticals have been evaluated in fish primary cells and fish cell lines indicating this 
potential (Laville et al. 2004). We assume that investigating pharmaceuticals in in vitro systems 
will not only allow a reduction of animal experiments, but also a better and more accurate 
characterization of possible targets of pharmaceuticals. These test systems not only allow the 
analysis of specific receptor interactions and target enzymes in animal and plant cells, but also 
a rapid screening of a large number of compounds.    
 
Pharmaceuticals are analyzed for possible ecotoxicological effects as single compounds and 
only rarely as mixtures (Cleuvers 2003). However, as other environmental pollutants 
pharmaceuticals are present in the environment in mixtures. Effects of mixtures most probably 
follow the concept of concentration addition, hence, the overall toxicity is the result of the sum of 
the individual concentration of each compound. Therefore effects may occur even at the NOEC 
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of individual compounds. It should also be recognized that even subtle changes of normal 
homeostasis including behavioral alterations may have direct and indirect effects, even if only 
minor ones, that eventually result in significant deteriorating effects on a species or population 
in the ecological context. The extreme case of the dramatic poisoning and population declines 
of Indian vultures is a case in point. The dimension of this population decline has no parallel in 
birds since the disappearance of peregrine falcons and other predatory birds in the 1960s due 
to the pesticide DDT. 
 
 
Conclusions and future directions 
One important aspect to solve the load of pharmaceutical residues in wastewater and surface 
water is to optimize STP processes. There is a need to increase the knowledge about the fate 
of pharmaceuticals during sewage treatment for implementation of better removal techniques. 
Future work on STP treatment optimization will show to what extend pharmaceuticals can be 
removed from wastewater and to what extent the implementation of an improved technology is 
feasible, taking into account other macro- and micro-pollutants as well as the broad variety of 
complex wastewater matrices. 
 
Our present knowledge about residues of pharmaceuticals in aquatic systems indicate that they 
are unlikely to pose a risk for acute toxicity. Environmental concentrations are in the range of 
103- 107-times lower than known LC50 or EC50 values (ratio of 103 between lowest acute effect of 
fluoxetine and highest environmental concentration; difference of 107 between highest LC50 of 
diazepam and highest environmental concentration). However, as the collapse of vulture 
populations in the Indian subcontinent indicates, important adverse effects can occur under 
certain circumstances. 
 
There is a general lack of chronic toxicity data on pharmaceuticals, in particular in fish. Many 
pharmaceuticals need more investigation about potential long-term ecotoxicological effects, 
particularly with respect to potential disturbances in hormonal homeostasis (endocrine 
disruption), immunological status, or gene activation and silencing during long-term exposure. 
For better understanding of possible effects, a mechanism-based approach focused on target 
molecules, tissues and organs should yield more meaningful results and insights than traditional 
acute toxicity testing. Current data on acute and chronic toxicity of pharmaceuticals support to 
the conclusion that more target- or biomolecule-oriented, or mode-of-action-based 
investigations, will allow more relevant insights into effects on survival, growth and reproduction 
than traditional standard ecotoxicity testing. Often, similar target biomolecules are present in 
non-mammalian organisms and so are the adverse effects. In vitro systems are very important 
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tools for both elucidating modes of action in lower vertebrates, and for screening of the 
ecotoxicological potential of pharmaceuticals prior to fish toxicity testing. Unless more is known 
about possible chronic effects of individual pharmaceuticals and mixtures thereof, conclusions 
concerning hazards or risks of pharmaceuticals to the aquatic ecosystem are premature. 
 
Drugs may also induce unexpected effects in non-mammalian organisms, however. This is 
based on the difference in pharmacokinetics and pharmacodynamics, important parameters for 
occurring species differences. Disturbances of the reproductive system and hormone system, 
immune depression, neurobehavioral changes, to name some key targets, may have far 
reaching effects on the population level. This has become evident for endocrine disrupters such 
as steroid hormones used in contraceptives resulting in important adverse effects at 
environmentally relevant concentrations (Jobling et al. 1998; Länge et al. 2001; Parrott and 
Blunt 2005; Thorpe et al. 2003).  
  
Comparison of available chronic toxicity data with environmental concentrations indicate that for 
most investigated pharmaceuticals concentrations are too low in aquatic systems to induce 
chronic effects on traditional laboratory organisms such as inhibition of algal growth and 
reproduction in Daphnia. For diclofenac, the LOEC for fish toxicity on an organ level was in the 
range of wastewater concentrations, however (Schwaiger et al. 2004), whereas the LOEC of 
propranolol and fluoxetine for zooplankton and benthic organisms were near to maximal 
measured STP effluent concentrations. Whether or not the margin of safety is narrow for 
additional human pharmaceuticals should be investigated in future studies. The future 
requirement of chronic testing with algae, daphnids and fish instead of only traditional acute 
toxicity studies is an important step forward (EMEA 2005). Moreover, the potential of combined 
effects of pharmaceutical mixtures should be addressed. In the ecological context, subtle 
changes and disturbances may have negative consequences for the organism’s fitness. As a 
consequence much more should be known about the potential for chronic effects of 
pharmaceuticals in the aquatic system.  
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Abstract 
Pharmaceuticals enter aquatic environments in unchanged form or as metabolites. 
Little is known about their potential hormonal activity, which is of particular interest due 
to potential long-term effects on fertility and reproduction in aquatic organisms. 
Moreover, there is a need to assess the combined activity of pharmaceutical mixtures. 
In this study, 37 pharmaceuticals have been analysed in vitro for estrogenic activity 
using a recombinant yeast system expressing the human estrogen receptor α. Six 
pharmaceuticals belonging to different therapeutic classes, cimetidine, fenofibrate, 
furosemide, paracetamol, phenazone and tamoxifen, exhibited weak estrogenic 
activity. Furosemide showed an almost full concentration-response curve, whereas the 
other compounds showed low efficacy. The half-maximal activities of the 
pharmaceuticals were in the range of 0.66-25.53 mM. Furthermore, binary mixtures of 
furosemide and 17β-estradiol (E2), and furosemide and phenazone, and mixtures of up 
to five active pharmaceuticals were assessed for their combinatory activity at different 
equipotent concentrations. The estrogenic activity of binary mixtures of furosemide with 
E2 and phenazone, respectively, followed the model of concentration addition (CA). 
Mixtures of other pharmaceuticals often deviated from the CA model, because 
extrapolations become inaccurate with only partial and non-parallel concentration-
response curves having low efficacy. This demonstrates that full and parallel 
concentration-response curves are a prerequisite for accurate predictions of mixture 
activity. Our study demonstrates for the first time weak estrogenic activity in vitro of 
some common pharmaceuticals and their mixtures.  
 
Key words: Pharmaceuticals; Estrogenic activity; Mixture activity; Ecotoxicological 
effects; Environmental toxicology; Endocrine disrupters 
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Introduction 
Pharmaceuticals are becoming increasingly important as potential environmental 
contaminants due to their widespread presence in aquatic ecosystems. Being designed 
for human or veterinary medicine, they may be of concern because of potential adverse 
effects on organisms in the environment. Pharmaceuticals have a specific mode of 
action that makes them effective in the therapeutic use at relatively low concentrations. 
Even though aquatic organisms lack some of the target receptors for pharmaceuticals, 
adverse effects can still occur via unspecific action (Fent et al. 2006). Currently, only 
very little information is available on acute and chronic effects despite aquatic 
organisms may be exposed to pharmaceuticals during their whole life span. As the 
ecotoxicological potential of pharmaceutical residues remains almost unknown 
(Daughton and Ternes 1999; Fent et al. 2006; Laville et al. 2004), it is necessary to 
evaluate the potential ecological risks of pharmaceutical residues in particular with 
respect to their hormonal activity, which may have consequences on the population 
level.  
The exposure of aquatic organisms to pharmaceuticals and their metabolites may be 
significant in view of the often considerable levels occurring in treated effluents of 
sewage treatment plants (STPs), contaminated waters (Fent et al. 2006; Halling-
Sorensen et al. 1998; Kolpin et al. 2002; Kümmerer 2004; Ternes et al. 2004) and 
landfill leachates (Fent 2004). Widely used pharmaceuticals are found in the ng/L to 
μg/L range in municipal wastewaters (Fent et al. 2006; Kümmerer 2004; Ternes et al. 
2004), which also holds for certain antibiotics (Hartmann et al. 1998; Heberer 2002; 
Kümmerer 2003). Pharmaceutical residues constitute a chronic exposure of wildlife at 
discharge sites (Ashton et al. 2004).  
Even in concentrations near the detection limit natural and synthetic sex hormones can 
cause adverse effects. At environmentally relevant concentrations 17β-estradiol (E2) 
and the synthetic 17α-ethinylestradiol (EE2) leads in fish to induction of the yolk 
precursor vitellogenin, effects on gonadal histology, reduction of fecundity and 
reproductive success (Cromlish and Kennedy 1996; Sumpter and Johnson 2005). The 
in vivo potency of EE2 is 10 to 50-fold higher than that of E2 (Cromlish and Kennedy 
1996; Thorpe et al. 2003), probably due to lower metabolism. Already 0.1 ng/L EE2 
induces the expression of vitellogenin in fish (Purdom et al. 1994), 0.1-15 ng/L can 
affect sex differentiation (Van Aerle et al. 2002), and 2-10 ng/L may affect fecundity 
negatively (Sacher et al. 2001). Life-long exposure to 5 ng/L leads to significant 
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reduction in fecundity in the F1 generation and complete population failure due to lack 
of fertilization (Nash et al. 2004). Thus, given its concentration in the environment 
frequently being between 0.5 and 7 ng/L, EE2 may be a significant contributor to 
reproductive dysfunction in wild fish. Besides sex hormones, a rising number of natural 
and man-made substances are able to disturb the endocrine and reproductive system 
of organisms by mimicking hormone action (Damstra et al. 2002) due to their binding to 
the estrogen receptors (Rajapakse et al. 2004). Among them are widely used 
compounds such as UV-filters (Kunz et al. 2004), bisphenol A (Vom Saal and Hughes 
2005) or phthalates (Swan et al. 2005) to mention a few. So far, pharmaceuticals have 
not been reported to have hormonal effects. 
Current methods of risk assessment usually focus on the assessment of single 
chemicals. This is in contrast to the exposure situation in aquatic ecosystems, where 
organisms are typically exposed to a variety of estrogenic compounds. Alone, these 
concentrations are rather unlikely to cause estrogenic effects with the exception of EE2 
and E2 (Sumpter and Johnson 2005). However, when acting together they can pose a 
hazard, which may be underestimated by focusing on individual compounds alone. It is 
difficult to assess the effects of a complex mixture of estrogenic substances 
(Kortenkamp and Altenburger 1998; Rajapakse et al. 2002; Rajapakse et al. 2004; 
Stumpf et al. 1999). Effects of mixtures cannot be calculated by simply adding the 
effects of the mixture components when applied alone, especially if the components 
have differently shaped dose-response curves (Payne et al. 2000). Two competing 
models are found widely spread in literature: the concept of concentration addition (CA) 
and the concept of independent action (IA) (Kortenkamp and Altenburger 1998). The 
CA concept is based on the assumption that the substances in a mixture have the 
same mode of action. Thus, one compound in a mixture can be replaced by another 
compound in a concentration that provokes the same respective effect. The effect of 
the mixture is therefore an addition of the effects of the single compounds in proportion 
to their relative fraction in the mixture. The IA model in contrast is applied when 
substances are involved that have a different mode of action. The effect of one 
compound is independent of the others. IA can therefore not be used, when the 
substances bind to the same receptor (Backhaus et al. 2004). By using a recombinant 
yeast system, mixtures of estrogenic compounds were shown to interact in vitro 
according to the CA model (Kortenkamp and Altenburger 1998; Rajapakse et al. 2002). 
The components in the mixture contribute to the overall effect by acting in relation to 
their potency, even at low-effect concentration below the threshold of detectable effects 
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(Stumpf et al. 1999). By using vitellogenin induction, the validity of the CA concept has 
also been demonstrated for mixture effects in vivo in fish (Cromlish and Kennedy 
1996). The estrogenic chemicals had the capacity to act together in an additive 
manner. Thus far, only very few estrogenic chemicals have been analysed for mixture 
activity, and none of the pharmaceuticals besides EE2.  
The compounds investigated in this study come from various therapeutic classes and 
have been chosen on the basis of its widespread use and potential hormonal activity. 
Nine pharmaceuticals can be assigned to the class of non-steroidal anti-inflammatory 
(NSAID)/analgesic/antiphlogistic drugs. Acetylsalicylic acid, ibuprofen, paracetamol, 
naproxen, and diclofenac are very often detected in sewage effluents and surface 
waters up to μg/L (Daughton and Ternes 1999; Fent et al. 2006). Rofecoxib is the 
active ingredient of Vioxx®, an anti-inflammatory agent. Five beta-blockers are 
considered as some of them were determined in wastewater (Fent et al. 2006). 
Antidepressants (fluoxetine, diazepam) and the antiepileptic carbamazepine, which is 
often found in wastewaters in concentrations of up to 2 μg/L (Gagne et al. 2005) are 
also considered. The blood-lipid lowering agents analysed in our study include seven 
statins and fibrates. Fenofibrate and clofibrate are widely used (Laville et al. 2004). 
Clofibric acid is the active metabolite formed via hydrolysis in organisms and the 
aquatic environment (Daughton and Ternes 1999). Gemfibrozil has been shown to 
have a potential for endocrine disruption in an in vivo study in goldfish (Mimeault et al. 
2005). Two diuretics (furosemide and hydrochlorothiazide) have been analysed as well 
as the anti-estrogens tamoxifen and OH-tamoxifen. Sildenafil is the active ingredient of 
Viagra® and was considered because of its increasing use. In addition, adrenaline ((±)-
epinephrine and (-)-epinephrine) have been analysed, and caffeine because of its 
ubiquity in the aquatic environment.  
The aim of our study was to analyse a series of pharmaceuticals for their estrogenic 
activity employing a widely used yeast reporter gene system (Routledge and Sumpter 
1996). To our knowledge, hormonal activity of pharmaceuticals occurring in the aquatic 
environment has not yet been reported. Generally, the potential estrogenic activity of 
pharmaceuticals remains elusive. As these substances are present in the environment 
as mixtures and at very low concentrations, the analysis of mixture effects is of 
particular interest. Our investigation demonstrates the estrogenic activity of five 
commonly used pharmaceuticals and the combined effect in mixtures. These in vitro 
data point to a further assessment of potential hormonal activity of pharmaceuticals in 
the environment. 
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Materials and Methods 
Chemicals. The substances analysed in this study are listed in Table 1. A few 
pharmaceuticals were obtained as a gift; atorvastatin, diclofenac, metoprolol, 
simvastatin, carbamazepine, fluoxetine and atenolol were from Novartis International 
AG (Basel, CH), bezafibrate and diazepam were from F. Hoffmann-La Roche Ltd 
(Basel, CH). Doxorubicin, rofecoxib, sildenafil base were from Sequoia Research 
Products (UK) and pravastatin from ChemPacific (USA). The remaining 
pharmaceuticals and the solvent dimethylsulfoxide (DMSO) were all purchased from 
Sigma AG (Buchs, CH). Chlorophenol red-β-D-galactopyranoside (CPRG) was 
obtained from Roche (Basel, CH). Ethanol and methanol for glassware cleaning were 
obtained from J.T. Baker (The Netherlands). Stock solutions of pharmaceuticals in 
DMSO were prepared at standard concentrations of 500 mM. Where insoluble, stock 
solutions were diluted until the substance was dissolved.  
 
Handling of recombinant yeast cells and YES-assay. Glassware was rigorously 
cleaned prior to use by washing twice with ethanol or once with methanol and once 
with ethanol. All work was carried out in a type II laminar flow cabinet. Glassware, test 
solutions, and assay medium were autoclaved after use for biosafety reasons. 
Recombinant yeast cells containing the human estrogen receptor (hERα) stably 
integrated into their main chromosome and expression plasmids carrying the reporter 
gene lac-Z were a gift from J. P. Sumpter, Brunel University, UK. Binding of an 
estrogen or xenoestrogen to the hERα in the yeast cell leads to the activation of the 
receptor controlling the expression of the reporter gene lac-Z. The enzyme β-
galactosidase, which is then produced, is secreted into the assay medium containing 
the yellow CPRG, which is thereby metabolized into a red product that can be 
measured spectrophotometrically at 540 nm. Yeast stocks were stored in cryogenic 
vials at -20°C and renewed after a maximum of 4 months.  
The YES-assay was carried out mainly as described by (Routledge and Sumpter 
1996). 125 μL of yeast stock were incubated with approximately 50 mL of growth 
medium overnight at 28°C and 110 rpm on an orbital shaker. Serial dilutions of 
pharmaceutical stock solutions were prepared in DMSO and 5 μL aliquots of these 
solutions were transferred to 96-well optically flat-bottom microtiter plates. Assay 
medium was prepared by adding 0.5 mL CPRG and approximately 2x106 yeast cells to 
50 mL fresh growth medium. 195 μL of assay medium was then added to each well on 
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the plates. Each plate contained a row of 2.5% DMSO as control and a positive control 
of E2 (2.5x10-6-1.22x10-9 mM) in triplicate used as a standard. Plates were then sealed 
with microtiter plate sealers, incubated at 30°C and shaken every day for 2 min at 
approximately 200 rpm on a microtiter plate shaker. After 72 h, the plates were read 
using a microtiter plate reader (GENios, TECAN, CH) at an absorbance of 540 nm to 
detect colour change of the assay medium, and at 620 nm to measure turbidity as an 
indicator of yeast growth. 
 
Data processing. Raw data were corrected for the DMSO controls and turbidity:  
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Blank
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−−=
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Some of the tested pharmaceuticals showed toxicity in the highest test concentrations 
and lead to cell lysis. As yeast growth in the wells is accompanied by turbidity, clear 
wells indicate a toxic pharmaceutical concentration. Corrected absorbance values from 
the plate reader are negative for wells containing toxic concentrations of test 
substances.  
Screens for estrogenic activity of single substances were carried out twice using two 
replicates each. Substances showing no colour change in the assay medium were then 
Table 1: Pharmaceuticals analysed 
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tested in quadruplicate, and the experiments were repeated twice. Pharmaceuticals 
showing induction were analysed in quadruplicates as well and experiments were 
repeated at least three times in order to get reliable concentration-response curves for 
mixture calculations.  
Concentration-response curves for all substances were calculated using a non-linear 
regression (curve fit) model by GraphPad Prism® (GraphPad Software, San Diego, 
USA) software. The four-parameter logistic equation fit is expressed by the following 
equation:  
 
HillSlopeXLogEC
BottomTopBottomY )*( 50101
)(
−+
−+=       (2) 
 
where Y is the response (absorption), Top the maximum and Bottom the baseline 
response respectively, LogEC50 corresponds to the logarithm of the half-maximal effect 
concentration,  HillSlope quantifies the steepness of the curve and is also called the 
slope factor. 
 
Mixture experiments. We considered only pharmaceuticals for mixture experiments 
showing an induction of β-galactosidase expression. Compounds showing an anti-
estrogenic effect in addition to the estrogenic effect were not included in mixture 
experiments, because estimates of mixture effects were not possible. All mixture 
assays were carried out identically to the single compound assay. The compound 
mixtures were diluted and transferred in 5 μL aliquots to the microtiter plates.  
First, equipotent mixtures of E2 and furosemide were considered in various ratios. 
Subsequently, several equipotent mixtures of two to five active pharmaceuticals were 
carried out in different concentrations. In total 23 different mixture combinations were 
analysed. The concentrations of each compound in the mixtures were defined in 
Table 2: Cytotoxic concentrations of pharmaceuticals in the YES-assay. 
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relation to the normalized effects obtained by E2; 25% of the maximal induction by E2 
was labelled the C25 concentration, 20% of maximal induction, the C20 concentration 
etc. Equipotent mixtures of all respective compounds were analyzed up to a 
concentration of C10 for each compound. Higher concentrations were not analysed, as 
fenofibrate exhibiting the lowest estrogenic activity had an activity of 14% relative to 
E2.  
Concentrations causing a 10 % increase in β-galactosidase expression range from 
3.48 x 10-5 M (E2) up to 11.042 mM (paracetamol). The individual compounds were 
serially diluted in DMSO at a ratio of 1:1. For various pharmaceutical mixtures C10 and 
C01 concentrations were analysed. Furosemide and phenzone were mixed at C20 and 
C25, and four different binary mixture combinations at C01 and C10. Four mixture 
combinations each consisting of three pharmaceuticals were analysed at C10. A 
mixture of cimetidine, fenofibrate, furosemide and phenazone was analysed at C01 and 
C10, and a mixture consisting of these four compounds and phanazone at C01. 
Furthermore, a mixture of cimetidine, fenofibrate, furosemide and phenazone at the no 
observed effect concentration (NOEC) was analysed. The NOEC was estimated as the 
concentration of a compound where 0.1% of effect is reached (C0.1) via interpolation 
using the concentration-response curves (Table 3). The calculated concentration was 
divided by two, in order to achieve a C0.05 concentration, which is labelled as the 
NOEC.  
 
Calculations for mixture effect estimations. Because none of the active 
pharmaceuticals showed a maximal response as the standard E2, it was not possible 
to mix the compounds at equipotent concentrations according to their effect 
concentrations (EC). First, a standard curve for E2 was established with ECs 1 to 99. A 
non-linear regression analysis using the four-parameter logistic equation performed 
with GraphPad Prism® for each estrogenic single substance then provided the 
concentrations at which each substance caused the respective absorptions. Thus, 
equipotent mixture concentrations could be calculated using an EC for E2 and a 
respective C value producing the same effect for single substances even for mixtures 
containing only substances producing a submaximal response or substances with non-
parallel concentration-effect curves. 
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Two competing concepts frequently used for the prediction of mixture effects were 
taken into account: Concentration Addition (CA) and Independent Action (IA). CA is 
expressed by the following equation (Altenburger et al. 2000):  
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⎜⎜⎝
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Mix ECx
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        (3) 
 
where ECxMix stands for the concentration of the mixture causing the x% effect and pi is 
the fraction of the component i in the given mixture. The number of components n 
ranged from two to five in the conducted assays. ECxMix was calculated using CA 
equation in steps of 1 from 1 to the maximal C value that was reached by all the 
involved substances. Using the GraphPad Prism® software, the best-fit values for a 
sigmoidal dose-response curve with variable slope were calculated and the missing 
values for higher concentrations of the mixture were then extrapolated in order to get a 
full dose-response curve.  
The mathematical formulation for the other considered concept of mixture prediction, IA 
is as follows (Altenburger et al. 2000):  
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Here, E(cMix) stands for the predicted effect of the mixture, ci is the concentration of the 
ith compound and E(ci) is the effect of this concentration if the compound was applied 
separately. Again, the IA curve was calculated as high as practicable and then 
extrapolated using the sigmoidal dose-response (variable slope) curve as above.  
 
Statistics. A one-sample t-test was used to compare the mean of values derived from 
the mixture experiments to the estimated mean calculated using the CA or the IA 
concept, respectively.   
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Results 
Estrogenic activity of single compounds 
At high concentrations, cytotoxicity was indicated in yeast cells when corrected 
absorbance values were lower than zero. This occurred at high levels with 24 
pharmaceuticals (Table 2). In case cytotoxicity occurred, the stock solution of the 
pharmaceutical was diluted prior to preparation of the serial dilutions to a non-toxic 
concentration. Cytotoxicity below 0.01 mM was found for doxorubicin, fluoxetine, OH-
tamoxifen and tamoxifen. Stock solutions for these substances were therefore diluted 
in order to determine their estrogenic potential in intact yeast cells.  
Out of the 37 pharmaceuticals analysed, 31 showed no induction of β-galactosidase 
expression in the YES assay. Six pharmaceuticals including cimetidine, fenofibrate, 
furosemide, paracetamol, phenazone, and tamoxifen showed an induction of β-
galactosidase expression. The dose-response curves differed between 
pharmaceuticals. Near- maximal activity was observed with furosemide (Fig. 1). The 
metabolite OH-tamoxifen showed a different pattern to the other compounds with only 
very low induction (Fig. 1). The anti-estrogenic tamoxifen and its metabolite OH-
tamoxifen are known to show an induction in the YES, because of their antagonistic 
and partial agonistic interaction with the hERα. Both compounds were therefore 
excluded from mixture experiments. Best-fit values for the sigmoidal dose-response fit 
of the respective substances are given in Table 3. The individual substances do not all 
reach their maximal induction in the tested concentration range according to the TOP 
values given in Table 3. The TOP values for the substances showing an estrogenic 
activity are between 14% (fenofibrate) and 89% (furosemide) of the standard E2.  
Furosemide that showed the highest estrogenic activity was subject to a further 
analysis to test for binding to the hERα. A concentration of 3.13 mM of furosemide, that 
induced β-galactosidase activity to a level of 65% of the maximal E2-induction, was 
added to the assay medium. The anti-estrogen OH-tamoxifen was then serially diluted 
Table 3: Best-fit values for substances showing an induction of β-galactosidase expression in 
the YES-assay. 
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in the concentration range from 10 nM to 10 μM and transferred to the microtiter plates 
in 5 μL aliquots to block the estrogenic activity of furosemide. A blank row of assay 
medium containing furosemide, but no OH-tamoxifen describes the response obtained 
by furosemide alone. Figure 2 shows that the induction caused by furosemide 
decreases with increasing OH-tamoxifen concentration. Therefore, OH-tamoxifen 
competing for hERα-binding blocks the estrogenic activity of furosemide in 
concentrations from about 100 nM in a dose-dependent manner. This is evidence that 
furosemide actually binds to the hERα in the recombinant yeast for exhibiting β-
galactosidase induction.  
Pharmaceuticals showing an estrogenic activity were further analysed for anti-
estrogenic activity. The assay was carried out as for estrogenicity except for the assay 
medium containing a single concentration of 8.43x10-8 M of E2, which corresponds to 
the EC65 value producing a submaximal response. An antagonistic interaction with the 
hERα is indicated by a decreasing β-galactosidase production and demonstrates an 
anti-estrogenic effect. Microtiter plates in the anti-estrogen assay contained a row of 
blanks (2.5% DMSO control, the only wells without E2) used for the corrections of the 
readings, three rows of the anti-estrogen OH-tamoxifen used as standard, and the 
pharmaceutical to be analysed in quadruplicate. Anti-estrogenicity assays were 
repeated at least three times. Apart from the expected anti-estrogenic tamoxifen and 
Figure 1: Dose-response curves for the pharmaceuticals showing an induction of β-galactosi-
dase expression in the YES-assay. The E2 standard curve represents the mean of all standard 
curves obtained with all plates (n = 54). Mean values with SEM for single pharmaceuticals from 
at least three independent experiments (n=12), anti-estrogens tamoxifen (n = 16) and OH-
tamoxifen (n = 8). A sigmoidal dose-response curve could not be fitted for OH-tamoxifen using 
the four-parameter logistic equation in GraphPad Prism®. 
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OH-tamoxifen, none of the five estrogenic pharmaceuticals exhibited an anti-estrogenic 
activity (data not shown).  
 
Estrogenic activity of compound mixtures 
As the steepness of the dose-response curves, best-fit parameters and maximal 
activities are different between the individual substances, estrogenic activities of 
pharmaceutical mixtures are difficult to predict. Moreover, the estrogenic activity of the 
pharmaceuticals did not reach the maximal response of E2. An EC50 for the individual 
substances cannot be calculated, if the maximal response lines for two substances are 
not equal, as in the case of cimetidine, fenofibrate, paracetamol and phenazone. 
Therefore, the EC50 values do not provide a comparable measurement category, as 
the top values are not the same for all substances. Instead, a concentration value C 
was defined for every β-galactosidase inducing substance to calculate the required 
concentration for the various equipotent mixtures.  
Figure 3: EC50 E2+C50 furosemide mixture 
with predictions according to the concen-tration 
addition (CA) and the independent action (IA) 
concept. Error bars for the measured data are 
SEM (n = 12). 
Figure 2: Decreasing estrogenic activity of 
furosemide with increasing OH-tamoxifen 
(dotted line) concentrations (n = 9). Furos-
emide concentration in all wells 3.125 mM. 
Dotted horizontal line represents the expected 
absorption reached by furosemide if applied 
alone at the indicated concentrations. 
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Figure 4: Ratios between measured and ex-
pected (CA) absorption values for the highest 
analysed concentrations of various E2+furose-
mide mixtures. Stars indicate significant dif-
ferences between measured and observed 
values ± SEM. Averages of n = 11-12. 
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Furosemide is the only pharmaceutical exhibiting a parallel dose-response curve to E2, 
but the estrogenic activity did not reach maximal values. Combinations of E2 and 
furosemide were analysed in binary mixtures in various ratios. Figure 3 shows the 
activities for the equipotent mixture of E2 and furosemide at the concentration at which 
50% of the maximal effect for E2 is reached. The fitted curve for various concentrations 
of the mixture follows more closely the predicted CA curve than the predicted IA curve, 
which were calculated according to the formulas (3) and (4) (see Materials and 
Methods). As shown in figure 4, the measured mean for the highest concentration 
follows the prediction at the EC80+C20 and EC40+C60 mixture, but differs in the other 
mixture ratios. The statistics in Table 4 demonstrates that the CA model adequately 
predicts the values for the E2 and furosemide EC80+C20 and EC40+C60 mixture, but 
not for EC20+C80.  
Figure 5 shows the analysis of the mixture effects using the isobole method 
(Kortenkamp and Altenburger 1998). The line connecting the iso-effective dose for E2 
on the x- axis and furosemide on the y-axis predicts that the combination is additive 
according to the CA model. Concave down-isoboles for mixtures indicate that mixture 
yield the same effect at lower concentrations and the compounds therefore act more 
Figure 5: Isoboles of binary mixtures of 
estrogenic pharmaceuticals. (A), E2+furose-
mide for effect level C50. (B), E2+furosemide 
for effect level C75. (C), E2 + furosemide for 
the effect level C25. Data points are 
interpolated values of the best-fit curves for the 
respective mixture. 
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than additive or synergistically. Concave-up isoboles indicate antagonistic mixtures. At 
the effect level C25 and C50 the binary mixture of E2 and furosemide seem to act 
synergistically. At the effect level C75, the data points scatter along the additivity line. 
Therefore, the combined mixture effects of E2 and furosemide follow the CA model 
with a trend to synergism, depending on the effect level.  
 
The equipotent binary mixtures of furosemide and phenazone at the C20 and C25 
levels follow the CA model predictions more closely than the IA prediction, but the 
difference between the predicted values is very minor (Fig. 6A, 6B). At lower 
concentrations activities are higher than predicted values according to both the CA and 
IA model, which is similar to the binary mixture of furosemide and E2. At the highest 
measured concentrations, measured and predicted values do not differ (Fig. 6C). 
Various combinations of two to five individual pharmaceuticals were mixed at their C01 
and C10 levels. The results shown in figure 7 indicate that even for binary mixtures it is 
not always possible to predict the outcome of the experiments using either the CA 
model or the IA model. The estimates based on the CA model and IA model are very 
similar for the mixtures analysed, and a distinction between the different models is not 
always possible. Seven mixtures followed the prediction of the CA model, but 8 
mixtures exhibited dramatically higher activities than expected. Of the six mixture 
combinations at the C01 level, three followed the CA model prediction, whereas one 
Table 4: One-sample t-test for the highest concentrations of all mixtures.
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mixture (furosemide and fenofibrate) showed lower activity than expected. The mixture 
of fenofibrate and cimetidine, and the mixture comprising of five pharmaceuticals at 
their C01 level had much higher activities than expected.   
The C10 mixtures of two active pharmaceuticals did not differ from the CA model. In 
contrast, the effects of the C10 mixture comprising of three and four pharmaceuticals 
(furosemide, phenazone, cimetidine and fenofibrate) were dramatically higher than 
expected. The activity of mixtures containing three compounds is underestimated by 
both the CA and the IA model. 
The mixture of four pharmaceuticals, cimetidine, fenofibrate, furosemide and 
phenazone, showed a dramatically higher activity than expected from the model 
prediction, when mixed at their C0.05 level (NOEC level) (Fig. 7). The pharmaceuticals 
mixed at extremely low –effect concentrations lead to a significant response. 
To compare the mean of measured values at the highest concentration to the 
hypothetical mean calculated using the CA or the IA model, respectively, a statistical 
evaluation using the one-sample t-test was performed (Table 4). P values were taken 
from the two-sided t-table for P=95%. There was no significant difference from the CA 
prediction in eleven out of 23 analysed mixtures. In twelve mixtures, the observed 
values deviate significantly from the CA model prediction (Table 4).  
The results of the various mixture experiments demonstrate that the limitations given 
by the diverse shapes of the compound’s concentration-response curves and maximal 
Figure 6: Binary mixtures of furosemide and 
phenazone. Concentration-effect curves and 
predictions according to the CA and IA model. 
Absorption values for C20 (A) and C25 mix-
tures (B). (C) Ratios between highest concen-
tration measured and expected values using 
the CA model. Bars are averages ± SEM of n= 
19-20 experiments.
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activities lead to results that deviate from the CA model predictions. For very low effect 
levels (C01, C0.05) we observed dramatically higher activities than expected. This 
clearly indicates that accurate predictions of mixture effects are only possible, if the 
shape of the concentration-response curves of single compounds are almost equal, 
and when the maximal activity is almost reached. 
 
 
Discussion  
In this work, we demonstrate the in vitro estrogenic activity of five pharmaceuticals that 
occur in the aquatic environment. We applied the YES assay which is a robust and 
simple assay providing important information on the binding of estrogenic chemicals to 
the hERα and ERE activation (Kunz et al. 2004; Routledge and Sumpter 1996). Out of 
the 37 pharmaceuticals, furosemide, phenazone, fenofibrate, cimetidine and 
paracetamol showed weak estrogenic activity (Fig. 1). Tamoxifen and furosemide 
exhibited a dose-response curve with almost full efficacy, whereas the other 
compounds did not reach maximal activity. Furosemide was demonstrated to exhibit 
estrogenic activity via binding to the hERα (Fig. 2). This pharmaceutical was about 107 
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Figure 7: Ratios between measured and expected (CA model) absorption values for various 
mixtures at the highest concentrations. Stars indicate significant differences between observed 
and predicted values. Measured values are highest analysed concentrations. Fu, furosemide; 
Ci, cimetidine; Pa, paracetamol; Ff, fenofibrate; Ph, phenazone; NOEC, no observed effect 
concentration. Error bars indicate SEM.
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times less potent than E2. Compared to 4-nonylphenol and bisphenol A, two 
substances with a known estrogenicity (Sohoni and Sumpter 1998), furosemide was 
about 1,000 times less potent. Furosemide, but also the other pharmaceuticals 
including phenazone, cimetidine, fenofibrate and paracetamol can be classified as very 
weak hERαagonists, as they exhibited no anti-estrogenic activity.  
The estrogenic potential of a substance is hardly predicted by its structure alone and 
the precise requirements for estrogenicity are not yet fully understood (Kunz et al. 
2004; Routledge and Sumpter 1996; Sumpter and Johnson 2005). The 
pharmaceuticals having estrogenic activity have no structural resemblance to natural 
estrogens (Fig. 8). The only molecular feature resembling those of other known 
estrogens is found with paracetamol that bears a phenol moiety.  
Many of the estrogenic compounds exert their effects via interaction with the estrogen 
receptor, as the estrogenic pharmaceuticals identified in this study. Whether or not the 
in vitro activity is paralleled by activity in vivo remains to be shown. In some cases, in 
Figure 8. Chemical structures of estrogenic pharmaceuticals identified in the YES-screen and of 
17β-estradiol. 
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vitro and in vivo activities clearly correlate, in other cases, in vitro activity cannot be 
extrapolated to the in vivo activity (Kunz et al. 2004). Only in vivo studies will show 
whether the estrogenicity is paralleled by in vivo activity. 
The half-maximal estrogenic activity found in the YES-assay was in the range of 0.66-
25.53 mM, or hundreds of μg/L to g/L. Typical environmental concentrations in STP 
effluents are in the ng/L to μg/L range (Fent et al. 2006; Ternes et al. 2004). 
Furosemide was found in all monitored wastewaters in Italy (Castiglioni et al. 2004). 
The daily loads in the STP influent was 277 mg/1,000 inhabitants and in the effluent 
195 mg/1,000 inhabitants with an average removal in the STP of 15%. In surface 
waters, the daily load in Italy was 66 mg/1,000 inhabitants, which indicates a 
widespread occurrence of furosemide. 
Table 5 compares the half-maximal values (EC50) found in the YES-assay of the 
present study with the maximal environmental concentrations reported. Except for E2, 
which was used as a standard throughout the study, and for tamoxifen, the EC50 
values are a factor of 105 to 106 higher than the maximal environmental concentrations. 
This indicates that the in vitro activities of these pharmaceuticals are weak. An 
estrogenic effect of the single pharmaceuticals that show an estrogenic potential in the 
YES-assay may therefore not be expected at environmental concentrations. Still, for 
hazard and risk assessments, it is important to know the estrogenic potential of 
pharmaceuticals that are ubiquitously found in the environment and may contribute to 
the complex mixtures. 
Comparisons of effect concentrations in the YES-assay with environmental 
concentrations can be regarded as a first hint at possible environmental hazards and 
risks. However, only in vivo experiments can account for metabolism and additional 
effects in animals and provide direct information on the estrogenic potential of the 
pharmaceuticals in an organism. It should also be noted that the ratios between effect 
concentrations found in the conducted in vitro studies and the current environmental 
concentrations are very high. 
Table 5: Ratios between observed EC50 values in the YES-assay and maximal environmental 
concentrations found in the literature for STP effluents. 
Estrogenic Activities of Pharmaceuticals 
 224
 
Effects of mixtures 
Aquatic organisms are generally exposed to a complex mixture of xenobiotics, 
particularly in environments contaminated by wastewater. Generally, the individual 
assessment of the hazard posed by single chemicals indicates a negligible risk, with 
the exception of E2 and EE2 (Sumpter and Johnson 2005). However, this does not 
account for the potential of endocrine active substances to act in combination. This 
may lead to the underestimation of hazards that exist in the actual exposure situation, 
resulting in erroneous assumption of absence of risk. The assessment of the toxicity or 
estrogenic activity of mixtures cannot be calculated by simply adding the effects of the 
mixture components when applied singly. As the YES-assay is based on the binding of 
substances to hERα, the concept of CA is likely to be applicable. Concentration 
addition is widely regarded as the appropriate concept for mixtures, whose components 
act in a similar mode of action such as on a defined receptor (Backhaus et al. 2004). 
The IA model in contrast is usually applied when mixtures consist of dissimilarly acting 
substances (Kortenkamp and Altenburger 1998). Both concepts require that all mixture 
components are known as well as their respective concentrations and effects, which 
holds true in a laboratory assay, but is difficult or even unrealistic to apply in an 
environmental sample where unknown chemicals in unknown quantities are present.  
The activity of binary mixtures of furosemide and E2 (Fig. 4, 5), and of furosemide and 
phenazone (Fig. 6) are estimated accurately by the CA model. The mixture 
combinations of E2 and furosemide (EC80 + C20 and EC40 + C60) are better 
estimated by the CA than IA model, as expected for similarly acting substances. 
However, for the analysed mixtures, the estimates discriminate only little between the 
CA and IA model. The isoboles in figure 5 indicate that the two compounds interacted 
in an additive manner, although at two mixture ratios (C25, C50) synergistic interaction 
is suggested. Mixtures of furosemide and phenazone also followed the CA model.  
Various combinations of two to five individual pharmaceuticals were mixed at their C01 
and C10 levels (Fig. 7). The estimates based on the CA model and IA model are very 
similar for the mixtures analysed, and a distinction between the different models is not 
always possible. The mixture of four pharmaceuticals at their NOEC level showed a 
dramatically higher activity than predicted by the models. Seven mixtures followed the 
prediction of the CA model, but 8 mixtures exhibited dramatically higher activities than 
expected. The results indicate that even for binary mixtures it is not always possible to 
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predict the outcome of the experiments using the CA model due to the following 
reasons.  
The concentrations of the pharmaceuticals in the analysed mixtures are very high as 
compared to E2. Moreover, pharmaceuticals did not reach maximal responses and 
dose-response curve were not identical, as required for the CA model. The curves of 
the single compounds used for the interpolations of the respective concentrations might 
be too unreliable at low effect concentrations, what makes predictions difficult. 
Therefore, the calculated values may deviate dramatically from the real mixture effects. 
These are the reasons why mixture effects of binary mixtures of pharmaceuticals at the 
C01 and C10 level and of mixtures of up to five weakly estrogenic pharmaceuticals 
were hardly predictable. Similarly, (Rajapakse et al. 2004) have also found deviations 
from expected mixture effects estimated by CA in mixtures of five and six estrogenic 
chemicals including genistein, 4-nonylphenol, 4-tert-octylphenol, 17β-estradiol, 17α-
ethinylestradiol, and bisphenol A. These were interpreted as interactions between the 
chemicals, which cannot be applied to our mixture experiments.  
Therefore, the results of the various mixtures analysed at different effect levels indicate 
that it is difficult or even not possible to accurately estimate the combined effect of low 
concentrations of weakly estrogenic compounds having only minimal efficacy. This 
emphasises that accurate predictions of mixture effects can only be made if the 
individual compounds exhibit identical shapes in their concentration-response curves 
and if they have maximal activity. When these conditions are not fulfilled, estimates are 
inaccurate or at least very difficult. However, compounds in the environment have such 
diverse concentration-effect relationships and therefore, our mixture experiments may 
mimic realistic environmental situations. The lack of appropriate predictions may also 
suggest limitations of this mixture concept. 
Despite these difficulties our data demonstrate that pharmaceuticals, which are mixed 
at extremely low concentrations such as at the NOEC or at the C01 level, exhibit a 
marked activity. The results clearly indicate that the estrogenic compounds mixed at 
extremely low-effect concentrations lead to a significant response. The concept that a 
mixture of estrogenic chemicals, each of which is present at very low-effect 
concentration, can induce a significant response (Cromlish and Kennedy 1996; Stumpf 
et al. 1999) is confirmed by our experiments with pharmaceuticals.  It gives further 
evidence to the observation that very low concentrations of estrogenic chemicals, 
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which appear to have little or no effect on their own, are nonetheless biologically active, 
and when combined with other estrogenic compounds, may exert effects. 
The interactions of estrogenic pharmaceuticals with other estrogens present in 
wastewater indicate that the principle of CA holds true for multicomponent mixtures of 
estrogenic compounds in vitro. Whether this translates directly to in vivo activity as with 
other estrogenic compounds remains to be shown in forthcoming experiments. The 
additive nature of the combined effects demonstrated that both components contribute 
to the overall effect of a mixture. This implies that the overall effects will exceed the 
highest individual effect of the mixture components. This is of particular importance for 
the environmental hazard and risk assessment of pharmaceuticals, because it 
indicates that concentrations of single chemicals that show no effect when applied 
singly may provoke substantial effects when acting in combination (Cromlish and 
Kennedy 1996). 
The European Medicines Evaluation Agency (EMEA) published a draft guideline on the 
environmental risk assessment of medicinal products for human use (EMEA 2005). 
This guideline applies mainly to new active substances and requires ecotoxicological 
investigations. In the European Union, a new system is planned for the assessment of 
environmental risks and effects on human health for a wide range of chemicals that 
include pharmaceuticals as well. The registration, evaluation and authorisation of 
chemicals (REACH) regulation would take into account not only new substances, but 
also established chemicals that are produced in large amounts. The in vitro analysis of 
estrogenic activity as shown in this study is a possible strategy for assessing 
pharmaceuticals within this framework. 
Experiments with mixtures of estrogenic substances showed that the prediction of the 
activity of complex mixtures consisting of substances that exert only a weak effect 
when applied singly are very difficult. Even at low concentrations, the effects may be 
much higher than expected from the concentration-response curves of the single 
compounds. In aquatic environments, many diverse estrogenic substances such as 
UV-filters, alkylphenols, bisphenol A, phthalates or steroid hormones, to mention only a 
few, are ubiquitous, particularly in sewage contaminated systems. Many of them show 
incomplete concentration-response curves. It would be interesting to further test the CA 
concept for reliability of the results presented in this study. Moreover, analysis of 
mixtures of a larger set of different pharmaceuticals would allow drawing a more 
realistic picture of the exposure situation in the environment.  
Appendix 2 
 227
 
Acknowledgement 
We thank Petra Kunz for her valuable and excellent support, Andreas Hartmann 
(Novartis International AG, Basel), and Jürg Straub (F. Hoffman-La Roche Ltd, Basel) 
for providing some of the pharmaceuticals and comments on the manuscript. The study 
was funded by the Bundesamt für Berufsbildung und Technologie (BBT), Kommission 
für Technologie und Innovation (KTI-Project 7114.2 LSPP-LS), Novartis International 
AG, Basel, F. Hoffmann-La Roche Ltd, Basel, and Springborn Smithers Laboratories 
(Europe) AG, Horn.  
 
 
References  
Altenburger, R., Walter, H., and Grote, M. (2000). What contributes to the combined effect of a 
complex mixture? Environ Sci Technol 38, 6353-6362. 
Ashton, D., Hilton, M., and Thomas, K. V. (2004). Investigating the environmental transport of 
human pharmaceuticals to streams in the United Kingdom. Sci Total Environ 333, 167-84. 
Backhaus, T., Arrhenius, A., and Blanck, H. (2004). Toxicity of a mixture of dissimilary acting 
substances to natural algal communities: predictie power and limitations of independent action 
and concentraion addition. Environ Sci Technol 38, 6363-6370. 
Castiglioni, S., Fanelli, R., Calamari, D., Bagnati, R., and Zuccato, E. (2004). Methodological 
approaches for studying pharmaceuticals in the environment by comparing predicted and 
measured concentrations in River Po, Italy. Regul Toxicol Pharmacol 39, 25-32. 
Cromlish, W. A., and Kennedy, B. P. (1996). Selective inhibition of cyclooxygenase-1 and -2 
using intact insect cell assays. Biochemical Pharmacology 52, 1777-1785. 
Damstra, T., Barlow, S., Bergman, A., Kavlock, R., and van der Kraak, G. (2002). Global 
assessment of the state of the science of endocrine disruptors. WHO/PCS/EDC/02.2. 
Daughton, C. G., and Ternes, T. A. (1999). Pharmaceuticals and personal care products in the 
environment: agents of subtle change? Environ Health Perspect 107 Suppl 6, 907-38. 
EMEA (2005). Note for guidance on environmental risk assessment of medicinal products for 
human use, CMPC/SWP/4447/draft.The European Agency for the evaluation of medicinal 
products (EMEA), London, 20 January 2005. 
Fent, K. (2004). Ecotoxicological effects at contaminated sites. Toxicology 205, 223-240. 
Fent, K., Weston, A. A., and Caminada, D. (2006). Ecotoxicology of human pharmaceuticals. 
Aquat. Toxicol. 76, 122-159. 
Gagne, F., Blaise, C., and Andre, C. (2005). Occurrence of pharmaceutical products in a 
municipal effluent and toxicity to rainbow trout (Oncorhynchus mykiss) hepatocytes. Ecotoxicol 
Environ Saf. 
Estrogenic Activities of Pharmaceuticals 
 228
Halling-Sorensen, B., Nors Nielsen, S., Lanzky, P. F., Ingerslev, F., Holten Lutzhoft, H. C., and 
Jorgensen, S. E. (1998). Occurrence, fate and effects of pharmaceutical substances in the 
environment--a review. Chemosphere 36, 357-93. 
Hartmann, A., Alder, A. C., Koller, T., and Widmer, R. M. (1998). Identification of 
fluoroquinolone antibiotics as the main source of umuC genotoxicity in native hospital 
wastewater. Environ. Toxicol. Chem. 17, 377-382. 
Heberer, T. (2002). Occurrence, fate, and removal of pharmaceutical residues in the aquatic 
environment: a review of recent research data. Toxicol. Lett. 131, 5-17. 
Kolpin, D. W., Furlong, E. T., Meyer, M. T., Thurman, E. M., Zaugg, S. D., Barber, L. B., and 
Buxton, H. T. (2002). Pharmaceuticals, hormones, and other organic wastewater contaminants 
in U.S. streams, 1999-2000: a national reconnaissance. Environ Sci Technol 36, 1202-11. 
Kortenkamp, A., and Altenburger, R. (1998). Synergisms with mixtures of xenoestrogens: a 
reevaluation using the method of isoboles. Sci Total Environ 221, 59-73. 
Kümmerer, K. (2003). Significance of antibiotics in the environment. J. Antimicrob Chemo 52, 5-
7. 
Kümmerer, K. (2004). Pharmaceuticals in the Environment. Springer Verlag 2nd edition. 
Kunz, P. Y., Galicia, H. F., and Fent, K. (2004). Assessment of hormonal activity of UV filters in 
tadpoles of frog Xenopus laevis at environmental concentrations. Mar Environ Res 58, 431-5. 
Laville, N., Ait-Aissa, S., Gomez, E., Casellas, C., and Porcher, J. M. (2004). Effects of human 
pharmaceuticals on cytotoxicity, EROD activity and ROS production in fish hepatocytes. 
Toxicology 196, 41-55. 
Mimeault, C., Woodhouse, A. J., Miao, X.-S., Metcalfe, C. D., Moon, T. W., and Trudeau, V. L. 
(2005). The human lipid regulator, gemfibrozil bioconcentrates and reduces testosterone in the 
goldfish, Carassius auratus. Aquat. Toxicol. 73, 44-54. 
Nash, J. P., Kime, D. E., Van der Ven, L. T., Wester, P. W., Brion, F., Maack, G., Stahlschmidt-
Allner, P., and Tyler, C. R. (2004). Long-term exposure to environmental concentrations of the 
pharmaceutical ethynylestradiol causes reproductive failure in fish. Environ. Health Perspect. 
112, 1725-1733. 
Payne, J., Rajapakse, N., Wilkins, M., and Kortenkamp, A. (2000). Prediction and assessment 
of effects of mixtures of four xenoestrogens. Environmental Health Perspectives 108, 983-987. 
Purdom, C. E., Hardiman, P. A., Bye, V. J., Eno, N. C., Tyler, C. R., and Sumpter, J. P. (1994). 
Oestrogenic effects of effluent from sewage treatment works. Chem. Ecol. 8, 275-285. 
Rajapakse, N., Silva, E., and Kortenkamp, A. (2002). Combining xenoestrogens at levels below 
individual no-observed effect concentrations dramatically enhances steroid hormone action. 
Environmental Health Perspectives 110, 917-921. 
Rajapakse, N., Silva, E., Scholze, M., and Kortenkamp, A. (2004). Deviation from additivity with 
estrogenic mixtures containing 4-nonylphenol and 4-tert-ocylphenol detected in the E-SCREEN 
assay. Environ Sci Technol 38, 6343-6352. 
Routledge, E. J., and Sumpter, J. P. (1996). Estrogenic activity of surfactans and some of their 
degradation products assessed using a recombinant yeast screen. Environ Toxicol Chem 15, 
241-248. 
Appendix 2 
 229
Sacher, F., Lange, F. T., Brauch, H.-J., and Blankenhorn, I. (2001). Pharmaceuticals in 
groundwaters:  Analytical methods and results of a monitoring program in Baden-Wurttemberg, 
Germany. Journal of Chromatography A 938, 199-210. 
Sohoni, P., and Sumpter, J. P. (1998). Several environmental oestrogens are also anti-
androgens. J Endocrinol 158, 327-339. 
Stumpf, M., Ternes, T. A., Wilken, R.-D., Silvana Vianna Rodrigues, and Baumann, W. (1999). 
Polar drug residues in sewage and natural waters in the state of Rio de Janeiro, Brazil. The 
Science of The Total Environment 225, 135-141. 
Sumpter, J. P., and Johnson, A. C. (2005). Lessons from endocrine disruption and their 
application to other issues concerning trace organics in the aquatic environment. Environ. Sci. 
Technol. 39, 4321-4332. 
Swan, S. H., Main, K. M., Liu, F., Stewart, S. L., Kruse, R. L., Calafat, A. M., Mao, C. S., 
Redmon, J. B., Ternand, C. L., Sullivan, S., and Teagur, J. L. (2005). Decrease in anogenital 
distance among male infants with prenatal phthalate exposure. Environ. Health Perspect. 113, 
1056-1061. 
Ternes, T., Jos, A., and Siegrist, H. (2004). Scrutinizing pharmaceutical and personal care 
products in wastewater treatment. Environ. Sci. Technol., 393-399. 
Thorpe, K. L., Cummings, R. I., Hutchinson, T. H., Scholze, M., Brighty, G., Sumpter, J. P., and 
Tyler, C. R. (2003). Relative potencies and combination effects of steroidal estrogens in fish. 
Environ. Sci. Technol. 37, 1142-1149. 
Van Aerle, R., Rounds, N., Hutchinson, T. H., Maddix, S., and Tyler, C. R. (2002). Window of 
sensitivity for the estrogenic effects of ethinylestradiol in early life-stages of fathead minnow. 
Ecotoxicology 11, 423-434. 
Vom Saal, F. S., and Hughes, C. (2005). An extensive new literature concerning low-dose 
effects of bisphenol A shows the need for a new risk assessment. Environ. Health Perspect. 
113, 926-933. 
 
 
Estrogenic Activities of Pharmaceuticals 
 230
 
 
 
Abbreviations 
 231
Abbreviations 
 
ABCX ATP-Binding Cassette belonging to the family X 
ATP Adenosine Triphosphate 
BCRP Breast Cancer Resistance Protein 
CYP Cytochrome P450 
FAO Fatty Acyl coenzyme A Oxidase 
EC50 half-maximal Effect Concentration 
LogD Partition Coefficient correlated to a specific pH-value 
MDR Multidrug Resistance 
MDR1 P-glycoprotein1 (ABCB1) 
MRP1 Multidrug Resistance-related Protein 1 (ABCC1) 
MRP3 Multidrug Resistance-related Protein 3 (ABCC3) 
MTT Mitochondrial Tthiazolyl blue Tetrazolium bromide 
MXR Multixenobiotic Resistance 
NR Neutral Red 
P-gp1 P-glycoprotein 1 (ABCB1, MDR1) 
PLHC-1  Poeciliopsis lucida Hepatocellular Carcinoma cell line 
PLHC-1/dox Doxorubicin-resistant subclone of PLHC-1 
PLHC-1/wt Wild type PLHC-1 
PPAR  Peroxisome Proliferator-Activated Receptors 
PPRE Peroxisome Proliferator Response Elements 
RTG-2 Rainbow Trout Gonadal cell line 
RxR  Retinoid X Receptor 
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